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Abbreviations 
2-MAG    2-monoacylglycerol 
ACAD     acyl-CoA dehydrogenase 
ACAT     acyl-CoA:cholesterol acyltransferases 
ACN     acetonitrile 
ACTH      adrenocorticotropic hormone 
ADP     adenosine diphosphate 
AGPAT    1-acylglycerol-3-phosphate acyltransferase 
AMP     adenosine monophosphate 
ATGL     adipose triglyceride lipase 
ATP     adenosine triphosphate 
BMDMs    bone marrow-derived macrophages 
BSA     bovine serum albumin 
C10     decanoic acid 
C11     C11 alkyne fatty acid 
C16     palmitate 
C17:2      alkyne palmitate 
C18     oleate 
C19     alkyne oleate 
CACT     carnitine-acylcarnitine translocase 
CE      cholesterol ester 
Cer      ceramide 
CoA     coenzyme A 
CPT1/2    carnitine palmitoyltransferase 1/2 
DAG     diacylglycerol 
DGAT1/2     diacylglycerol acyltransferase 1/2 
DHAP     dihydroxyacetone phosphate 
DMEM     Dulbecco’s Modified Eagle Medium 
ER     endoplasmic reticulum 
Eto     Etomoxir 
FA     fatty acid    
FABPpm     plasma membrane associated fatty acid binding protein 
FADH2     flavin adenine dinucleotide 
FATP     fatty acid transport proteins 
FAO     fatty acid oxidation 
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FFA     free fatty acid 
G3P     glycerol-3-phosphate  
GPAT     glycerol-3-phosphate acyltransferase 
HESI     high voltage electrospray ionization 
HSL     hormone sensitive lipase 
LCFA     long chain fatty acid 
LCT     long-chain triglyceride 
LD     lipid droplet 
LPA     lysophosphatidic acid 
LPAAT    lysophosphatidic acid acyltransferase 
LPC      lysophosphatidylcholine  
LPCAT    lysophosphatitylcoline acyltransferase 
LPS     lipopolysaccharides 
MCDG     medium-chain diglyceride 
MCFA      medium chain fatty acid 
MCT      medium-chain triglyceride 
MFQL     molecular fragment query language 
MGAT     monoacylglycerol acyltransferase 
MGL     monoacylglycerol lipase 
MS      mass spectrometry 
NADH      nicotinamide adenine dinucleotide 
NAFLD    non-alcoholic fatty liver disease 
NFC     normalized fold change 
PA      phosphatidic acid 
PA     phosphatidic acid 
PBS     phosphate buffered saline 
PC      phosphatidylcholine  
PE     phosphatidylethanolamine 
PG     phosphatidylglycerol  
PI     phosphatidylinositol 
PKA     cyclic AMP dependent protein kinase 
PPAR     peroxisome proliferators  
SD     standard deviation 
TAG      triacylglycerol      
TLC     thin layer chromatography 
VLDL      very low-density lipoprotein 
WT     wildtype 
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Summary 
Fatty acids form a class of important biomolecules, serving as essential elements of lipid 
molecules. Stored in triacylglycerol (TAG), the main constituent of plant oils and animal fats, 
they from an inseparable part of the daily human diet. Differing carbon chain length and 
saturation degrees, lead to a great variety of fatty acids in which long-chain-fatty acids 
(LCFAs) from the major part. The class of medium-chain fatty acids (MCFAs) are mainly 
found in a variety of plant oils like palm kernel oil and they possess different biochemical and 
physiochemical properties then LCFAs. Although the cellular metabolism of MCFAs has 
been object to research for many decades, it is still insufficiently studied in certain details. 
This thesis connects to previous work in our laboratory where it was proposed that 
diacylglycerol acyltransferase 2 (DGAT2) plays predominant role in MCFA-TAG synthesis 
and that cytosolic MCFA-CoAs for TAG synthesis are provided in a carnitine 
palmitoyltransferase 1 (CPT1)-dependent manner, as treatment with the CPT1 inhibitor 
Etomoxir reduced MCFA-TAG levels. This present work puts its emphasis on investigating 
the hepatic metabolism of DGAT-dependent MCFA incorporation into TAG upon treatment 
with small molecule inhibitors, targeting either DGAT enzymes or mitochondrial CPT1. 
Freshly isolated primary hepatocytes from wildtype (WT)- or DGAT1-/--mice were treated with 
inhibitors and pulsed with alkyne fatty acids, followed by lipid extraction and subsequent 
analysis of the lipid metabolites via thin layer chromatography or mass spectrometry (MS). 
Here, a novel MS- based methodology to analyze alkyne labeled lipids which was recently 
developed in our group, was utilized. As observed with the Etomoxir treatment, it was found 
that a DGAT1 inhibition in WT hepatocytes resulted as well in a MCFA-TAG reduction. Also, 
a combination of both inhibitors reduced MCFA-TAG levels even further. A DGAT2-inhibition, 
however, did not alter MCFA-TAG levels. Further, pulse-chase analysis with unlabeled 
decanoic acid revealed similar effects upon DGAT1 and Etomoxir treatment. Analysis of the 
lipid profile in DGAT1-/--mice revealed altered MCFA-TAG levels, independent from inhibitory 
treatment. Interestingly, in DGAT1-/- hepatocytes, Etomoxir-treatment did lead to a similar 
change in TAG levels as in the WT control. Additionally, in vivo lipopolysaccharide (LPS)- 
stimulated mice showed overall enhanced lipid levels, but similar responses to the DGAT 
inhibitor and Etomoxir treatment. Teglicar, another CPT1 inhibitor, did show enhanced TAG 
synthesis upon treatment. This thesis was concluded by introducing the hypothesis, that 
hepatic DGAT1 but not DGAT2 is responsible for MCFA incorporation into TAG, which can 
be compensated partially by DGAT2. It was postulated, that Etomoxir can also act as a 
potent DGAT inhibitor, predominantly targeting DGAT1, when both DGATs are present. This 
putative off target effect was not seen with the second CPT1 inhibitor Teglicar. 
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1. Introduction 
One of the most important class of biomolecules are fatty acids (FA). Fatty acids are 
carboxylic acids with a hydrocarbon chain, usually consisting of an even number of carbon 
atoms. They are essential elements of many lipid molecules (e.g. phospholipids) and serve 
as an energy source for catabolic processes, covalent modification of some proteins, as 
signaling molecules in metabolic processes or as regulators of gene expression.  
Fatty acids are classified according to their chain length and their number of double bonds 
within the acyl chain (saturation). Fatty acids with under 8 carbon atoms are called short-, 
with 8 to 12 carbon atoms medium-, over 12 carbon atoms as long- and over 22 carbon 
atoms very long-chain fatty acids. Monounsaturated fatty acids possess one double bond 
within the acyl chain. Fatty acids which possess more than one double band are called 
polyunsaturated and fatty acids with no double bonds are classified as saturated. These 
structural differences cause different biochemical and physical properties of the fatty acids, 
influencing water solubility, lipophilicity and oxidative capacity. According to their chain length 
and saturation, fatty acids undergo different metabolic fades in terms of uptake, transport, 
storage and catabolism.  
Long chain fatty acids (LCFA) with 16 or 18 c-atoms, including oleic acid (C18:1) and palmitic 
acid (C16:0), are the most abundant FAs within animal tissues and most animal diets (Bruss, 
2008) and therefore have been well characterized research objects for many decades.  
In most plant oils (e.g. rapeseed, sunflower and olive oil) which are used for nutritional 
purposes throughout the globe and especially in the western world, saturated and 
unsaturated LCFA, stored as triacylglycerols (TAG), comprise the main fatty acids. With 
globally increasing prevalence of diet induced obesity and its associated metabolic disorders 
like non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus and hypertension 
(Botchlett and Wu, 2018), the interest in research on defining more healthy, alternative 
nutrients arises.  
In the course of this, medium-chain triglycerides (MCT) came into focus. Naturally occurring 
as a component of coconut- or palm kernel oil and milk (Marten et al., 2006), MCT mainly 
consist of saturated medium chain fatty acids (MCFAs) (Papamandjaris et al., 1998). 
Ongoing research on MCFA has revealed several possible positive associations with MCT as 
a healthy alternative to LCFA-rich TAGs (McCarty and DiNicolantonio, 2016). The cellular 
metabolism of MCFAs, however, is still insufficiently studied in certain aspects. In this thesis, 
the murine hepatic metabolism of MCFAs is investigated in more detail, focusing on the 
DGAT-dependent incorporation of MCFAs into TAGs.  
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1.1. Medium-chain fatty acids and medium-chain TAG 
Medium chain fatty acids are comprised of a fully saturated acyl chain containing 8-12 
carbon atoms namely C8:0 (Octanoic acid), C10:0 (Decanoic acid) and C12:0 (Dodecanoic 
acid) (Papamandjaris et al., 1998). The lack of double bonds and the length of the acyl chain 
gives MCFA different physiochemical properties than LCFA, leading as well to differences 
within the metabolism of these two groups of fatty acids and their TAG counterparts. Upon 
digestion there is already a metabolic discrimination between MCT and long-chain TAG 
(LCT) within the stomach and gut. The digestion of dietary MCT and LCT starts with the 
hydrolysis through lingual lipase in the stomach and continues through hydrolysis with 
pancreatic and gastric lipases within the duodenum. All these enzymes preferably hydrolyze 
TAG ester bonds at 1 and 3 position, resulting in 2-monoacylglycerol (2-MAG) and two free 
fatty acids and show a higher activity on MCFA than LCFA (Bach and Babayan, 1982). 
LCFA, are usually reesterified with 2-MAG to LCT, incorporated into chylomicrons and 
transported via the lymphatic system, initially bypassing the liver (Bach and Babayan, 1982) 
(You et al., 2008). In contrast, MCFA can be absorbed directly from the small intestinal cells, 
where they are afterwards transported to the liver, bound to albumin, via the portal vein for 
hepatic metabolism (Bach and Babayan, 1982; You et al., 2008), see Figure 1.   
In the liver, MCFA can be reesterified to MCT to some extent, when longer fatty acids are 
present to generate diacylglycerol (DAG) first, which serves, together with the MCFA, as a 
substrate for DGAT enzymes (Mayorek and Bar-Tana, 1983) The majority of the MCFA, 
however, undergo rapid catabolism through oxidative pathways including mitochondrial β-
oxidation and peroxisomal oxidation (Papamandjaris et al., 1998). In summary, dietary MCTs 
are hydrolyzed faster than LCTs and the resulting MCFAs are absorbed quickly into the 
intestinal lumen and transported directly to the liver via the portal vein. In the liver, they 
undergo mainly catabolic processes and only a small amount is stored in TAG, implicating a 
shorter half-life in the body and therefore pose a reduced risk of promoting obesity through 
direct storage in adipocytes (Bach et al., 1996; McCarty and DiNicolantonio, 2016) . Within 
the last decades, many studies discuss specialized MCFA- and MCT-rich foods as a dietary 
option for prevention or treatment of certain diseases. Apart from the already mentioned 
lower incorporation into TAGs, MCTs have been shown to trigger thermogenesis (Hill et al., 
1989) and might help to reduce body weight, when used as an alternative oil source, 
compared to LCT-rich oils  (Papamandjaris et al., 1998; Mumme and Stonehouse, 2015). 
One of the key pathological features in patients suffering from a metabolic syndrome is the 
increased level of “ectopic fat metabolites” in the affected tissues (McCarty and 
DiNicolantonio, 2016). These include DAG, which is associated with hepatic insulin 
resistance via activation of protein kinase Cε (Jornayvaz and Shulman, 2012), and 
Ceramide, de novo synthetized from palmitate, promoting inflammatory processes (Gao et 
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al., 2012). On the contrary, MCFAs do not give rise to these metabolites in such extend 
(Mayorek and Bar-Tana, 1983) and have the potential to partly restore mitochondrial 
respiration rates under inflammatory conditions (Hecker et al., 2014). Additionally, medium 
chain diglycerides (MCDGs) have been shown to reduce inflammatory responses in vitro (Yu 
et al., 2017).  
 
Figure 1: Schematic representation of the digestion and absorption process of dietary MCTs 
and LCTs. Upon digestion, the hydrolysis of TAG is mediated first by lingual lipases followed by 
gastric and pancreatic lipases in the small intestine. After hydrolysis to 2-MAG and free fatty acids, the 
intestinal absorption follows. The main part of MCFAs are directly transported to the liver via the portal 
vein, bound to albumin. LCFAs are reesterified with 2-MAG to LCT and incorporated into chylomicrons 
and enter the lymphatic system, where they are transported to adipose tissue or muscle tissue for 
either storage or oxidation. Remnants of chylomicrons are finally transported to the liver. Scheme of 
the intestine is adapted from: https://biorender.com/.  
 
Taken together, MCFAs have been identified as promising candiates in alternative diets, 
beneficial for the treatment of patients suffering from metabolic diseases involving  accessive 
accumulation of fatty acids and their metabolites.  
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Previous studies in our group described the ability of freshly isolated hepatocytes to 
incorporate MCFAs into TAGs, in accordance with already published data (Mayorek and Bar-
Tana, 1983; Brandes et al., 1985; Klizaite, 2017). It was also shown by our group, that after 
8-18 hours, de-differentiating hepatocytes start losing the ability to incorporate C11-FA 
(alkyne labeled decanoic acid) but nor C19-FA (alkyne labeled oleic acid) into TAG (Klizaite, 
2017). Transcriptomic analysis of de-differentiating hepatocytes showed a correlation 
between the loss of C11-FA incorporation into TAG and DGAT2-expression in vivo, but not in 
vitro using cell lysates (Klizaite, 2017). Inspired by these findings, our group hypothesized 
that hepatic DGAT2 is essential for in vivo-C11-FA incorporation into TAG. In the study by 
Klizaite, it was also shown, that the inhibition of CPT1 through Etomoxir (Turnbull et al., 
1984) reduced the C11-FA incorporation  intro TAG in hepatocytes. It was hypothesized, that 
hepatic CPT1 converts mitochondrial MCFA-carnitines to acyl-CoAs, which are shuttled into 
the cytosol via the carnitine shuttle (Pande, 1975; Klizaite, 2017). The second hypothesis, 
stating that cytosolic MCFA-CoAs are needed for TAG synthesis by DGAT enzymes in a 
CPT1-dependent manner was termed “the Etomoxir-effect”. 
1.2. The function, biosynthesis and catabolism of TAG 
As the work in this thesis focuses mainly on the hepatic incorporation of MCFAs into TAG, 
the following chapters will give an introduction on the cellular processes involved in TAG 
synthesis with a special emphasis on the acylation of DAG to TAG via diacylglycerol 
acyltransferases (DGATs). 
1.2.1. Function of TAG 
Being the major group of neutral lipids, TAGs form a heterogenous group of molecules, 
consisting of three fatty acids esterified to a glycerol backbone (Yen et al., 2008). The major 
function of TAG in living organisms is the storage of fatty acid molecules for energy utilization 
(Yen et al., 2008). In the adipose tissue TAGs are produced for energy storage (Yen et al., 
2008). In the liver, TAGs are produced for the assembly in very low-density lipoprotein 
(VLDL) particles to enable the transportation of neutral lipids to other tissues (Yen et al., 
2015). In the mammary gland, TAGs are synthetized in the form of milk fat globules, enabling 
fatty acid delivery to mammalian neonates (Yen et al., 2015). In the intestine, the synthesis of 
TAG is associated with the enterocytic absorption of dietary fats (Bach and Babayan, 1982; 
Yen et al., 2015).  
The synthesis of TAG and their storage in lipid droplets functions also as a protection 
mechanism of cells against the potential toxic effects of excessive intracellular free fatty 
acids and their acyl-CoAs (Yen et al., 2008; Aon et al., 2014). TAGs also play an important 
role in forming the moisture barrier of the skin and serve as an insulator (Coleman and 
Mashek, 2011). 
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Unphysiologically high concentrations of TAG in adipose tissue, however, are a key 
pathological feature of obesity (Yen et al., 2008). In the liver, an excessive TAG 
accumulation is associated with the pathology of NAFLD and insulin resistance (Ipsen et al., 
2018). In the heart, pathological TAG accumulation associates with cardiomyopathy (Unger, 
2002).  
1.2.2. TAG biosynthesis 
Biosynthesis of TAG can be accomplished via two different pathways, namely the glycerol 
phosphate pathway or the monoacylglycerol pathway (Yen et al., 2008). In the following, both 
pathways will be described in brief and are schematically summarized in Figure 2.  
In both pathways, fatty acids are utilized as acyl-CoAs by the enzymes involved in the 
respective steps. First, free fatty acids from the blood need to enter the cell. Although 
passive translocation is possible, this is mainly accomplished by fatty acid transport proteins 
(FATPs) and the fatty acid translocase, together with the plasma membrane associated fatty 
acid binding protein (FABPpm) (Doege and Stahl, 2006).  In order to maintain high oxidation 
rates, tissues like the liver, heart and skeletal muscle also have cytoplasmatic fatty acid 
binding proteins, facilitating faster intracellular fatty acid movement (Houten and Wanders, 
2010). Once inside the cell, the fatty acids are quickly activated as acyl-CoAs. Acyl-CoAs are 
synthetized via a thioesterification from a fatty acid with coenzyme A (CoA) by enzymes 
called acyl-CoA synthetases. Currently 26 genes were identified in the human genome 
encoding for this enzyme class (Watkins et al., 2007). Acyl-CoA synthetase are categorized 
in short-chain (ACSS), medium-chain (ACSM) and long chain (ACSL) CoA-synthetases 
according to the chain length of their preferred fatty acid substrate (Grevengoed et al., 2014).  
Glycerol-3-phosphate (G3P) is the initial acceptor substrate for the TAG synthesis via the 
glycerol phosphate pathway. In the liver it can be synthetized either from the glycolysis 
intermediate dihydroxyacetone phosphate (DHAP), from free plasma glycerol via glycerol 
kinase and from pyruvate originating from gluconeogenesis (Kalhan et al., 2001).  
The rate limiting step in TAG synthesis via the glycerol phosphate pathway is the sn1-
acylation of G3P with acyl-CoA, catalyzed by the glycerol-3-phosphate acyltransferase 
(GPAT) enzymes (Yamashita et al., 2014). This enzyme class has four known isoforms, with 
GPAT1 and 2 residing on mitochondria and GPAT3 and 4 locating to the ER, whereas 
GPAT4 has also been found on lipid droplets (Takeuchi and Reue, 2009; Wilfling et al., 
2013). The resulting 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid (LPA)) is further 
acylated with another acyl-CoA at the sn2 position of the glycerol backbone by enzymes of 
the 1-acylglycerol-3-phosphate acyltransferase (AGPAT) family, also named 
lysophosphatidic acid acyltransferases (LPAATs) (Takeuchi and Reue, 2009). This family 
consists of at least 10 described isoforms, having different enzymatic activities like GPAT- or 
lysophosphatidylcholine acyltransferase (LPCAT) activity (Yamashita et al., 2014). AGPAT1 
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and 2 are best characterized, both showing LPAAT activity for a broad spectrum acyl-CoAs 
in terms of chain length and saturation (Yamashita et al., 2014). Although both AGPAT1 and 
2 have a broad tissue distribution, AGPAT1 is mainly expressed in the testis, spleen and gut, 
whereas AGPAT2 is mainly expressed in the adipose tissue, liver, pancreas and heart 
(Yamashita et al., 2014). Both AGPAT1 and 2 are localized at the endoplasmic reticulum 
(ER) (Eberhardt et al., 1999). This reaction marks an important branching point in TAG 
synthesis, as  the resulting phosphatidic acid (PA) is not only a precursor for diacylglycerol 
(DAG) but also for Cytidine-diphosphate diacylglycerol (CDP-DAG), which itself is further 
metabolized to phosphatidylglycerol (PG) and phosphatidylinositol (PI) (Yamashita et al., 
2014).  
PA is dephosphorylated by a subfamily of enzymes from the phosphatidic acid phosphatase 
(PAP) family, also known as lipins. This gene family encodes for three members (Reue, 
2009). All three lipins show a unique tissue expression pattern, which suggests different 
physiological roles (Reue, 2009). PAPs in general have been shown to be localized in the 
cytosol and being translocated to the ER upon activation (Takeuchi and Reue, 2009); 
(Gomez-Muñoz et al., 1992). It has been shown that lipin1 is phosphorylated and 
translocated in an insulin-dependent manner (Harris et al., 2007).  
DAG is also synthetized via the monoacylglycerol (MAG) pathway, and both pathways 
converge at the final step of  TAG synthesis, acylating DAG to TAG (Yen et al., 2015).  
The MAG pathway occurs predominantly in the intestinal enterocytes, where MAG, as a 
product of dietary TAG hydrolysis, is acylated with acyl-CoA to DAG via monoacylglycerol 
acyltransferase (MGAT) activity (Shi and Cheng, 2009; Yen et al., 2015). So far, three 
isoforms of MGATs have been identified, all showing strong MGAT activity and are localized 
to the ER (Yen et al., 2002; Cheng et al., 2003; Cao et al., 2003). MGAT3 is only found in 
higher mammals and possesses a stronger sequence homology to DGAT2 than the other 
MGATs and is also shown to have DGAT activity (Cao et al., 2007). DAG itself is not only the 
immediate precursor for TAG but also for the two phospholipids phosphatidylcholine (PC) 
and phosphatidylethanolamine (PE).  Eventually, the last step of TAG synthesis is carried out 
by DGAT enzymes. 
1.2.3. DGAT enzymes: catalyzing the final step in TAG synthesis 
There are two enzymes known to catalyze the final step in TAG synthesis, namely DGAT1 
and DGAT2. These enzymes do not share a sequence homology and thus are associated 
with different gene families (Yen et al., 2008). The DGAT1 gene sequence is associated with 
the gene family of acyl-CoA:cholesterol acyltransferases (ACAT) (Cases et al., 1998), 
whereas the DGAT2 gene sequence is associated with a family which also includes MGATs 
and wax synthases (Yen et al., 2005a). Both enzymes exist in a variety of eukaryotes (Yen et 
al., 2008). DGAT1 and 2, have been proven experimentally to catalyze TAG synthesis from a 
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variety of FA-CoAs and DAG substrates, when overexpressed in either plant, insect or 
mammalian cells (Cases et al., 1998; Cases et al., 2001; Yen et al., 2008). DGAT1 has been 
shown to exhibit additional acyltransferase activity, catalyzing the synthesis of diglycerides, 
waxes and retinol esters (Yen et al., 2005b). The expression pattern of DGAT enzymes in 
humans is mostly similar to those in mice (Cases et al., 1998; Cases et al., 2001). Both 
enzymes are ubiquitously expressed but show distinct cellular and tissue specific expression 
patterns (Cases et al., 1998; Cases et al., 2001; Buhman et al., 2002). DGAT1 has its 
highest expression in the small intestine, adipose tissue and the mammary gland, but is also 
expressed in the liver (Li et al., 2015; Yen et al., 2015). DGAT2 has its highest expression 
level in the liver, the adipose tissue and as well in the mammary gland and the intestine (Yen 
et al., 2015; McLaren et al., 2018). Both DGATs are located at the ER and DGAT2 is also 
shown to localize on lipid droplets (LDs) (Stone et al., 2006; Kuerschner et al., 2008; Stone 
et al., 2009; Wurie et al., 2011). The metabolic importance of both DGATs is underlined 
through the phenotypes resulting from a global knockout of the enzymes in mouse models. A 
loss of DGAT2 is not compatible with life, as the newborn mice die shortly after birth, with 
severely reduced TAG levels and an impaired barrier function of the skin (Stone et al., 2004). 
A suppression of DGAT2 with antisense oligonucleotides has been shown to reverse a diet 
induced NAFLD phenotype in rats (Choi et al., 2007). DGAT1 knockout mice are viable, 
show a delayed intestinal fat absorption, have a higher energy expenditure and show a 
resistance towards high-fat diet induced obesity, insulin resistance and hepatic steatosis 
(Smith et al., 2000; Chen et al., 2002; Buhman et al., 2002). Additionally, a pharmacological 
inhibition of DGAT1 in Leptin deficient db/db mice also leads to reduced body weight, 
reduced hyperlipidemia and reduced hepatic steatosis in these animals (Zhang et al., 2010). 
Intestine specific overexpression of DGAT1 in a DGAT1-/--background reverses the effects of 
a global DGAT1 knockout. Despite of lacking DGAT1 in the liver and adipose tissue, the 
animals show no resistance towards HF diet-induced hepatic steatosis or obesity any more 
(Lee et al., 2010). In mice, DGAT1 deficiency is also associated with a congenital diarrheal 
disorder (Haas et al., 2012). Interestingly, this phenotype has also been shown for humans 
suffering from loss-of-function mutations of DGAT1 in the intestine (van Rijn et al., 2018). A 
intestine specific overexpression of DGAT2 leads to increased TAG secretion from the 
enterocytes and an increased response of hepatic TAG storage resulting in an exacerbated 
steatotic phenotype (Uchida et al., 2013).  
There are several publications, dealing with distinct preferences of acyl-CoAs in terms of 
chain length and saturation for both DGAT enzymes, as well as and the roles of both 
enzymes in cellular energy metabolism. In a study, using specific small molecules inhibitors 
against either DGAT enzymes in murine hepatocytes, it has been shown that DGAT1 and 2 
can compensate for each other in TAG synthesis, but that triacylglycerol synthesized by 
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DGAT1 is preferentially used for β-oxidation, whereas TAG synthetized by DGAT2 is 
destined for very low–density lipoprotein assembly (Li et al., 2015). It has been reported, that 
DGAT2 may act upstream of DGAT1 in utilizing nascent diglycerides with de-novo 
synthesized fatty acids (Wurie et al., 2012) and that DGAT1 catalyzes the synthesis of TAGs 
via utilization of exogenously supplied fatty acids (Qi et al., 2012).  
In an in vitro competition assay, mammalian DGAT1 which was expressed in insect cells 
favored monounsaturated oleoyl-CoA (C18:1) over saturated palmitoyl-CoA (C16:0), 
whereas another study concluded otherwise (Cases et al., 2001; Hiramine and Tanabe, 
2011). DGAT2 purified from the fungus Mortierella Ramanniana showed an enhanced 
activity towards the medium-chain acyl-CoA dodecanoic acid-CoA (C12:0-CoA) in 
comparison to oleoyl-CoA (C18:1) as well as higher activities with medium chain DAGs as 
acceptor substrates (Lardizabal et al., 2001). However, a seed specific DGAT1 isoform from 
the plant Cuphea avigera var pulcherrima has been identified, showing an enhanced activity 
towards the medium-chain acyl-CoA decanoic acid-CoA (C10:0-CoA) (Iskandarov et al., 
2017). This enhanced activity of DGAT1 towards medium-chain fatty acid acyl-CoAs has also 
been shown in seed oil production from other plant species (Aymé et al., 2015; Rigouin et al., 
2018). A study, dealing with the genetic diversity of DGAT1 transcripts in lactating river 
buffalos, revealed a variety of polymorphisms of the DGAT1 enzyme with association 
towards extreme phenotypes in milk fat content (Gu et al., 2017).   
Taken together, even though both DGAT enzymes have been subject to intensive research 
for decades, there are still many open questions regarding the distinct metabolic properties 
of both enzymes in cellular-, tissue and species-specific function on TAG synthesis.  
As the inhibition of both DGAT enzymes have been of interest as targets for the treatment of 
metabolic diseases like hepatic steatosis, obesity and diabetes, a variety of well 
characterized small molecule inhibitors, selectively targeting either DGAT1 or DGAT2, were 
developed and have also been utilized in this present work (Yen et al., 2008; King et al., 
2010; Qi et al., 2010; Qi et al., 2012; Li et al., 2015). 
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Figure 2: Schematic overview on the pathways involved in TAG synthesis as described in 
chapters 1.2.2 and 1.2.3. Abbreviations: FA-CoA: fatty acid-coenzyme A, GPAT: glycerol-phosphate 
acyltransferase, AGPAT: acylglycerol-phosphate acyltransferase, CDP-DAG: Cytidine-diphosphate 
diacylglycerol, PAP: phosphatidic acid phosphohydrolase, MGAT: acyl CoA: monoacylglycerol 
acyltransferase and DGAT1/2: diacylglycerol acyltransferases 1/2. Scheme is adapted from: (Yen et 
al., 2008).  
 
1.2.4. TAG mobilization and mitochondrial β-oxidation 
Upon cellular energy demand of the organism, the TAG depot, stored in the adipose tissue, 
is broken down and the generated free fatty acids (FFA) are transported to other tissues via 
the bloodstream bound to albumin for mitochondrial β-oxidation and ATP production (Lass et 
al., 2011). The process of cellular TAG storage and subsequent mobilization upon energy 
demand is not restricted to adipocytes (Lass et al., 2011). However, non-adipose cells do not 
secrete FFA, derived from intracellular TAG depots, but rather use them in an autonomous 
intracellular manner for β-oxidation or lipid synthesis (Lass et al., 2011).  The lipolysis of TAG 
is achieved by three lipases, the adipose triglyceride lipase (ATGL), the hormone sensitive 
lipase (HSL) and the monoacylglycerol lipase (MGL), which sequentially hydrolyze TAG, 
forming FFAs and glycerol. ATGL is the key enzyme which catalyzes the initial, rate limiting 
step in TAG hydrolysis in both adipose and non-adipose tissues (Zimmermann et al., 2004; 
Watt and Steinberg, 2008). In this first step, ATGL predominantly generates sn-1,3 and sn-
2,3 DAG (Eichmann et al., 2012). In the hepatic metabolism, resulting FFAs are either used 
for oxidation or for re-esterification at the ER, where newly synthetized TAGs are 
incorporated into apolipoprotein-B-containing VLDL for secretion and transportation to other 
tissues (Yao et al., 2013; Grasselli et al., 2015). DAG can be further hydrolyzed by HSL, 
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resulting in monoacylglycerol and a free fatty acid. HSL is mainly expressed in adipose 
tissue, and is stimulated by hormones like catecholamines, ACTH and glucagon, which is 
facilitated via phosphorylation through cyclic AMP dependent protein kinase (PKA) (Yeaman, 
1990; Kraemer and Shen, 2002). The resulting MAG is finally hydrolyzed by MGL, forming a 
last FFA and glycerol. MGL is a serine hydrolase, both found in the brain and peripheral 
tissues such as adipose tissue and heart (Karlsson et al., 1997). The free fatty acids from the 
subsequent hydrolysis steps are activated by thioesterification with CoA (see: Chapter 1.2.2). 
On demand, they will be used for lipid synthesis or for mitochondrial or peroxisomal β-
oxidation. Mitochondrial β-oxidation covers the major part of oxidation of short-, medium-, 
and long-chain fatty acids. LCFAs, originating from dietary fats represent the predominant 
source for energy production via oxidative phosphorylation generating ATP (Reddy and 
Hashimoto, 2001). The translocation of acyl-CoAs trough the mitochondrial membrane is 
facilitated by the carnitine shuttle system, although it has been proposed that the 
translocation of MCFA-CoAs can also be facilitated without the carnitine shuttle system 
(Bremer, 1983; Odle et al., 1991; Violante et al., 2013). The first enzyme involved is the 
carnitine palmitoyl transferase 1 (CPT1), catalyzing the conversion of acyl-CoAs to acyl-
carnitines (McGarry and Brown, 1997; Houten and Wanders, 2010). There exist at least two 
known isoforms of CPT1, namely the liver isoform (CPT1A), which has its highest expression 
in the liver, and the skeletal muscle isoform (CPT1B) which is highly expressed in the heart 
and skeletal muscle (Houten and Wanders, 2010). CPT1 is evidently induced by peroxisome 
proliferators (PPAR) and by fatty acids/ acyl-CoAs and can be inhibited by malonyl-CoA 
(Reddy and Hashimoto, 2001; Houten and Wanders, 2010). The acyl-carnitines present are 
translocated through the inner mitochondrial membrane via the carnitine-acylcarnitine 
translocase (CACT), exchanging carnitines from the mitochondrial matrix with acyl-carnitines 
form the intermembrane space. The acyl-carnitines are converted back into acyl-CoAs by the 
carnitine palmitoyltransferase 2 (CPT2), located at the inner mitochondrial membrane 
(Houten and Wanders, 2010). The acyl-CoAs are then able to enter the mitochondrial β-
oxidation cycle. 
The peroxisomal β-oxidation has been shown to additionally be present in all cells in which 
also mitochondrial β-oxidation is facilitated (Reddy and Hashimoto, 2001). Here, the process 
is catalyzed by different enzymes and plays a functionally complementary but different role 
(Reddy and Hashimoto, 2001). It has been shown that very long chain fatty acids (VLCFAs) 
with over 20 carbon atoms are almost exclusively β-oxidized in peroxisomes because 
mitochondria do not possess a very-long-chain acyl-CoA synthetase (Reddy and Hashimoto, 
2001). There is also experimental evidence, showing a compensation in acylcarnitine levels 
through peroxisomal metabolism, when mitochondrial β-oxidation is deficient or overloaded 
(Violante et al., 2013).  
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1.3. Click labeling in lipid research 
In order to follow the metabolism or cellular localization of any lipid of interest, preferably the 
molecule needs to have a label, which can be used for the detection method of choice. In 
contrast to proteins, lipids cannot be modified with genetically encoded reporters, for 
instance by attaching a traceable tag to the protein of interest through a molecular cloning 
approach. Lipids need to be modified chemically and the tags need to be as small as 
possible, that their structure does not interfere with the biochemical properties of the lipid in 
the cellular environment. For decades, isotopes such as carbon (14C) or deuterium (D) have 
been used for this purpose (Rittenberg, D., and R. Schoenheimer, 1937). Isotope labeling 
does not interfere with the biochemical properties of the lipid and it allows its detection by 
several methods including chromatography or MS. Drawbacks of this technology however 
are the high expense of isotope labeled lipids and the need for specialized laboratories and 
regulations, when working with radioactivity. Also, radioactive isotopes, relevant for fatty acid 
tracing (14C and 3H), have moderate to low specific activities and therefore this detection 
method is limited in sensitivity or requires long exposure times to generate meaningful results 
(Thiele et al., 2012). Another approach to generate a labeled molecule which is traceable in 
living systems, is the use of biorthogonal chemical reactions and labels (Sletten and Bertozzi, 
2009). One of these reactions is the 1,3-dipolar [3+2] cycloaddition of terminal alkynes with 
an azide under high temperatures or pressures, originally described by Huisgen in 1963 
(Huisgen, 1963). In 2002, two independent groups (Tornøe et al., 2002; Rostovtsev et al., 
2002) described that the addition of Cu(I) as a catalyst could enable the reaction under mild 
conditions at room temperature (Figure 3), thus making it more suitable for the use in 
biological systems. 
Figure 3: Schematic visualization of the Cu(I) catalyzed click reaction.   
 
Since then, the use of an alkyne group as a small biorthogonal label, found its way into 
biological applications. 
Our group has established several methods in which lipids, labeled with terminal alkynes, are 
used to trace lipid metabolism (Thiele et al., 2012; Gaebler et al., 2013; Gaebler et al., 2016).  
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When fed to cells, the fatty acids are incorporated into cellular lipids in a similar manner as 
their native counterparts (Thiele et al., 2012).  
After lipid extraction, the alkyne labeled lipid can be reacted with any suitable azido-labeled 
reporter group for further detection. In this work, two different detection methods, developed 
in our group, were used. One is the reaction of the alkyne labeled lipids to azido-coumarin, 
followed by lipid separation through thin layer chromatography (TLC) and the visualization by 
fluorescent imaging (Figure 4): 
 
Figure 4: Schematic visualization of the workflow used to trace lipid metabolism with alkyne 
labeled fatty acids with the use of azido-coumarin as a fluorescent dye. Alkyne labeled oleate is 
fed to cells and once metabolized, it results in a variety of alkyne labeled lipid species. The lipids are 
then extracted and clicked to azido-coumarin. The clicked lipids are separated on a TLC and the 
fluorescent coumarin signal is captured. Figure is adapted from: (Thiele et al., 2012).  
 
Although this method is a fast and versatile tool, enabling a broad range coverage of 
metabolic pathways in lipid biochemistry, it has limitations in terms of lipid species resolution. 
Here the sum of all species within a lipid class is represented in one band on the TLC plate. 
In order to analyze species within the lipid class, a detection method with a higher resolution 
is required.  
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The study of the lipidome by MS finds its biggest challenge in the complexity of lipid extracts 
from biological sources with hundreds of lipid classes subdivided in thousands of lipid 
species (Brügger, 2014). Brügger and colleagues were the first to approach the quantitative 
analysis of membrane lipids from unprocessed lipid extracts via tandem MS (Brügger et al., 
1997). This approach was further refined by Ejsing and colleagues, who established a global 
analysis of the yeast lipidome by quantitative shotgun MS, as an efficient resource for 
eukaryotic lipidome analysis (Ejsing et al., 2009).   
Characterization of lipids in MS predominantly uses heated electrospray ionization (heated 
ESI) as a soft ionization technique with minimal in-source fragmentation, generating positive 
or negative lipid ions (Fenn et al., 1989). For modern lipidomics, mass spectrometers with 
high mass resolution and high accuracy such as hybrid orbitrap tandem mass spectrometers 
are used. In tandem MS (MS/MS), ions are first separated by their mass-to-charge ratio 
(m/z). So called precursor ions with a distinct (m/z)-ratio are then selected and collided with 
an inert gas (e.g. nitrogen) in a collision cell. The process which follows is called collisionally 
activated dissociation (CAD). Precursor ions are fragmented into product ions and 
corresponding neutral fragments, which are termed neutral loss (NL). By applying high 
resolution tandem mass spectrometers with precursor ion and neutral loss scanning to the 
shotgun-lipidomics approach (Han and Gross, 2005), it became possible to distinguish 
between most isobaric lipid species from different lipid classes within total cellular lipid 
extracts (Schwudke et al., 2011).   
The use of stable heavy isotopes is an established method for tracing and, to some extent, 
also applicable for MS. However, identification and quantification of metabolites originated 
from isotope labeled compounds in cellular extracts comprises an even bigger challenge, 
especially tracing fatty acid metabolism with hundreds of possible metabolic products (Parks 
and Hellerstein, 2006).  
Our group has recently developed several azido-labeled reporter compounds which can be 
detected by tandem MS, transferring the advantages of alkyne-labeled lipid tracing to this 
technology and enabling lipid species resolution with high sensitivity (Thiele et al., 2019) 
One of these reporter groups is the compound C171 (Figure 5). It consists of a quaternary 
ammonium group, a C4 linker and an azido group for click reacting it to terminal alkynes. 
This structure offers three features for mass spectrometric detection. First, the 
permanent positive charge of the quaternary ammonium group enhances the ionization of 
the labeled lipid. This effectively enhances the transmission into the mass spectrometer, 
especially for neutral lipid species such as TAG. Second, when reacted, C171 gives all 
labeled lipids a nominal mass shift of +171 Da, allowing direct detection in the mass 
spectrometer. Third, upon collision in MS/MS analysis, the reacted C171 shows a 
characteristic fragmentation pattern with a characteristic neutral loss (NL) of 73.09 Da, 
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corresponding to the dimethlyethlyamine group eliminated at low collision energies in the 
orbitrap (Figure 5). 
Figure 5: Structure, click reaction and fragmentation pattern of the compound C171. The azido 
labeled compound is first reacted with an alkyne labeled lipid (R) via the Cu(I) catalyzed click reaction, 
giving it a mass shift of 171 Da. Upon collision during a tandem MS analysis (MS/MS), reacted C171 
shows a fragmentation pattern with a stereotypic neutral loss (NL) of 73.09 Da and the corresponding 
fragment ion. 
 
This NL can be used as a diagnostic reaction applicable for a variety of lipid species 
(Thiele et al., 2019). Both, the mass shift of 171 Da and the neutral loss of 73.09 Da in 
MS/MS analysis, can be used for automated computational identification of the labeled lipids 
by the LipidXplorer program (Herzog et al., 2011).  
Furthermore, our group transferred the methodology of using isobaric labeling for MS/MS- 
based multiplex analysis on the C171 reporter compound. 
In Proteomics, the use of isobaric labeling is a well-established methodology, namely TMT 
(Tandem Mass Tags (Thompson et al., 2003)) and iTRAQ (isobaric Tags for Relative and 
Absolute Quantification (Ross et al., 2004)), for analyzing several biological samples at once. 
This increases sample throughput and reduces inaccuracies such as technical background 
noise.  
Our approach on lipid analysis benefits strongly form multiplexing due to many technical 
difficulties in sample processing, such as handling small volumes of organic solvents in the 
extraction process or spray- and fragmentation- variations in the mass spectrometer.  
For combining the benefits of multiplex analysis with the properties of the C171 reporter 
compound for MS, different combinations of deuterium- and 13C-atoms were used to 
generate four isobarically labeled C171 compounds (Figure 6, A) (Thiele et al., 2019). 
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Figure 6: Structures (A) and biological application (B) of the isobarically labeled C171 
compounds for multiplex analysis. A: The compound C171 has been modified with specific 
combinations of deuterium- and 13C-atoms, in order to establish four different compounds bearing 
nearly identical masses of 175,18 Da. In MS2 fragmentation however, all four compounds generate 
different neutral losses of either 73 Da (C175-73, A), 75 Da (C175-75, B), 76 Da (C175-76, C) and 77 
Da (C175-77, D). B: Lipid extractions from four different biological samples with alkyne labeled lipids 
are individually reacted with one C175-XX compound each, pooled and analyzed by MS. In MS all 
labeled lipids from each sample are detected with the same monoisotopic mass. Fragmentation during 
MS/MS leads to four different neutral losses and their corresponding fragment ion, each representing 
its original sample. R=lipid residue, L=label, H=Headgroup, MS=Mass spectrometry, MS/MS=tandem 
mass spectrometry. 
 
All resulting molecules bear nearly identical masses of 175,18 Da in MS1 analysis, but have 
different neutral losses of 73 Da, 75 Da, 76 Da and 77 Da in their MS/MS fragmentation 
pattern. In the following work they are referred to as C175-XX. These properties allow the 
analysis of four biological samples at once using MS/MS (Figure 6, B). Normalization to the 
internal alkyne labeled standards used in this work, namely TAG, DAG, PC, PA, CE, Cer and 
a double labeled TAG, allows the absolute quantification of these lipid classes under 
experimental conditions.  
In this work the click labeling method for either TLC or MS application was used to 
investigate the hepatic metabolism of DGAT-dependent MCFA incorporation into TAG under 
the influence of small molecule inhibitors, targeting either DGAT enzymes or mitochondrial 
CPT1.  
All MS-based experiments presented in this work were accomplished with the use of the 
C175-XX compounds.  
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2. Aim of the Thesis 
The work in this thesis continues the previous study from our group by K. Klizaite (Klizaite, 
2017). There, it was hypothesized that in hepatocytes DGAT2 might play a predominant role 
over DGAT1 in MCFA-TAG synthesis and that MCFA-CoAs for DGAT-dependent TAG 
synthesis are provided in a CPT1-dependent manner. 
This thesis aims to deepen the understanding of the MCFA metabolism in primary murine 
hepatocytes, following the two hypotheses by focusing on these key questions: 
 
• Does one of the DGAT enzymes play a predominant role in hepatic MCFA 
incorporation into TAG?  
• Is the effect of diminished MCFA incorporation into TAG caused by Etomoxir due to 
its CPT1-specific inhibition, or generated by a possible off-target effect of the 
inhibitor? 
• Does a loss of DGAT1 in hepatocytes affect the MCFA incorporation into TAG, and is 
this comparable to the effects of a DGAT1-specific inhibition? 
• How does the inhibition of DGAT enzymes affect the hepatic lipid metabolism during 
an LPS-induced short term inflammatory response? 
• Are the effects caused by Etomoxir reproducible, using another CPT1 inhibitor? 
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3. Material 
3.1. Chemicals and reagents 
Name Source 
3-azido-7-hydroxycoumarin C. Thiele (Thiele et al., 2012) 
Acetic acid (AcA) VWR International GmbH 
Acetonitrile (ACN) VWR International GmbH 
CaCl2 · 2H2O AppliChem GmbH 
Chloroform (CHCl3), stabilized with          
0.9 % EtOH 
VWR International GmbH 
Collagen (type I) from rat tail Sigma Aldrich/ Merck KgaA 
Collagenase NB G4 from Clostridium 
histolyticum 
Nordmark Arzneimittel GmbH 
Dimethyl-Sulfoxide (DMSO) Sigma Aldrich/ Merck KgaA 
EGTA Carl Roth GmbH 
Ethanol (EtOH) VWR International GmbH 
Ethyl acetate  VWR International GmbH 
HBSS (Hanks’ Balanced Salt Solution)  Sigma Aldrich/ Merck KgaA 
Heparin-Natrium-25000-ratiopharm® Ratiopharm GmbH 
Hexane (mixture of isomers) VWR International GmbH 
Hünig’s base                                                             
(N,N-diisopropylethylamine) 
Sigma Aldrich/ Merck KgaA 
isotonic 0.9 % NaCl solution B. Braun Melsungen AG 
KCl Sigma Aldrich/ Merck KgaA 
KH2PO4 Sigma Aldrich/ Merck KgaA 
LC-MS grade acetic acid (LiChropur®) Sigma Aldrich/ Merck KgaA 
LC-MS grade isopropanol (LiChrosolv®) VWR International GmbH 
LC-MS grade methanol (LiChrosolv®) VWR International GmbH 
LC-MS grade water (Chromanorm®) VWR International GmbH 
LPS O111:B4 from E. coli  Sigma Aldrich/ Merck KgaA 
Methanol (MeOH) VWR International GmbH 
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Na2HPO4 Sigma Aldrich/ Merck KgaA 
NaCl AppliChem GmbH 
NaOH (sodium hydroxide pellets) Honeywell 
Narketan 100 mg/ml 
(Ketaminhydrochloride) 
Vetoquinol GmbH 
Rompun 2% (Xylazinhydrochloride) Bayer AG 
Tetrakis(acetonitrile)copper(I) 
Tetrafluoroborate 
TCI Deutschland GmbH 
Trypan blue solution  Sigma Aldrich/ Merck KgaA 
 
3.2. Cell culture media and supplements 
Product Source 
Fetal Calf Serum  Thermo Fisher Scientific Inc.  
L-glutamine Solution 200 mM (100x) Thermo Fisher Scientific Inc.  
Penicillin-Streptomycin Solution (100x) Thermo Fisher Scientific Inc.  
Seahorse XF RPMI Medium  Agilent Technologies  
William’s medium E PAN Biotech GmbH 
 
 
3.3. Consumables 
Product Source 
1.5 ml reaction tubes Sarstedt AG & Co 
 
1.5 ml reaction tubes “Eppis”,  
for MS applications 
Eppendorf AG 
Biosphere® filter Tip 10 µl, 200 µl,  
1000 µl, for cell culture applications 
Sarstedt AG & Co 
Cannula BD Neoflon™ 26 G 
0.6 x 19 mm, 13 ml/min 
BD Biosciences 
Capillaries, sodalime-glass, cut ends 
100 mm length, 0.1 mm outer diameter 
Hilgenberg GmbH 
Cell strainer, 100 µm Sarstedt AG & Co 
Falcon™ tubes 25 ml, 50 ml  Corning Inc. 
Fast-Read 102® cell counting chambers VWR International GmbH 
Pasteur pipets, glass, long tip VWR International GmbH 
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Pipet tips 10 µl, 200 µl, 1000 µl  Sarstedt AG & Co 
Pipet tips 10 µl, 200 µl, 1000 µl, for MS 
applications 
Eppendorf AG 
Seahorse XF Calibrant solution Agilent Technologies 
Seahorse XF96 cell culture microplates Agilent Technologies 
Seahorse XF96 sensor cartridge Agilent Technologies 
Serological pipets 5ml, 10ml, 25 ml Sarstedt AG & Co 
Syringe 1ml Sub-Q, 26 G, 
0.45 mm x 12,7 mm 
BD Biosciences 
TC 24 well plate, Standard Sarstedt AG & Co 
TLC plates (glass), TLC silica gel 60 Merck KgaA 
 
3.4. Small molecule inhibitors 
Name Producer, CAS or Catalogue Number 
Etomoxir (Eto) Cayman Chemical, CAS № 828934-41-4 
A922500 (D1) Sigma-Aldrich, Cat. No. A1737 
JNJ-DGAT2A (D2) Tocris, Cat. No. 5853 
PF-04620110 (PFD1) Pfizer/Sigma-Aldrich, Cat. No. PZ0207 
PF-06424439 (PFD2) Pfizer/Sigma-Aldrich, Cat. No. PZ0233 
ST1326/Teglicar (Tegli) Avanti Polar Lipids, Cat. No. 870853 
 
3.5. General solutions 
Name Contents 
10x Phosphate Buffered Saline (PBS)  
for 1000 ml 
80 g NaCl                                                         
2.0 g KCl                                                                    
14.4 g Na2HPO4                                                                             
2.4 g KH2PO4                                                                                                        
in ddH2O                                                                                   
adjust to pH 7.4                                                  
1x PBS  Diluted from 10x PBS  
Ammonium acetate solution (100 mM) 7.708 g ammonium acetate in 1000 ml 
ddH2O 
EGTA solution (100 mM) 9,509 g in 250 ml ddH2O, adjust to pH 8.01,   
sterile filtered 
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CaCl2 solution (2,5 M) 18.376 g in 50 ml ddH2O, sterile filtered 
HBSS (Hanks’ Balanced Salt Solution) with 
NaHCO3- 
1 Package (HBSS, 9.5 g), 0.35 g NaHCO3-       
in 1 l ddH2O  
Ketamin/Xylazin solution 1:1 in 10 parts isotonic 0.9 % NaCl solution  
LPS for injection 1 mg/ml in sterile ddH2O 
Collagen solution  0.33 mg/ml rat tail collagen in sterile 0.2% 
acetic acid 
 
3.6. Equipment 
Name Company 
Accu-Jet® pro, pipette controller  Brand GmbH & Co KG 
ATC2000 (Animal Temperature Controller) World Precision Instruments 
Centrifuge 5424 Eppendorf GmbH 
Centrifuge Allegra® X-15R Beckman Coulter GmbH 
CO2 Incubator Midi 40 Thermo Fisher Scientific Inc. 
Concentrator Plus  
Vacuum concentrator 
Eppendorf GmbH 
Eppendorf Research® plus pipettes: 
2,5 µl, 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl 
Eppendorf GmbH 
Fusion 101, dual channel syringe pump Chemyx Inc. 
Gastight Syringes (500 µl (1700 series), 
1000 µl (1000 series) 
Borosilicate glass, PTFE 
Hamilton Company 
Heatlamp (150 W) 
 
Local Zoo Shop 
Peristaltic Pump Drive PD 5001 Heidolph Instruments GmbH 
Q Exactive™ Plus Hybrid Quadrupole-
Orbitrap™ mass spectrometer 
Thermo Fisher Scientific Inc. 
Rolera MGI plus EMCCD camera Decon science Tec GmbH 
ThermoStat Plus, Thermoblock system Eppendorf GmbH 
TLC developing chamber for a 20 x 20 cm 
plate 
VWR International GmbH 
Vacuum pump, Vacusafe comfort  INTEGRA Biosciences AG 
Vortex Genie 2 Scientific Industries Inc. 
Water bath  Memmert GmbH 
Seahorse XF 96 Analyzer Agilent Technologies 
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3.7. Computer programs 
Name Usage Company/Developer 
ImageJ Image processing Wayne Rasband (NIH) 
Microsoft Office 2019 Word processing, 
Spreadsheed calculations, 
Image processing 
Microsoft Corporation 
Adobe Illustrator CS5 Image processing Adobe Systems Inc. 
GelPro Analyzer 6.0 Analysis of TLC plates  Media Cybernetics 
GraphPad Prism 6, 7  Statistics, Data processing GraphPad Software Inc. 
Seahorse Wave Controller 
2.4  
Seahorse XF Analyzer: 
instrument control and data 
acquisition/ processing 
Agilent Technologies 
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3.8. Alkyne labeled lipids and their nomenclature 
All experiments presented in this work used alkyne labeled fatty acids.  
Three alkyne fatty acids, termed C11, C17:2 and C19, were chosen to trace MCFA-, 
saturated LCFA- and monounsaturated LCFA-metabolism, respectively (see: Figure 7). 
  
Figure 7: Structure of alkyne labeled lipids used for metabolic tracing. The underlined simplified 
names are used throughout the text. A (C11): 10-Undecynoic acid (alkyne-decanoic acid, C11:2). B 
(C17:2): 16-Heptadecynoic acid (alkyne-palmitate). C: (C19): Nonadec-9-cis-en-18-ynoic acid (alkyne-
oleate, C19:3). 
 
In experiments, where the alkyne metabolites are detected through TLC, the resulting lipid 
classes are designated with the addition of the respective alkyne-FA name. For example, 
TAGs that have one C11-FA incorporated are named C11-TAGs, representing the group of 
MCFA-TAGs (or MCTs). The same naming scheme is used for C17:2- and C19-FAs, both 
resembling groups of LCFA-TAGs (or LCTs). 
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Alkyne-palmitate (C17:2) was used in all experiments in which the labeled lipids were 
analyzed through MS. Since MS enables lipid species resolution (chapter 1.3), a broad 
variety of alkyne labeled lipid species within all analyzed lipid classes can be detected and 
analyzed.  
Yet, in comparison to their natural counterparts, all alkyne labeled fatty acids used here 
contain one more c-atom and two additional double bonds due to the alkyne group. This 
results in odd numbered and seemingly double unsaturated lipid species, when an alkyne 
fatty acid was metabolically incorporated. As an example, Figure 8 shows a TAG-molecule 
where alkyne-palmitate was introduced. 
 
Figure 8: Structure of triacylglycerol labeled with alkyne palmitate (C17:2). R1 and R2 stand for 
any other fatty acid, incorporated into the molecule. 
 
Assuming, that R1 is decanoic acid (C10:0) and R2 is oleic acid (C18:1), this TAG molecule 
would be named as TAG [45:3], for C17:2 + C18:1 + C10:0. In contrary, when natural 
palmitate (C16:0) would have been introduced the resulting TAG molecule would be stated 
as TAG [44:1], for C16:0 + C18:1 + C10:0. This applies to all lipid species. In this thesis, a 
TAG molecule, consisting of alkyne-palmitate (C17:2), one molecule of decanoic acid 
(C10:0) and one more additional fatty acid, resulting in a total number of carbon atoms of 47 
or below is defined as an MCFA-TAG. All analyses of the lipid species TAG, DAG, PC and 
PA which are presented in this work, were applied on single alkyne labeled lipids. These lipid 
molecules are a single alkyne labeled FA and are named aTAG, aDAG, aPC and aPA. For 
information regarding double alkyne-labeled lipid species, see: Supplementary chapter 10.3. 
Absolute quantification of the lipid classes aTAG, aDAG, aPC, aPA, aCeramide (aCer), 
aCholesterol ester (aCE) and dlTAG were accomplished using internal standards (see: Table 
2). As absolute amounts of alkyne labeled Cer and CE species were very low (always under 
10 pmol total), these species were only included in calculations for relative amounts (mol per 
mille) and not included in any figures. On the validation of the accuracy of the internal 
standardization, see: Supplementary chapter 10.4.           
All alkyne labeled lipids, including all internal standards used for MS analysis, were 
synthesized by Prof. Dr. C. Thiele (see: Table 1 and 2) except the commercially available 
C11 FA. Detailed information on the synthesis protocol for alkyne-palmitate and alkyne-
oleate is published in: (Thiele et al., 2012). The synthesis protocol for the alkyne labeled lipid 
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species used as internal standards for MS analysis is published in: (Thiele et al., 2019). As a 
native MCFA, decanoic acid (C10) was used (see: Table 1). 
 
Table 1: Name and composition of the stock solution from the alkyne labeled fatty acids/ native 
decanoic acid used for metabolic tracing.  
Alkyne/native lipid (Name used in 
thesis), stock solution compostition 
Producer/Source 
C11 (alkyne-decanoic acid),                   
14.7 mM in 80% EtOH 
TCI Deutschland GmbH 
C17:2 (alkyne-palmitate),                                                        
20 mM in 80% EtOH 
Synthesis by Prof. Dr. C. Thiele 
C19 (alkyne-oleate),                                                    
100 mM in 80 % EtOH 
Synthesis by Prof. Dr. C. Thiele 
C10 (Decanoic acid, C10:0),  
20 mM in 80% EtOH 
Sigma Aldrich/ Merck KgaA 
 
Table 2: Name, synthesis procedure and masses of alkyne labeled lipids used as internal 
standards for MS analysis.  
Standard name Synthesis procedure Calculated and measured 
masses (m/z) 
aPC (16:0/a18:3) Acylation of LPC (16:0) using 
EDC/DMAP 
[M+H]+  
measured: 756.551  
calculated: 756.554 
 
aPA (a17:2/17:1) Acylation of sn-glycerol-3 
diethylphosphate and  
subsequent deprotection with 
bromotrimethylsilane  
(Gaebler et al., 2013) 
[M-H]-  
measured: 669.451  
calculated: 669.450 
aCer (d18:1/a18:3) Acylation of sphingosine with 
a18:3-NHS 
[M+H]+  
measured: 560.502  
calculated: 560.504 
aTAG (14:0/17:1/a17:2) Acylation of DAG (14:0/17:1) 
using EDC/DMAP 
[M+NH4]+ 
measured: 818.721  
calculated: 818.723 
aCE (a18:3) Acylation of cholesterol using 
EDC/DMAP 
[M+NH4]+  
measured: 664.602  
calculated: 664.603 
aDAG (a17:2/15:0) Acylation of MA 
G (a17:2) using EDC/DMAP 
[M+NH4]+ 
measured: 582.508  
calculated: 582.509 
dlTAG 
(a17:2/15:0/a19:3) 
Acylation of DAG (a17:2/15:0) 
using EDC/DMAP 
[M+NH4]+ 
measured: 856.735  
calculated: 856.739 
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4. Methods 
4.1. Animal experiments 
As a mouse strain, the C57Bl/6NCrl strain from Jackson Laboratories was used. 
Mice were kept on a regular light-dark cycle (12/12 h) in a specific, pathogen free 
environment, using ventilation cages at 21± 2ºC room temperature and 55±5 % humidity. 
The animals were kept ad libitum on a regular chow diet (LASQCdiet® Rod16 (main caloric 
intake: fat 4.3%, protein 16.9%)) from LASvendi, in Soest, Germany. 
For all experiments, male mice aged for 8 weeks were used. 
All animal experiments were performed according to the European Directive 2010/63/EU in 
compliance with national laws (deutsches Tierschutzgesetz vom 01.01.2019, Tierschutz-
Versuchstierordnung vom 13.08.2013). 
For the experiments done in collaboration with Christina Leopold (PhD) within the group of 
Prof. Dr. Dagmar Kratky at the Medical University of Graz, Austria, DGAT1-/- mice (Smith et 
al., 2000) and respective WT control animals were used. These animals were aged for 10-12 
weeks, and as well kept at a regular light-dark cycle (12 h/12 h) in a clean and temperature-
controlled environment and fed a regular chow diet (11.9% caloric intake from fat; Altromin 
Spezialfutter GmbH, Lage, Germany). All animal experiments were performed according to 
the European Directive 2010/63/EU in compliance with national laws and approved by the 
Austrian Federal Ministry of Education, Science and Research, Division of Genetic 
Engineering and Animal Experiments, Vienna, Austria 
4.1.1. Induction of an in vivo LPS-stimulation 
For an in vivo LPS-stimulation, 8 weeks old, WT C57Bl6/NCrl males were weighted and i.p. 
injected with 15 mg/kg LPS according to their respective weight. During the incubation time 
of 1.5 hours, the animals were kept ad libitum with water and food. After incubation, the mice 
were proceeded for liver perfusion, followed by isolation of primary hepatocytes (see: 
Chapter: 4.2.2.).  
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4.2. Primary hepatocyte cell culture 
All experiments in this work were performed on murine primary hepatocytes, which were 
freshly isolated on the day of the experiment, using the procedure as described below.  
4.2.1. Collagen coating of cell culture plates 
The cell culture plates used for cultivation of primary hepatocytes were coated with rat tail 
collagen, in order to generate an environment which mimics some properties of the liver 
extracellular matrix, to ensure a good adhesion of the cells. For collagenization, 200 µl sterile 
collagen-solution (see: Materials 3.5.) was added per well of a 24 well plate and allowed to 
incubate for 30 minutes at room temperature. This procedure was done under sterile 
conditions in a cell culture hood. After the incubation, the solution was removed and stored 
for further usage (up to five times) at 4 ºC. The plates were dried under UV-light radiation in 
the cell culture hood and stored at room temperature for up to 2 weeks.  
4.2.2. Liver perfusion and isolation of primary hepatocytes 
Primary hepatocytes were isolated by collagenase perfusion of the liver by an adapted 
protocol as previously described (Berry, 1969; Kaytor et al., 1997; Stoeckman and Towle, 
2002). 
All buffers and solutions (see: Table 3) used for the procedure were prewarmed in a water at 
37ºC. A mouse was first injected i.p. with 200 µl heparin solution. After 10 minutes the animal 
was given an intraperitoneal injection of a Ketamin/Xylazin mixture. Anesthetic depth of the 
animal was monitored by pinching the feet, using surgical forceps. When the mouse was in 
deep anesthesia, it was fixed at a surgical desk. The abdomen was cut open and the 
intestine moved to the right side in order to expose the portal vein. Once exposed, the portal 
vein was picked using a butterfly canula with the catheter attached to a “third hand” in order 
to keep the catheter in place. Then the catheter was connected to the tube from the 
peristaltic pump, and the liver was perfused with pre-perfusion buffer (see: Table 3) for 2 min 
at a flow rate of 4 ml/min corresponding to 52 rpm. During this time a rectal temperature 
probe was attached on top of the liver and a thermal heat lamp was used so keep the liver at 
37ºC. After these procedures the tubing was changed to the perfusion buffer (see: Table 3) 
containing the collagenase. The liver was perfused with 20 ml of the buffer for about seven 
minutes. Afterwards the liver was carefully dissected by cutting into the diaphragm and 
attaching blood vessels. A beaker glass was filled with 40 ml of prewarmed adhesion 
medium (see: Table 3) in which the liver was shaken and rubbed against the glass in order to 
dissolve the liver. The achieved liver cell suspension was transferred into a falcon tube and 
centrifuged at 20 g for 2 minutes. 
The supernatant was removed, and the pellet containing the hepatocytes was resuspended 
again in 40 ml prewarmed adhesion medium. The suspension was passed through a 100 µm 
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cell strainer into a fresh falcon tube. The living cell number was assessed in a cell counting 
chamber using trypan blue staining. Once counted, 7.5 x 104 cells were plated in every well 
of a 24-well plate. All plates were pre coated with collagen (see: Chapter: 4.2.1.). The plated 
hepatocytes were allowed to adhere for two hours. The cells were kept at 37ºC and 5% CO2 
in a humidified incubator. Prior the experiment the medium was removed, and the cells were 
washed once with prewarmed adhesion medium. 
 
Table 3: Buffers and media used for hepatocyte isolation. 
Name Composition 
Pre-perfusion Buffer 50 µl Heparin (25000 i.E/ 5ml)                                                                                 
250 µl EGTA (100 mM EGTA, pH 7.4 in ddH2O, sterile filtered)                                                    
in 50 ml HBSS (Hanks’ Balanced Salt solution + 0.35 g/l NaHCO3) 
Perfusion Buffer 36 µl 2.5 M CaCl2                                                                                      
250 µl Collagenase (0.35 U/ml) in dd in ddH2O                                          
in 25 ml Williams Medium E (w/o any supplements)  
Adhesion Medium Williams Medium E, supplemented with:                                                                                  
10 % (v/v) fetal calf serum                                                                                
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution   
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4.3. Metabolic lipid tracing  
In order to analyze the hepatic lipid metabolism upon different experimental conditions, 
alkyne labeled lipids were used (see: Chapter 3.8.) in either pulse or pulse-chase 
experiments. All experimental conditions were carried out as technical triplicate 
determinations. After the respective labeling experiment, the lipids were extracted and 
processed for either TLC or quantitative lipidomic MS (see: Chapters 4.4.1 and 4.4.2 for 
extraction and click reaction and Chapters 4.5.1 and 4.5.2 for detection). In the following 
these experimental procedures are described.  
4.3.1. Pulse experiments 
These experiments were carried out in 24-well plates with 7.5 x 104 cells per well. 
Hepatocytes were preincubated with either small-molecule inhibitors in various combinations 
(see: Materials 3.4) or the respective vehicle as a negative control in 400 µl preincubation 
medium for one hour (see: Table 4). Following the preincubation 100 µl pulse medium, 
containing different combinations of alkyne-labeled and native fatty acids (see: Table 4) was 
added. After one hour of incubation (pulse) the cells were washed once with cold adhesion 
medium (see: Table 3). The second washing step was done with either ice cold 1xPBS or ice 
cold 100 mM ammonium acetate, depending on the lipid extraction procedure. 1xPBS was 
used in the extraction protocol prior to TLC while ammonium acetate was used in the 
extraction procedure prior to quantitative lipidomic MS. After the last washing step, as much 
liquid was removed as possible, and the plates were either stored at -80ºC until the lipid 
extraction procedure or extracted directly. 
 
Table 4: Media used for pulse experiments. Inhibitor and fatty acid concentrations are stated as 
final assay concentrations. 
Name Basic composition Inhibitors /  
Fatty acids 
Preincubation 
Medium 
Williams Medium E, supplemented with:                                                                                      
10 % (v/v) fetal calf serum                                                                                
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution   
- 50 µM Eto in ddH2O
- 3 µM D1 in DMSO                     
- 15 µM D2 in DMSO
- 5 µM PFD1 in DMSO              
- 5 µM PFD2 in ddH2O             
- 10, 20, 50 µM Teglicar                      
d in DMSO                                                            
Pulse 
Medium 
Williams Medium E, supplemented with:                                                                                      
10 % (v/v) fetal calf serum                                                                                
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution   
- 50 µM C11
- 50 µM C17:2      
- 50 µM C19                                   
- 50 µM C10  
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4.3.2. Pulse-chase experiments 
In order to analyze the dynamics of the hepatic lipid metabolism with a special focus on the 
DGAT1-dependent incorporation of medium chain fatty acids into TAG, a pulse-chase 
experiment (Hou et al., 2013) with alkyne palmitate as a lipid tracer was carried out.  
The experiments were performed in 24-well plates with 7.5 x 104 cells per well. The cells 
were preincubated with either a DGAT1-inhibitor, Etomoxir, a combination of both inhibitors, 
and the respective vehicle as a negative control in 400 µl preincubation medium for one hour 
(see: Table 5). Then 100 µl pulse medium (see: Table 5) was added for two minutes. After 
the incubation, the pulse medium was discarded, and the cells washed rapidly with 500 µl 
prewarmed adhesion medium (see: Table 3). Then, 250 µl prewarmed Chase medium, 
containing unlabeled decanoic acid and the respective inhibitor combination (see: Table 5), 
was added to each well. Lipid metabolism was stopped after different time points by washing 
the cells once with ice cold adhesion medium and once with ice cold 100 mM ammonium 
acetate, taking care to remove as much liquid as possible after the last washing step. Cells 
were then frozen at -80ºC until the lipid extraction procedure. 
 
Table 5: Media used for pulse-chase experiments. Inhibitor and fatty acid concentrations are stated 
as final assay concentrations. 
Name Basic composition Inhibitors /  
Fatty acids 
Preincubation 
Medium 
Williams Medium E, supplemented with:                                                                                      
10 % (v/v) fetal calf serum                                                                                
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution   
- 50 µM Eto in ddH2O
- 3 µM D1 in DMSO                    
Pulse 
Medium 
Williams Medium E, supplemented with:                                                                                      
10 % (v/v) fetal calf serum                                                                                
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution   
- 100 µM C17:2
Chase  
Medium 
Williams Medium E, supplemented with:                                                                                      
10 % (v/v) fetal calf serum                                                                                
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution   
- 100 µM C10
- 50 µM Eto in ddH2O
- 3 µM D1 in DMSO
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4.4. Lipid extraction and click reaction 
All lipid extractions were done directly from the cell culture plates. The extraction procedures 
were adapted from a previously described, full lipid extraction method (Bligh and Dyer, 
1959).  
For detection, the alkyne labeled lipids were then reacted with azido-reporter molecules 
namely 3-azido-7-hydroxycoumarin for fluorescent detection on a TLC plate (see: Chapter 
4.5.1.) or a newly developed set of azido-reporter molecules for multiplexed lipid MS (see: 
Chapter 4.5.2.). 
4.4.1. Lipid extraction and click reaction for TLC 
When frozen, the plates were thawed, and as much as possible of the remaining liquid was 
removed. Then 800 µl CHCl3/MeOH (1/3) was added directly in each well. The plates were 
agitated gently for 30 seconds and the monophasic solution from each well was transferred 
into a sperate 1.5 ml reaction tube. Precipitated proteins were sedimented by centrifugation 
at 2 x 104 g for two minutes and the supernatant containing the extracted lipids was 
transferred into a new 1.5 ml reaction tube. Then 200 µl CHCl3 and 600 µl 1% Acetic acid in 
ddH2O was added to generate a biphasic solution. The mixture was vigorously vortexed for 
one minute and then centrifuged again for two minutes at 2 x 104 g resulting in a clear phase 
separation. The upper phase consisting of methanol and water contains all non-lipids and the 
lower phase consisting of chloroform containing the lipids. The chloroform phase was 
carefully transferred into a fresh 1.5 ml reaction tube. The chloroform phase was then 
evaporated in a vacuum concentrator at 45ºC for twenty minutes. The lipids were redissolved 
in 50 µl CHCl3 and vortexed for 5 minutes. The click reaction was performed with 10 µl from 
the lipid extract. The remaining lipid extract was stored at -20ºC.  
For the click reaction, 40 µl of 3-azido-7-hydroxycoumarin reaction mixture (see: Table 6) 
was added beforehand in a 1.5 ml reaction tube. Then 10 µl from the full lipid extract was 
added, the mixture was shortly centrifuged and incubated overnight at 43ºC in a heat block. 
As a standard, each 1 µl of a 50 µmol solution of synthetized alkyne labeled lipids in CHCl3 
was reacted directly in 30 µl click reaction mixture (for information on the internal standards 
see: (Thiele et al., 2012)). 
 
Table 6: Composition of the click reaction mixture for TLC detection.  
Name Composition 
3-azido-7-hydroxycoumarin 
Reaction Mixture 
-10 µl 3-azido-7-hydroxycoumarin (2 mg/ml in ACN)                       
- 250 µl 10 mM Cu(I)-TFB in ACN                                          
- in 850 µl 100% EtOH 
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4.4.2. Lipid extraction and click reaction for MS 
The following procedure is also published in: (Thiele et al., 2019). 
When frozen, the plates were thawed, and as much as possible of the remaining liquid was 
removed. Then 500 µl MeOH/CHCl3 extraction mixture for MS (see: Table 7) was added in 
each well, using a gas tight Hamilton syringe. The entire plate was then sonicated for one 
minute in a bath sonicator. The monophasic extract from each well was transferred in a 1.5 
ml Eppendorf reaction tube. Precipitated proteins were centrifuged down for 5 min at 2 x 104 
g. The supernatant was transferred in a new 1.5 ml Eppendorf reaction tube. After addition of 
300 CHCl3 and 600 µl 1% LC-MS grade acetic acid in H2O the samples were shaken for 30 
seconds and centrifuged for 2 minutes at 2 x 104 g. Form the resulting biphasic solution, the 
lower organic phase was transferred in a new 1.5 ml Eppendorf reaction tube. The organic 
phase was evaporated in a vacuum centrifuge at 45ºC for 20 minutes. The Lipids were 
redissolved in 10 µl CHCl3 and vortexed for 30 seconds. The samples were spun down and 
reacted with the respective azido reporter molecules for multiplexed MS. To each sample 40 
µl of reaction mixture (see: Table 7) containing either the azido reporter C175-73, -75, -76 or 
-77 was added. All samples were sonicated for 5 minutes followed by incubation at 40ºC for 
16 hours in a heat block. 
 
Table 7: Compositions of buffers used for extraction and click reaction of alkyne labeled lipids 
for MS. 
Name Composition 
Extraction Mixture 
For MS  
For 36 samples:                                                                                
- 14.7 ml MeOH (LC-MS grade)                                                             
- 2.94 ml CHCl3                                                                       
- 360 µl internal standard mixture for alkyne labeled lipids in  
dCHCl3/MeOH (1:1) containing 118 pmol TAG [48.3],                      
d16.7 pmol DAG [32:2], 29 pmol CE [18:2],                                  
d8.4 pmol Cer [18:2],14 pmol PA [34:4],125 pmol PC [34:3],                                         
dand 22.5 pmol double labeled TAG [51:5] per 10 µl                  
Click Reaction Mixture  - 10 µl 100 mM C175-73,-75,-76,-77 in 50 % MeOH                                      
- 100 µl 10 mM Cu(I)-TFB in acetonitrile                                         
- in 900 µl 100 % EtOH 
Spray Buffer - 16 ml isopropanol (LC-MS grade)                                                                               
- 10 ml MeOH (LC-MS grade)                                                                                   
- 1720 µl H2O (LC-MS grade)                                                                                        
- 280 µl 1 M ammonium acetate in water 
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Figure 9: Schematic visualization of the experimental design, used in the pulse and pulse-
chase experiments with alkyne labeled lipids, to analyze the effect of DGAT-inhibitors, 
Etomoxir and Teglicar on the incorporation of MCFA into hepatic TAGs, by multiplexed lipid 
MS in a 24 well setup. All experiments were done in triplicate determinations comprising a control 
group (neg, lane A) and three treatments consisting of different inhibitors and their combinations (Inh. 
A-C, lane B-D). After lipid extraction, samples from each lane were clicked to a different C175-XX 
azido reporter group. Samples from every row were then pooled, resulting in only 6 from the originally 
24 samples. Finally, the pooled samples were analyzed by MS (see: Chapter 4.5.2.).  
 
After incubation, 100 µl of CHCl3 was added to each sample and the samples for multiplexing 
were pooled, as depicted in Figure 9. To the pooled samples 600 µl of LC-MS grade H2O 
was added, the mixture briefly shaken for 30 seconds and centrifuged at 2 x 104 g for two 
minutes. This re-extraction step was done in order to reduce the copper ion concentration in 
the samples to a minimum, since the samples were sprayed directly into the mass 
spectrometer without any further HPLC method. The upper phase was removed, and the 
lower phase was evaporated at 45ºC for 20 min in a vacuum centrifuge. Each sample was 
redissolved in 800 µl spray buffer (see: Table 7), sonicated for five minutes and lipids were 
then analyzed by MS. 
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4.5. Detection methods for alkyne labeled Lipids 
4.5.1. Detection of clicked alkyne labeled lipids by TLC 
TLC is a separation method to analyze compositions of diverse sample mixtures. Separation 
is achieved on a stationary phase (in this case a silica gel) on which the analytes are 
separated due to their polarity differences in a solvent mixture as a mobile phase (Fuchs et 
al., 2011).  
After the click reaction as described in chapter 4.4.1, the reaction tubes were centrifuged to 
collect the evaporated solvents condensed under the lid. The samples were then vortexed for 
10 min. Meanwhile a TLC plate was prepared as follows: a line was drawn 2 cm from the 
bottom of the plate and spaces for lipid loading were marked. After the plate was prepared, 
the samples were centrifuged one again and the samples were loaded on the TLC plate 
using glass capillaries. The plate was then placed in a developing chamber, saturated with a 
solvent (Solvent Mixture I, see: Table 8) developed to separate polar and medium polar lipids 
(for example phospholipids). The plate was kept in the chamber for about 20 minutes until 
the front line reached a height of 10 cm measured from the line were the lipids were loaded.  
The plate was then taken out, dried and placed in a second developing chamber saturated 
with a solvent (Solvent Mixture II, see: Table 8) developed to separate apolar lipids such as 
triacylglycerol or cholesteryl esters. In this step the plate was kept in the chamber until the 
solvent front line reached the near top of the plate. Finally, the plate was taken out, dried, 
soaked in 4 % Hünig’s base solution (see: Table 8) and dried again.  
Click labeled alkyne lipids were then detected using a laboratory intern system described in 
(Thiele et al., 2012). The fluorescent reporter clicked to the lipids was excited using a 420 nm 
LED lamp with a glass emission filter. Images were acquired with an EMCCD camera system 
equipped with a 494/20 (coumarin fluorescence signal) and 528/28 (noise signal) bandpass 
emission filter set. In each channel eight images were acquired with exposure times between 
20 milliseconds and 5 seconds. For samples with a very low fluorescence signal, images 
form the 528-filter channel were subtracted from the 494-filter channel for background 
correction. Images were acquired and final quantification was done using the GelPro 
analyzer software. Fluorescence signals were saved as integrated optical density (IOD) 
values for further analyzation in any spreadsheet software. TAG signals were normalized by 
setting the sum of both TAG bands in the negative control, originating from either C11 or 
C19/C17:2 fatty acids, as 1. Changes upon inhibitor treatment were then calculated in for 
each TAG in relation to the negative control. 
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Table 8: Composition of solvents used for TLC development. 
Name Composition 
Solvent Mixture I  - 65 (v/v) CHCl3                                                                             
- 25 (v/v) MeOH                                                                              
- 4 (v/v) H2O                                                                                 
- 1 (v/v) acetic acid (glacial) 
Solvent Mixture II - 1 (v/v) isohexane                                                                            
- 1 (v/v) ethyl acetate 
Hünig’s Base Solution - 4 % (v/v) N,N-Diisopropylethylamine in isohexane 
4.5.2. Multiplexed MS of reporter-labeled alkyne lipids 
The following procedure is also published in: (Thiele et al., 2019). 
The mass spectra were recorded on a Thermo Scientific Q Exactive Plus Hybrid quadrupole-
orbitrap mass spectrometer. The device is equipped with an atmospheric pressure ion (API) 
source (Bruins, 1994), which is operating in the high-voltage electrospray ionization (HESI) 
modus (Banerjee and Mazumdar, 2012). The sample was directly injected using a gastight 
Hamiltion syringe operated by a syringe pump under the control of the Tune instrument 
software. The syringe port was connected directly to the HESI source with no additional 
connection tubings in order to minimize dead volume. The samples were sprayed at a flow 
rate of 10 µl/min in spray buffer (see: Table 7). The following parameters were used: sheath 
gas 4, aux gas 2, sweep gas 0, gas heating off, spray voltage positive mode 4.0 kV, ion 
transfer capillary temperature 280 ºC. Since the lipids clicked with the C175-XX reporter 
molecules result only in positive ions, the mass acquisition was done in positive ion mode. 
For all samples form cellular extracts, MS1 spectra were recorded in segmented overview 
scans with ranging mass to charge rations (m/z) from 300-1400 in 100 m/z windows for 1.2 
minutes. This was followed by MS/MS (MS2) scans by data independent acquisition (DIA) 
(Alcoriza-Balaguer et al., 2019) for 16.8 minutes, using inclusion lists from m/z 305.373-
1400.119 in intervals with m/z 1.0006 to reflect the typical mass defect of lipids at the 
respective masses. Scan parameters were as followed: for MS1: automatic gain control 
(AGC) target 3 x 106, maximum ion time 800 ms, resolution 280000, peak mode centroid, for 
MS2: automatic gain control (AGC) target 2 x 105, maximum ion time 700 ms, resolution 
140000, no spectral multiplexing, dynamic first mass, isolation window m/z 1.0, stepped 
normalized collision energy (NCE) 10, 30, 35, spectrum data type centroid. In addition, a 
second scan for double charged species was performed in the scan range of m/z 300 - 700 
with MS2 scans from m/z 300.8052 - 700.0648 at intervals of m/z 0.5002 and an isolation 
window of m/z 0.7. To identify the labeled lipids, the generated .raw files were first converted 
to .mzml files using the MSconvert program. Files were then analyzed using the program 
LipidXplorer (Herzog et al., 2011). For identification and quantification of labeled lipids, 
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molecular fragment query language (MFQL) scripts were written that identify the species by 
the presence of a peak corresponding to the expected masses of the labeled lipid class 
combined with the characteristic neutral loss. All MFQL scripts for the respective lipid classes 
can be found in the supplementary data (see: Supplements 10.5.). The .mzml files were first 
imported into LipidXplorer, then the associated MFQL scripts for the lipid classes to be 
analyzed were chosen and the program could be executed. As a data output a .csv file was 
written, which could be further analyzed by any spreadsheed software.  
4.6. Live cell oxygen consumption rate (OCR) measurements 
In order to measure the oxygen consumption in primary hepatocytes to investigate the 
influence of different small molecule inhibitors on the mitochondrial β-oxidation rate and 
cellular oxygen consumption in general, the Seahorse XF Analyzer (Agilent Technologies) in 
a 96 well format, was used. The assay was done as an adaption of the protocol for the 
Seahorse XF Flux Kit in a 96 well format. One day prior to the assay, the sensor cartridge 
was humidified in water at 37ºC in a non- carbonated incubator.  
On the day of the assay, primary hepatocytes were isolated as described in chapter 4.2.2. 
Then 1000-2000 cells were plated in each well of a collagen coated (see: Chapter 4.2.1.) 96-
well cell culture microplate for Seahorse XF Analyzer applications in 200 µl adhesion medium 
(see: Table 3). The cells were allowed to adhere for two hours, then the medium was 
changed by carefully adding 200 µl prewarmed assay medium (see: Table 9), then removing 
the same volume and repeating this step for three times. Finally, 40 µl was removed from 
each well, resulting in a final volume of 160 µl per plate. To avoid cooling, the plate was kept 
on a heater plate at 37ºC during this procedure. The plate was then placed in a non-
carbonated incubator at 37ºC for at least one hour prior to the assay. During that time the 
injection ports of the sensor cartridge were loaded with inhibitor solutions in assay medium, 
as indicated in Table 9. As a negative control the respective vehicle was diluted in assay 
medium. The sensor cartridge was then incubated in Seahorse XF Assay calibrant (see: 
Table 9) and as well incubated at 37ºC in a non-carbonated incubator for at least one hour. 
Finally, the sensor cartridge was placed in the Seahorse XF Analyzer for instrument 
calibration. When calibration of the sensor cartridge was done, the experiment was started 
by placing the cell culture plate in the analyzer. The experimental setup was as followed: first 
baseline OCR measurement for 30 minutes, then injection of the inhibitor solutions, followed 
by 45 minutes of OCR measurements. The measurement cycles were set to measure every 
5 minutes.  
After the experiment was done, the data was exported from the instrument software (Wave 
2.4) as an .xlsx file which could be further analyzed by any spreadsheet data. 
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Table 9: Composition of solvents used for Seahorse XF Analyzer experiments. 
Name Composition/ Catalogue Number 
Seahorse XF Analyzer  
Calibrant 
Cat. No.: 100840-000 
Seahorse XF Analyzer  
Assay Medium 
Agilent Seahorse XF RPMI Medium (Cat. No.: 103576-100) 
supplemented with:                                                                                                               
10 % FCS (v/v)                                                                      
1 % (v/v) penicillin/streptomycin solution                                                                         
1 % (v/v) 200 mM L-glutamine solution 
Inhibitor Solutions As 10x concentrates in Seahorse XF Analyzer Assay 
Medium for following final assay concentrations:           
- 50 µM Etomoxir in ddH2O                                                                          
- 50 µM Teglicar in DMSO                                                                               
- 3 µM A922500 (D1) in DMSO                                                           
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4.7. Statistical analysis and data evaluation 
If not otherwise stated, the data is presented as mean values ± standard deviation (SD). 
Within one biological replica, all values were raised from triplicate determinations. For all 
experimental sets at least 3 biological replicas were performed. Raw data analysis was 
executed using Microsoft Excel and final statistical analysis was done using the GraphPad 
software (Prism 6 or 7). For comparison of two groups an unpaired t-test was used. For 
comparisons of more than two groups within one experimental data set, an ordinary one-way 
ANOVA with Dunnetts’s multiple comparison test (comparison of the mean values from the 
treatment group with the mean values from the control group (neg)) was applied. When 
multiple comparisons were done within two or more experimental data sets, an ordinary two-
way ANOVA with Sidak’s multiple comparison test (comparison of the mean values from the 
treatment group with the mean from the control group (neg) within one experimental data set) 
was applied. * stands for p≤0.0332, ** for p≤0.0021, *** for p≤0.0002, **** for p≤0.0001 and 
ns stands for not significant. All lipid signals from MS analysis were quantified by internal 
standardization with the standards shown in chapter 3.8. Absolute amounts are shown in 
pmol. Relative amounts (mol per mille) of each lipid class were calculated by multiplication of 
the pmol value from the respective lipid class times 1000, followed by dividing this value 
through the value of total labeled lipids (from aCE, aCer, aDAG, aPC, aPA and aTAG (in 
pmol)) within that sample. These values were used to calculate the “fold change 
concentration”, which shows overall changes of the respective lipid class under experimental 
conditions in comparison to the negative control within one biological replica. To take 
advantage of the information provided by species resolution in our mass spectrometric 
methodology, changes from lipid species (namely TAG) upon treatment conditions within one 
lipid class were analyzed. However, a large variation of relative abundances form lipid 
species within its class and the change of total class abundance, often hinders a systematic 
evaluation of a lipid species spectra. To overcome that problem, the data from the aTAG 
species (in pmol), was first divided by the corresponding aTAG species from the 
respective negative control to obtain fold changes (FC). This normalizes for the relative 
abundance within the class. Individual FC values were then averaged to obtain the 
average FC of the lipid class. Next, individual FC were divided by the class average FC 
to obtain normalized FC values. These NFC arrays indicate the change of the species 
spectrum under experimental conditions of a class, independent of the changes in total 
abundance of the class and independent of the relative abundance of the species within 
the class. 
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5. Results 
In the following, the hypothesis by Klizatie (Klizaite, 2017), regarding the MCFA preference of 
DGAT2 was tested by monitoring the C11-FA and C19-FA metabolism in hepatocytes under 
the influence of specific small molecule inhibitors against DGAT1 and DGAT2. 
5.1. Analysis of C11-FA and C19-FA incorporation into TAGs upon 
DGAT inhibition 
Freshly isolated hepatocytes were first preincubated with either 3 µM DGAT1 inhibitor 
(A922500 (D1)), 15 µM DGAT2 inhibitor (JNJ-DGAT2-A (D2)) or a combination of both 
inhibitors. As a negative control the cells were incubated with only the vehicle (in this case 
DMSO). After preincubation, cells were pulsed with 100 µM of either C11- or C19- alkyne 
fatty acid. The incorporation of both alkyne fatty acids into TAG was monitored through 
capturing the fluorescent signal of azido-coumarin reacted to the alkyne labeled lipids on a 
TLC plate. Changes under inhibitory conditions were quantified in comparison to the negative 
control. 
These experiments revealed two main results. First, the incorporation of C11-FAs into TAG 
was far more reduced than of C19-FAs. The presence of both inhibitors resulted in a near 
total reduction of C11-TAG (Figure 10: A, C, in lanes/ filled  red/blue bars labeled: D1/D2), 
whereas C19-TAGs were only slightly, but still significantly reduced (Figure 10: B, C, in 
lanes/ hatched red/blue bars labeled: D1/D2). Second, C11-FA incorporation into TAGs was 
already significantly reduced by about a half, when only the DGAT1 inhibitor was present 
(Figure 10: A, C, C11 TAG in lanes/ filled red bars labeled: D1). In contrary to our initial 
hypothesis, these results already indicated that not DGAT2, but DGAT1 might play a more 
important role in hepatic MCFA metabolism. A slight accumulation of 1,3 C19-DAG-, C19- 
PE- and C19-PC- bands were visible, when both inhibitors are present (Figure 10, B, lanes 
labeled D1/D2, data not quantified). On the opposite, these effects were not visible for the 
C11 fatty acid. Here, an inhibition of DGAT activity, resulted not only in a reduction of labeled 
TAG, but also in total reduction of alkyne labeled lipids (Figure 10, A, lanes labeled D1 and 
D1/D2, data not quantified). 
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Figure 10: Analysis of aTAGs upon DGAT inhibition in primary hepatocytes, pulsed with either 
C11- or C19-fatty acids. After isolation, primary mouse liver hepatocytes were plated in 24 well plates 
with 7.5x104 cells per well.  Cells were preincubated with either 3 µM DGAT1-Inhibitor (D1), 15 µM 
DGAT2-Inhibitor (D2) or a combination of both inhibitors (D1/D2) for 1 hour, in comparison to the 
respective vehicle as a negative control. Cells were then pulsed for 1 hour with either 100 µM C11- (A) 
or C19- (B) fatty acid. The cells were washed, lipids were extracted and click reaction for TLC was 
performed. Finally, lipids were separated on a TLC plate and the signal was captured by fluorescent 
imaging (panel A and B). Panel C illustrates the normalized quantification of fluorescent intensities 
from C11-TAG (filled bars) and C19-TAG (grey hatched bars) upon either D1- (red), D2- (blue) and a 
combination of both (blue/red) inhibitors, in comparison to the negative control (black: C11, grey: C19). 
The data represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, ** for p≤0.0021 and 
**** for p≤0.0001. Ns=not significant.       
 
For further validation of these findings, 50 µM of C11- and C19- alkyne fatty acids were 
pulsed simultaneously under the same inhibitory conditions. As already shown by Klizaite 
(Klizaite, 2017), two groups of TAG species are formed, each originating from either C11- or 
C19 fatty acids. Conveniently, these can be detected as two distinct bands on the TLC plate 
(Figure 11, A, bands marked C19-TAG, C11-TAG). Under native conditions, both alkyne 
lipids got almost equally introduced into TAG, with a slightly higher concentration of C11-
TAG (not significant (Figure 11, A: lanes marked as neg, B: black and grey bars, labeled as 
neg). Upon DGAT inhibition, C11 fatty acid metabolism, showed nearly the same phenotype 
in TAG concentrations, as when pulsed alone. When DGAT1 was inhibited, C11-TAG was 
significantly reduced by half, whereas a combination of both DGAT1- and DGAT2-inhibitors 
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resulted in a near total reduction of C11-TAG (Figure 11, A: lanes labeled D1 and D1/D2 
(C11-TAG), B: filed bars C11 (D1 (red), D1/D2 (red/blue)).    
 
Figure 11: Analysis of aTAGs upon DGAT inhibition in primary hepatocytes, co-pulsed with 
C11- and C19-fatty acids. After isolation, primary mouse liver hepatocytes were plated in 24 well 
plates with 7.5x104 cells per well.  Cells were preincubated with either 3 µM DGAT1-Inhibitor (D1), 15 
µM DGAT2-Inhibitor (D2) or a combination of both inhibitors (D1/D2) for 1 hour, in comparison to the 
respective vehicle as a negative control. Cells were then pulsed for 1 hour with a combination of 50 
µM C11- and 50 µM C19-fatty acid. The cells were washed, lipids were extracted and click reaction for 
TLC was performed. Finally, lipids were separated on a TLC plate and the signal was captured by 
fluorescent imaging (A). Panel B illustrates the normalized quantification of fluorescent intensities from 
C11-TAG (filled bars) and C19-TAG (grey hatched bars) upon either D1 (red), D2 (blue) and a 
combination of both (blue/red) inhibitors, in comparison to the negative controls (black: C11, grey: 
C19). The data represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, ** for 
p≤0.0021 and *** for p≤0.0002. ns=not significant. 
 
Upon DGAT2 inhibition the concentration of C11-TAG was slightly elevated in comparison to 
the negative control (Figure 11, B: filled blue bars labeled D2). The concentration of C19- 
TAG did not change significantly throughout all conditions (Figure 11, A: bands labeled C19- 
TAG, B: hatched bars labeled C19). Yet, an antiparallel effect on C11-TAG and C19-TAG 
levels was observable: Upon DGAT1 inhibition, C11-TAG was reduced, and C19-TAG was 
slightly (but not significantly) elevated and upon DGAT2 inhibition this effect was reversed. 
However, these changes were only significant for C11-TAG but not for C19-TAG. When both 
inhibitors were present, there was also an accumulation of DAG species observable (data 
not quantified). These should mainly consist of species labeled with C19-fatty acids, as the 
accumulating bands are those running higher on the plate due to their more hydrophobic 
nature (Figure 11, A: bands labeled as C11/C19 DAG). Since both alkyne fatty acids are 
metabolized in parallel, forming DAG species labeled with either one of the alkyne fatty 
acids, which could not be resolved via this TLC-detection method.  
This was true for all other lipid species (except TAG in this case), thus making a specific 
quantification in this detection system unrealizable. However, the analysis of the two TAG 
classes and their response to the DGAT inhibitor treatment, indicated a metabolic 
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discrimination in between DGAT enzymes and their favored fatty acid substrates in terms of 
fatty acid chain length.  
5.2. Etomoxir and a DGAT1-Inhibitor show similar effects on C11-
TAG levels 
Taking advantage to simultaneously trace the incorporation of C11- and C19-fatty acids into 
TAG via TLC analysis, this experimental setup was used next, to analyze the findings by 
Klizaite (Klizaite, 2017) regarding Etomoxir in greater detail. 
Freshly isolated hepatocytes were treated with either 50 µM Etomoxir (Eto), 3 µM A922500 
(D1) or a combination of both inhibitors for one hour and then co-pulsed with C11- and C19- 
fatty acid for one hour, and the TAG levels were analyzed as described before. 
 
Figure 12: Analysis of aTAGs upon DGAT1 inhibitor-, and Etomoxir-treatment in primary 
hepatocytes, co-pulsed with C11- and C19-fatty acids. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well.  Cells were preincubated with 
either 3 µM DGAT1-Inhibitor (D1), 50 µM Etomoxir (Eto) or a combination of both inhibitors (D1/Eto) 
for one hour, in comparison to the respective vehicle as a negative control. Cells were then pulsed for 
1 hour with a combination of 50 µM C11- and 50 µM C19-fatty acid. The cells were washed, lipids 
were extracted and click reaction for TLC was performed. Finally, lipids were separated on a TLC plate 
and the signal was captured by fluorescent imaging (A). Panel B illustrates the normalized 
quantification of fluorescent intensities from C11-TAG (filled bars) and C19-TAG (grey hatched bars) 
upon either D1 (red), Etomoxir (orange) and a combination of both (orange/red) inhibitors, in 
comparison to the negative controls (black: C11, grey: C19). The data represent mean ±SD for n=3 
biological replicates. ** stands for p≤0.0021 and **** for p≤0.0001. ns=not significant.     
   
As in the studies by Klizatie (Klizaite, 2017), the treatment with Etomoxir led to decreased 
C11-TAG levels, whereas the C19-TAG levels were signficantly elevated (Figure 12: A: 
bands named  C19 TAG/C11-TAG in the lane labeled Eto, B: filled/hatched orange bars, 
labeled Eto). As shown before, treatment with the D1-inhibitor led to the same reduction of 
C11-TAG, with no altered levels of C19-TAG (Figure 12: A, lane D1, B: filled/hatched red 
bars). A combinaton of Etomoxir with the DGAT1-inhibitor led to the same phenotype as the 
combination of both DGAT-inhibitors. Here C11-TAG levels were strongly reduced, whereas 
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C19-TAG levels were slightly elevated (Figure 12: A, lane Eto/D1, B: filled/hatched 
orange/red bars). Triggered by these findings, similar pulse experiments were caried out, 
where Etomoxir was combined with the DGAT2-inhibitor. 
 
Figure 13: Analysis of aTAGs upon DGAT2 inhibitor-, and Etomoxir-treatment in primary 
hepatocytes, co-pulsed with C11- and C19-fatty acids. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well.  Cells were preincubated with 
either 15 µM DGAT2-Inhibitor (D2), 50 µM Etomoxir (Eto) or a combination of both inhibitors (D2/Eto) 
for one hour, in comparison to the respective vehicle as a negative control. Cells were then pulsed for 
1 hour with a combination of 50 µM C11- and 50 µM C19-fatty acid. The cells were washed, lipids 
were extracted and click reaction for TLC was performed. Finally, lipids were separated on a TLC plate 
and the signal was captured by fluorescent imaging (A). Panel B illustrates the normalized 
quantification of fluorescent intensities from C11-TAG (filled bars) and C19-TAG (grey hatched bars) 
upon either D2 (blue), Etomoxir (orange) and a combination of both (orange/blue) inhibitors, in 
comparison to the negative controls (black: C11, grey: C19). The data represent mean ±SD for n=3 
biological replicates. * stands for p≤0.0332 and ** for p≤0.0021. ns=not significant.      
  
In this experimental setup, hepatocytes were preincubated with 50 µM Etomoxir, 15 µM JNJ-
DGAT2-A (D2) or a combination of both inhibitors, followed by a co-pulse of C11- and C19- 
fatty acids. 
Surprisingly, a combination of Etomoxir with the DGAT2-inhibitor did not lead to a complete 
reduction of C11-TAG (Figure 13, A: lanes labeled Eto/D2). Here the reduction was only as 
prominent as with Etomoxir alone (Fig 13, B: filled orange and orange/blue bars (Eto, 
Eto/D2)).  However, the combination of both inhibitors led to a slightly stronger accumulation 
of DAG species, like in the experiments where both DGAT inhibitors were combined (Figure 
13, A: lanes Eto/D2 C11/C19 DAGs (data not quantified)).  
In order to verify the effects of the DGAT inhibitors and Etomoxir on TAG levels in 
hepatocytes, the experiments were repeated with a different set of DGAT inhibitors used in a 
study by Li and colleagues (Li et al., 2015).  
Here, similar results could be observed, confirming these effects due to a DGAT1/2 specific 
inhibition. For more information on this matter, see Supplementary chapter 10.1.  
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Alkyne palmitate (C17:2) is another alkyne fatty acid, which is regularly used for lipid-tracing 
experiments in our group.  
Since both C19- and C17:2-alkyne fatty acids have a different profile of lipid-classes and 
species in which they are incorporated (Thiele et al., 2012), it appeared reasonable to repeat 
the previously described experiments with a co-pulse of C11 and C17:2 under the same 
inhibitory conditions. In the following section, the results from these assays are illustrated.  
First, freshly isolated hepatocytes were preincubated with a either Etomoxir, A922500 (D1) or 
a combination of both and afterwards co-pulsed with either 50 µM of C11 and C17:2. 
As previously described (Thiele et al., 2012), hepatocytes incorporate more alkyne palmitate 
into PC and less into TAG, whereas alkyne oleate was preferably incorporated into TAG.  
Likewise, this effect was visible in under these experimental conditions. In comparison to the 
C11/C19 pulse experiments, where C11- and C19-fatty acids were equally incorporated into 
TAG, C17:2 fatty acid was incorporated into TAG at only a quarter in comparison to C11- 
TAG levels under control conditions (Figure 14, A: lanes labeled as neg, B: black (C11) and 
grey (C17:2) bars).  
 
Figure 14: Analysis of aTAGs upon DGAT1 inhibitor-, and Etomoxir-treatment in primary 
hepatocytes, co-pulsed with C11- and C17:2-fatty acids. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well.  Cells were preincubated with 
either 3 µM DGAT1-Inhibitor (D1), 50 µM Etomoxir (Eto) or a combination of both inhibitors (D1/Eto) 
for one hour, in comparison to the respective vehicle as a negative control. Cells were then pulsed for 
1 hour with a combination of 50 µM C11- and 50 µM C17:2-fatty acid. The cells were washed, lipids 
were extracted and click reaction for TLC was performed. Finally, lipids were separated on a TLC plate 
and the signal was captured by fluorescent imaging (A). Panel B illustrates the normalized 
quantification of fluorescent intensities from C11-TAG (filled bars) and C17:2-TAG (grey hatched bars) 
upon either D1 (red), Etomoxir (orange) and a combination of both (orange/red) inhibitors, in 
comparison to the negative controls (black: C11, grey: C17:2). The data represent mean ±SD for n=3 
biological replicates. *** stands for p≤0.0002 and **** for p≤0.0001. ns=not significant.      
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The effects of Etomoxir and A922500 regarding C11-TAG levels, in relation to C17:2-TAG 
levels, however, were similar to those in C11/C19 co-pulse experiments. Here, C11-TAG 
levels showed the same response upon inhibitor treatment, whereas C17:2-TAG levels did 
not change significantly throughout all conditions (Figure 14, A: lanes labeled Eto, D1, 
Eto/D1, B: C11: filled bars, C17:2 hatched bars).  
Figure 15: Analysis of aTAGs upon DGAT2 inhibitor-, and Etomoxir-treatment in primary 
hepatocytes, co-pulsed with C11- and C17:2-fatty acids. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well.  Cells were preincubated with 
either 15 µM DGAT2-Inhibitor (D2), 50 µM Etomoxir (Eto) or a combination of both inhibitors (D2/Eto) 
for one hour, in comparison to the respective vehicle as a negative control. Cells were then pulsed for 
1 hour with a combination of 50 µM C11- and 50 µM C17:2-fatty acid. The cells were washed, lipids 
were extracted and click reaction for TLC was performed. Finally, lipids were separated on a TLC plate 
and the signal was captured by fluorescent imaging (A). Panel B illustrates the normalized 
quantification of fluorescent intensities from C11-TAG (filled bars) and C17:2-TAG (grey hatched bars) 
upon either D2 (blue), Etomoxir (orange) and combination of both (orange/blue) inhibitors, in 
comparison to the negative controls (black: C11, grey: C17:2). The data represent mean ±SD for n=3 
biological replicates. * stands for p≤0.0332 and ** for p≤0.0021. ns=not significant.    
 
Upon combination of Etomoxir with the D2 inhibitor JNJ-DGAT2-A, C17:2-TAG levels 
responded differently to the treatment with the D2 inhibitor in contrast to C19-TAG levels in 
the C11/C19 experiments. C17:2-TAG was significantly reduced when the D2 inhibitor was 
present, whereas in combination of both inhibitors, C17:2-TAG levels were significantly 
elevated (Figure 15, A: lanes labeled D2, Eto/D2, B: hatched bars labeled D2, Eto/D2). 
Yet, C11-TAG levels were significantly reduced upon treatment with Etomoxir (Figure 15, B: 
filled bars). Because all inhibitors were added before the hepatocytes were treated with the 
fatty acids, in order to ensure an equal distribution within all cells another control experiment 
was done. Here, Etomoxir was co-pulsed with C11-fatty acid directly. Under these conditions, 
there were no significant reduction of C11-TAG levels visible (Figure 16).Since the active 
inhibitory form of Etomoxir is its CoA-ester, to which it needs to be converted first (Kiorpes et 
al., 1984), it seems likely that the effect is due to either a competition between C11-CoA and 
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the CoA-form of Etomoxir or an unspecific off-target effect. This matter, however, will be 
analyzed later in greater detail, using MS-based detection technology. 
 
Figure 16: Analysis of C11-TAG in primary hepatocytes simultaneously co-pulsed with C11-
fatty acid and Etomoxir. After isolation, primary mouse liver hepatocytes were plated in 24 well 
plates with 7.5x104 cells per well. Cells were co-pulsed with 50 µM Etomoxir (Eto) and 100 µM C11-
fatty acid for 1 hour. As a negative control only the C11-fatty acid was pulsed. The cells were washed, 
lipids were extracted and click reaction for TLC was performed. Finally, lipids were separated on a 
TLC plate and the signal was captured by fluorescent imaging (panel A). Panel B illustrates the 
normalized quantification of fluorescent intensities from C11 TAG upon Etomoxir treatment (orange 
bar), in comparison to the negative control (black bar). The data represent mean ±SD for n=3 
biological replicates. ns=not significant.       
 
Taken together, the results from the TLC experiments suggest that, in contrary to the 
hypothesis by Klitzaite (Klizaite, 2017), DGAT1 and not DGAT2 is the main enzyme 
responsible for the introduction of MCFA into TAG. The effects on the MCFA-TAG level upon 
Etomoxir treatment did resemble those caused by DGAT1 inhibition, and a combination of 
both inhibitors even led to a mutually increased effect, which might hint towards a direct 
interaction of Etomoxir with the DGAT enzymes, especially DGAT1.   
However, these findings were restricted due to the TLC-based detection methodology to 
trace alkyne labeled lipids (see: Chapter 1.3), giving only lipid class resolution. Another 
limitation is the temporal resolution, only allowing an interpretation of the metabolic state 
after one hour of a continuous pulse of alkyne fatty acids. All the effects described above are 
due to an inhibition of DGAT enzymes via its respective small molecule inhibitors. Free fatty 
acids are introduced into DAG, followed by their DGAT-dependent conversion into TAG in a 
matter of minutes, due to the fast hepatic metabolism (Stein and Stein, 1967). Therefore, it 
would be interesting to conduct a pulse-chase experiment with a short pulse of an alkyne 
fatty acid, followed by several short chase time-points with an unlabeled MCFA. Here, one 
could directly monitor the DGAT-dependent introduction of the unlabeled MCFA into the 
labeled DAG pool. Given our newly established methodology for MS alkyne lipid tracing 
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(Thiele et al., 2019), it became possible to overcome both limitations mentioned above and 
conducting the detailed analysis of DGAT1-dependent MCFA metabolism. 
5.3. DGAT1 acts as the main enzyme for MCFA incorporation into 
TAG 
The results in this chapter investigate the role of DGAT1 in hepatic MCFA metabolism in 
more detail, with a focus on the role of Etomoxir as a possible DGAT inhibitor.  
5.3.1.  Pulse-chase experiments upon DGAT1 inhibition 
In order to study the DGAT-dependent introduction of MCFA into TAG under the influence of 
either a DGAT1 inhibitor or Etomoxir, a pulse-chase experiment was conducted, followed by 
MS analysis of the alkyne labeled lipids. 
Freshly isolated hepatocytes were first preincubated with either 3 µM A922500 (D1), 50 µM 
Etomoxir or a combination of both inhibitors. Then the cells were pulsed for 2 minutes with 
100 µM alkyne-palmitate (C17:2) in order to generate a pool of alkyne labeled lipids via the 
glycerophospholipid-pathway. As already shown by our group, a 2-minute pulse time of the 
given concentration of the alkyne fatty acid, does not saturate the hepatic metabolism with 
the FA. Under this conditions the concentration of early onset metabolites such as PA and 
DAG is still high, while the endpoint metabolites like TAG and PC continue rising (Piotrowitz, 
2016).  
The cells were chased for several short time points (0, 1, 2, 5, 10 minutes) with 100 µM of 
the native MCFA decanoic acid (C10). The lipids were then extracted, clicked and analyzed 
according to the protocol for multiplexed MS analysis of alkyne labeled lipids described in the 
chapters 4.4.2 and 4.5.2.  
First, the four lipid classes aTAG, aDAG, aPC, aPA were analyzed and are presented in 
Figure 17 as relative amounts in mol per mille, based on absolute amounts of aTAG, aDAG, 
aPA, aPC, aCE and aCer through internal standardization (see: Chapter 3.8. and 4.7.).  
In accordance with the TLC-based pulse-chase data published by Piotrowitz (Piotrowitz, 
2016) in our group, a fast introduction of alkyne lipids into aDAG, followed by the rise of 
labeled aTAG and aPC throughout the chase, could be measured (Figure 17, panels A-C 
(aTAG, aDAG, aPC) black lines labeled: neg). Also, the fast decline of labeled PA species 
within the short chase period agrees with this data (Figure 17, panel D (aPA), black line 
labeled: neg). These results from the negative controls provide evidence for the technical 
accuracy of the experiment.  
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Comparing the data from the negative controls with the respective values from the cells 
treated with the inhibitors, a major impact of both inhibitors on aTAG and aDAG levels could 
be observed. In line with the data acquired from the TLC-based pulse-experiments, both 
inhibitors significantly reduced the synthesis of aTAG species, decreasing even further when 
both inhibitors were combined (Figure 17, panel A, lines labeled Eto, D1 and Eto+D1). 
Figure 17: Relative amounts (mol per mille) of alkyne-labeled TAG (A), DAG (B), PC (C) and PA 
(D) species based on pmol from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from WT mice, treated with different inhibitor combinations, pulsed with 
alkyne-palmitate and chased with decanoic acid. After isolation, primary mouse liver hepatocytes 
were plated in 24 well plates with 7.5x104 cells per well. Cells were preincubated with either 50 µM 
Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1) or a combination of both inhibitors (Eto+D1). Cells were 
then pulsed with 100 µM alkyne palmitate (C17:2) for 2 minutes and chased with 100 µM decanoic 
acid (C10) for either 0, 1, 2, 5 or 10 minutes in the presence of the respective inhibitor. Lipids were 
extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and click 
reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. 
Mass signals were identified using LipidXplorer MFQL analysis with internal standard quantification for 
aTAG, aDAG, aPC, aPA, aCE and aCER. Relative concentrations are based on pmol from the internal 
standard quantifications and were calculated as described. The data represent mean ±SD for n=3 
biological replicates. ** stands for p≤0.0021, *** for p≤0.0002 and **** for p≤0.0001. ns=not significant. 
Statistical significances are only indicated for the last timepoint (chase time 10 min). 
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Respectively, an accumulation of aDAG species could be observed (Figure 17, panel B). 
Etomoxir treatment did not lead to a significant increase in aDAG species, however there 
was an apparent tendency toward aDAG accumulation. The treatment with the DGAT1 
inhibitor (D1) did lead to a visibe aDAG accumulation throughout every chase timepoint. This 
effect was even stronger when Etomoxir was combined with the DGAT1 inhibitor. Overall, 
aTAG species were decreased around 1.5 times upon treatment with A922500 and Etomoxir, 
respectively. When both inhibitors were combined aTAG levels decreased at about the half. 
aDAG levels corresponded with merley similar accumulation dynamics, as the aTAG 
decreased. No significant changes in aPA levels and only a significanct rise in aPC levels 
was observable when both inhibitors were present (Figure 17, panels C and D).  
However, this data is shows basically the same changes in overall lipid levels in respond to 
the inhibitor treatment, as already obverved on the TLC experiments.  
Since the MS-based detection method allows species resolution within all classes, one can 
directly analyze the DGAT-dependent introduction of C10 into aTAG. This effect should be 
clearly observable, since decanoic acid should not be present in the cells in detectable levels 
before adding the chase medium. LCFA-aTAG- and MCFA-aTAG levles should also 
correspond differently to the respective inhibitory treatments. 
Indeed, when one observes the absolute amount (in pmol) of the most abundant alkyne 
labeled LCFA-TAG species, namely TAG [51:4], [51:3], [53:5] and [53:4], there was a strong 
reduction visible, solely in the presence of both inhibitors (Figure 18, panel B, brown line 
(Eto+D1). Treatment of either D1 or Etomoxir alone did not lead to a strong reduction of 
these species (Figure 18, panel B, orange line (Eto), red line (D1)).  
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Figure 18: Absolute amounts of aTAG species isolated from WT mice, treated with different 
inhibitor combinations, pulsed with alkyne-palmitate and chased with decanoic acid. After 
isolation, primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. 
Cells were preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1) or a 
combination of both inhibitors (Eto+D1). Cells were then pulsed with 100 µM alkyne palmitate (C17:2) 
for 2 minutes and chased with 100 µM decanoic acid (C10) for either 0, 1, 2, 5 or 10 minutes in the 
presence of the respective inhibitor. Lipids were extracted with simultaneous addition of an internal 
standard mix for alkyne labeled lipids and click reaction with C175-XX reagents was performed. 
Multiplex samples were pooled and analyzed by MS. Mass signals were identified using LipidXplorer 
MFQL analysis with internal standard quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. 
Absolute amounts of the lipid species within the lipid classes of MCFA-aTAGs (A) (Σ of [43:3], [43:2], 
[45:4], [45:3]) and LCFA-aTAGs (B) (Σ of [51:4], [51:3], [53:5], [53:4]) are shown in pmol. The data 
represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, *** for p≤0.0002 and **** for 
p≤0.0001. ns=not significant. 
 
When one observes the absolute amounts summed up from the four most abundant MCFA-
aTAG species, namely TAG [43:3], [43:2], [45:4] and [45:3], the chase effect with the 
decanoic acid and the impact of both inhibitors becomes clearly observable. 
These aTAG species increased during the chase period from no detectable value at 0 min 
chase up to 25 pmol (mean value) after 10 minutes chase (Figure 18, panel A, black line 
labeled neg). This dataset illustrates the direct DGAT-dependent introduction of the MCFA 
decanoic acid into a labeled DAG pool.  
The treatment with the DGAT1 inhibitor and Etomoxir, both led to a significant decrease in 
the MCFA-aTAG levels, decreasing even further when both inhibitors were present (Figure 
18, panel A, orange- (Eto), red- (D1) and brown line (Eto+D1)). With one of both inhibitors 
present, the analyzed MCFA-aTAG levels only reached about 10-15 pmol (mean values) 
after 10 minutes chase. With a combined Etomoxir- and A922500-treatment, MCFA-aTAG 
levels reached only 3 pmol (mean value) after a 10 min chase. For better visualization, both 
the aTAG and the corresponding aDAG species upon each inhibitor treatment are co-
illustrated (Figure 19).  
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The analyzed aTAG species correspond to the four major aDAG species namely, [33:3], 
[33:2], [35:4] and [35:3] (Figure 19, panels A-D, dashed lines) to which decanoic acid (+10 
more c-atoms) was introduced through the postulated DGAT1 activity, resulting in the four 
TAG species named above (Figure 19, panels A-D, solid lines). Panel E of figure 19 is a 
schematic illustration on the postulated DGAT1 activity, which is inhibited by either A922500 
or Etomoxir.  
After 2 minutes pulse time with alkyne palmitate, 18 aDAG species could be detected. 
However, the four aDAG species mentioned above, did comprise about 80 percent of the 
total amount of labeled DAG in the negative control groups (Supplementary figure 3). 
Therefore, the main corresponding aTAG species in which decanoic acid was incorporated, 
naturally originate from these four aDAG species.  
Since the inhibition of DGAT1 does not only lead to the specific decrease of decanoic acid 
incorporation into aTAG, but also to a decreased incorporation of all fatty acids that belong to 
the spectrum of DGAT1, the accumulation effect of aDAG species should be observable in 
accordance to the data shown in figure 17. Indeed, the inhibition of MCFA-aTAG synthesis 
was paralleled by the accumulation of corresponding aDAG species (Figure 19, panels A-D, 
dashed lines).  
Taken together this data illustrates not only the direct effect of reduced MCFA-incorporation 
upon DGAT1 inhibition, but also the systemic effect of DGAT1 inhibition on fatty acid 
incorporation into aTAG during the dynamics of a fatty acid pulse-chase experiment.  
Furthermore, this data shows that treatment with Etomoxir does lead to decreased aTAG 
synthesis, similar to the specific inhibition of DGAT1 through the well characterized DGAT1 
inhibitor A922500 (Qi et al., 2012). This dataset supports the hypothesis on the effects in 
reduced MCFA-TAG levels through Etomoxir, to be due to a DGAT1 inhibition as a possible 
off-target effect of Etomoxir, in contrary to the previously mentioned hypothesis by Klizaite 
(Klizaite, 2017). 
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Figure 19: DGAT1-dependent incorporation of decanoic acid into aDAG species in hepatocytes, 
isolated from WT mice, treated with different inhibitor combinations, pulsed with alkyne-
palmitate and chased with decanoic acid. After isolation, primary mouse liver hepatocytes were 
plated in 24 well plates with 7.5x104 cells per well. Cells were preincubated with either 50 µM Etomoxir 
(Eto), 3 µM DGAT1-Inhibitor (D1) or a combination of both inhibitors (Eto+D1). Cells were then pulsed 
with 100 µM alkyne palmitate (C17:2) for 2 minutes and chased with 100 µM decanoic acid (C10) for 
either 0, 1, 2, 5 or 10 minutes in the presence of the respective inhibitor. Lipids were extracted with 
simultaneous addition of an internal standard mix for alkyne labeled lipids and click reaction with 
C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. Mass signals 
were identified using LipidXplorer MFQL analysis with internal standard quantification for aTAG, 
aDAG, aPC, aPA, aCE and aCER. Absolute amounts of the lipid species within the lipid classes of 
TAG (Σ of [43:3], [43:2], [45:4], [45:3]) and DAG (Σ of [33:3], [33:2], [35:4], [35:3]) are shown in pmol. 
Panels A-D show the direct incorporation of decanoic acid (C10) into the main DAG species (dashed 
lines) resulting in the respective TAG species (solid lines) over time, in the presence of Etomoxir (B), 
D1-Inhibitor (C), a combination of both Inhibitors (D) or the negative control (A). Panel E is a 
schematic visualization of this process. Note that in this scheme, the possible stereochemistry 
(sn1/sn3 or sn2) of DGAT1-dependent incorporation of the FFA is not considered. The data represent 
mean ±SD for n=3 biological replicates.  
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5.3.2. Analysis of the lipid profile in hepatocytes isolated form DGAT1-/- mice upon 
treatment with DGAT-specific inhibitors and Etomoxir 
Through a cooperation with the group of Prof. Dr. Dagmar Kratky at the Medical University of 
Graz, Austria, it became possible to analyze the effects of Etomoxir and the DGAT inhibitors 
in hepatocytes isolated from DGAT1-/- mice (Smith et al., 2000). All experiments presented in 
this chapter (5.3.2.) are the result of this collaboration. 
These experiments should firstly serve as a control for the effects seen the on hepatic aTAG 
metabolism upon DGAT inhibitor treatment. Second, in direct comparison to the respective 
WT hepatocytes, the hepatic DGAT1-/- lipid metabolism should give deeper insights into the 
putative role of DGAT1 in MCFA metabolism. And thirdly, the previously described off-target-
effect of Etomoxir could be analyzed in greater detail. 
In this collaborative project, pulse experiments, like in the TLC experiments described in 
chapter 5.1 and 5.2, were conducted.  
All necessary consumables such as tissue culture plates and media were prepared at our 
lab, snap frozen and send to the Medical University of Graz on dry ice. There, the 
hepatocytes were isolated, treated with inhibitors and pulsed with alkyne fatty acids 
according to the protocol described in chapter 4.3.1. These procedures were handled by 
Christina Leopold (PhD) a postdoc in the lab of Prof. Dr. Dagmar Kratky. The cells were then 
directly frozen on the culture plates and shipped on dry ice back to our lab, were the lipid 
extraction followed by either MS- or TLC-analysis was done. In the figure legends of each 
data set in which the isolation and the pulse of the fatty acids were performed by Christina 
Leopold (CL) and the subsequent lipid extraction and MS analysis was done by Klaus 
Wunderling (KW), the respective part from each researcher will be stated as: Isolation of 
hepatocytes and fatty acid pulse was done by CL, lipid extraction and MS/TLC analysis were 
done by KW. For all experiments intended for MS analysis, hepatocytes were preincubated 
with different combinations of either DGAT inhibitors (3 µM A922500 (D1), 15 µM JNJ-
DGAT2-A (D2)) or 50 µM Etomoxir and pulsed afterwards with a combination of 50 µM 
alkyne palmitate (C17:2) and 50 µM decanoic acid (C10). For the TLC experiments cells 
were preincubated with the inhibitors as described above and afterwards pulsed with a 
combination of 50 µM alkyne oleate (C19) and 50 µM alkyne decanoic acid (C11).  
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First, the lipid profile of DGAT1-/- hepatocytes under native conditions from the negative 
controls was analyzed in comparison to WT hepatocytes.  
In the four major alkyne labeled lipid classes which were analyzed, only aPC was 
significantly elevated in DGAT1-/- hepatocytes (Figure 20, panels A,B,D  (aTAG, aDAG, aPA) 
and panel C (aPC), bar graph labeled ΔDGAT1, values are displayed as absolute amounts in 
pmol).  
Figure 20: Absolute amounts of alkyne-labeled lipid classes from primary hepatocytes, isolated 
from wildtype mice (WT: black bars) or mice lacking DGAT1 (ΔDGAT1: red hatched bars), 
pulsed with alkyne-palmitate and decanoic acid. After isolation, primary mouse liver hepatocytes 
were plated in 24 well plates with 7.5x104 cells per well. Cells were co-pulsed with 50 µM alkyne 
palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were extracted with simultaneous 
addition of an internal standard mix for alkyne labeled lipids and click reaction with C175-XX reagents 
was performed. Multiplex samples were pooled and analyzed by MS. Mass signals were identified 
using LipidXplorer MFQL analysis with internal standard quantification for aTAG, aDAG, aPC, aPA, 
aCE and aCER. Absolute amounts of the lipid classes aTAG (A), aDAG (B), aPC (C) and aPA (D) are 
shown in pmol. The data represent mean SD± for n=18 technical replicates in n=3 biological 
replicates. ** stands for p≤0.0021. ns=not significant. Isolation of hepatocytes and fatty acid pulse was 
done by CL, lipid extraction and MS/TLC analysis were done by KW.  
  
However, the analysis of single species within the lipid classes, revealed some striking 
differences between DGAT1-/- and WT hepatocytes within the spectra of aTAG species 
(Figure 21, Heatmap array of mean values from white (0 pmol) to dark red (highest pmol 
value within each lipid class)).  
Having nearly the same amount of labeled TAG, the DGAT1-/- hepatocytes had significantly 
lower amounts of shorter aTAG species compared to the WT hepatocytes (Figure 21, panel 
A, TAG [41:3] - [49:2]). This effect was compensated in these cells through the amount of 
aTAG species with longer acyl chains (Figure 21, panel A, TAG [51:7] - [57:5]). This outcome 
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was primarily visible within the main aTAG species in its carbon chain length class, namely 
TAG [43:3], [43:2], [45:4] and [45:3] representing the main MCFA-aTAG species and TAG 
[51:4], [51:3], [53:5] and [53:4] representing the major LCFA-aTAG species. 
 
Figure 21: Absolute amounts of alkyne-labeled lipid species from primary hepatocytes, isolated 
from wildtype (WT) mice or mice lacking DGAT1 (ΔDGAT1), pulsed with alkyne-palmitate and 
decanoic acid. After isolation, primary mouse liver hepatocytes were plated in 24 well plates with 
7.5x104 cells per well. Cells were co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic 
acid (C10) for 1 hour. Lipids were extracted with simultaneous addition of an internal standard mix for 
alkyne labeled lipids and click reaction with C175-XX reagents was performed. Multiplex samples were 
pooled and analyzed by MS. Mass signals were identified using LipidXplorer MFQL analysis with 
internal standard quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Absolute amounts of the 
lipid species within the lipid classes of aTAG (A), aDAG (B) and aPC (C) are shown in pmol. The data 
represent mean values for n=3 biological replicates. Isolation of hepatocytes and fatty acid pulse was 
done by CL, lipid extraction and MS/TLC analysis were done by KW. 
 
On the side of the alkyne labeled DAG, only three species, namely DAG [35:4], [35:3] and 
[39:8] showed significantly higher concentrations in the DGAT1-/- hepatocytes, whereas all 
other species were either equally concentrated or slightly underrepresented (Figure 21, panel 
B (aDAG)). The overall significantly higher concentration of alkyne labeled PC in DGAT1-/- 
hepatocytes originated mainly from two species, namely PC [35:4] (over 200 pmol (mean 
value) more) and [39:8] (about 100 pmol (mean value) more) (Figure 21, panel C (aPC)).  
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On the side of the aTAG the effects in DGAT1-/- hepatocytes fit to those, observed in 
hepatocytes treated with a DGAT1 inhibitor, best seen in the effects described in the pulse 
experiments with C11- and C19-fatty acids upon D1 inhibitor treatment (Chapter 5.1, Figure 
11). There, reverse effects, like those described in this experimental data, set could be 
observed. 
Next, the influence of the treatment with DGAT inhibitors and Etomoxir within DGAT1-/- 
hepatocytes and the respective WT controls were investigated. 
Overall effects on aTAG and aDAG levels in WT hepatocytes upon treatment of either 
DGAT1-, DGAT2-, or a combination of both inhibitors, were comparable to the results 
presented in chapter 5.1. These are summarized in Figure 22, visualized as fold changes 
upon inhibitory treatment, calculated from the relative concentrations (mol per mille) as 
described in chapter 4.7. 
Figure 22: Fold change analysis of alkyne-labeled TAG (A) and DAG (B) based on relative 
amounts (mol per mile) from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from WT mice, treated with different inhibitor combinations, pulsed with 
alkyne-palmitate and decanoic acid. After isolation, primary mouse liver hepatocytes were plated in 
24 well plates with 7.5x104 cells per well. Cells were preincubated with either 3 µM DGAT1-Inhibitor 
(D1), 15 µM DGAT2-Inhibitor (D2) or combinations of both inhibitors (D1+D2). Cells were then co-
pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were 
extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and click 
reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. 
Mass signals were identified using LipidXplorer MFQL analysis with internal standard quantification for 
aTAG, aDAG, aPC, aPA, aCE and aCER. Fold changes (FC) in relative concentrations (from mol per 
mille) of each lipid species for each inhibitor treatment were calculated by normalization to the 
negative control. The data represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, ** 
for p≤0.0021 and **** for p≤0.0001. ns=not significant. Isolation of hepatocytes and fatty acid pulse 
was done by CL, lipid extraction and MS/TLC analysis were done by KW. 
 
Upon treatment with D1 inhibitor alone, overall labeled TAG levels were significantly 
decreased and labeled DAG levels showed a signficant accumulation (Figure 22, panel A, B, 
red bar graphs (D1)). Treatment with D2 inhibitor alone did not show any significant changes 
in labebed TAG levels and a slight accumulation of labeled DAG species (Figure 22, panel A, 
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B, blue bar graphs (D2)). When both inhibitors were combined, overall aTAG levels 
decreased strongly (about a half reduced) and aDAG levels displayed increased fold 
changes of about 6 times (Figure 22, panel A, B, red/blue hatched bar graphs (D1+D2)). 
Following, the normalized fold changes (NFC) within every single aTAG species from the 
data set displayed in Figure 22 were analyzed. As described in chapter 4.7., this method 
enables the anaysis of changes from single lipid species within a class, independent of the 
changes in total abundance of the class itself and independent of the relative abundance 
of the species within the class. 
Figure 23: A: Detailed normalized fold change (NFC) analysis of alkyne-labeled TAG species 
from primary hepatocytes, isolated from WT mice, treated with inhibitor combinations and 
pulsed with alkyne-palmitate and decanoic acid. B: schematic representation of the fatty acid 
profile affected through either DGAT1 or DGAT2 inhibition. A: After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were preincubated with 
either 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-Inhibitor (D2) or a combination of both (D1+D2). 
Cells were then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 
hour. Lipids were extracted with simultaneous addition of an internal standard mix for alkyne labeled 
lipids and click reaction with C175-XX reagents was performed. Multiplex samples were pooled and 
analyzed by MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Normalized fold changes (NFC) in 
concentrations of each lipid species for each inhibitor treatment were calculated by normalization to 
the negative control and to the average class fold change. The data represent mean values for n=3 
biological replicates. B: NFCs from TAGs with [57] c-atoms upon DGAT1 and DGAT2 inhibition with a 
schematic visualization of which fatty acids within one c-atom group are affected through either 
inhibition of DGAT1 or DGAT2. Isolation of hepatocytes and fatty acid pulse was done by CL, lipid 
extraction and MS/TLC analysis were done by KW. 
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While on the TLC plate MCFA- and LCFA-aTAGs were only represented through one band, 
here the change in the pattern can be visualized with 39 different aTAG species, which can 
be subdivided in the two groups responding to the inhibitor treatment. aTAG species ranging 
from 41 to 47 c-atoms can be classified as MCFA-aTAG, whereas all aTAG species with 
more than 47 c-atoms can be classified as LCFA-aTAG. 
Changes upon treatment with D1, D2 and a combination of both inhibitors, can be displayed 
as a heatmap where a white-to-blue color pattern represents negative fold changes 
(decreased concentration in comparison to the negative control, all values below 1) and a 
white-to-red color pattern represents positive fold changes (increased concentration in 
comparison to the negative control, all values above 1). No change in the concentration of a 
species compared to the negative control is displayed as a 1 and is represented as a clear 
white color.  
As well as in the TLC experiments, DGAT1 inhibition led to a decrease in the MCFA- aTAG 
species (Figure 23 A, lane labeled D1, TAG [41:2] - [47:4], displayed through a blue color 
pattern), while basically all other species had higher concentrations than the negative control, 
displayed through a red color pattern. An exception were five aTAG species, containing 
highly polyunsaturated fatty acids, namely TAG [49:6], [49:8], [51:7], [53:8] and [57:12]. 
These species were also downregulated, represented through a blue color pattern.  
Upon DGAT2 inhibition, the aTAG species pattern showed opposite effects as upon DGAT1 
inhibition. Here, MCFA-aTAG species (TAG 41-47) were upregulated, were all other aTAG 
with longer acyl chains were downregulated or had no change in their concentration (Figure 
23 A, lane labeled D2). The species TAG [51:7] was as well an exception, as it was 
upregulated upon DGAT2 inhibition.  
In line with the TLC-based pulse experiments, a combination of both inhibitors reduced the 
levels of MCFA-aTAGs even further (Figure 23 A, lane labeled D1+D2, TAG 41-47). Here, 
fold changes were always below 0.3, displaying a very strong downregulation of these 
species.   
Fold changes of aTAGs with longer and polyunsaturated fatty acids however, revealed a 
complex pattern of up- or downregulated species. Figure 23 B gives a schematic 
visualization on the interpretation of changes within the LCFA species range due to either 
DGAT1- or DGAT2 inhibition. 
For the range of aTAG 49-53, the NFC followed the pattern as upon DGAT1 inhibition alone, 
with even further up- or downregulation of the respective species. The species TAG [51:7], 
for example, was further downregulated and the three main species, namely TAG [51:5], 
[51:4] and [51:3], were the most upregulated with an NFC of 2,3-2,55. For aTAG species with 
55 and more c-atoms, all species with lesser saturation in their group followed the pattern as 
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upon DGAT2 inhibition alone. With higher saturation within the acyl chains, the pattern 
changes towards the patters as observed upon DGAT1 inhibition alone. 
In general, one could observe, that upon combination of both inhibitors the effects of the 
DGAT1 inhibitor were predominant over the changes upon DGAT2 inhibition, with a 
compensating effect on the main abundant species within the range of C49-C57.  
This method of analysis as described in Figure 22 and 23 was now applied on experiments, 
in which hepatocytes, isolated form WT and DGAT1-/- mice, were treated with Etomoxir and 
the DGAT inhibitors in different combinations. 
Overall effects on aTAG and aDAG levels of due to inhibitory treatment are displayed as fold 
changes from relative concentrations in Figure 24 (panel A (aTAG), panel B (aDAG)).  
In WT hepatocytes, the treatment with Etomoxir showed the same reduction of labeled TAG 
and the associated increase of labeled DAG, as the treatment with the DGAT1 inhibitor 
(Figure 24, panel A (aTAG), B (aDAG), WT: lanes labeled Eto, D1). 
A combination of Etomoxir with either one of the DGAT inhibitors decreased the amount of 
labeled TAG further, with a corresponding increase of aDAG levels (Figure 24, panels A 
(aTAG), B (aDAG), WT: lanes labeled Eto+D1, Eto+D2). 
In DGAT1-/- hepatocytes, the treatment with Etomoxir only led to a minimal decrease in 
overall aTAG levels and no significant change in aDAG levels (Figure 24, panels A (aTAG), 
B (aDAG), ΔDGAT1: lanes labeled Eto). As expected, the treatment with DGAT1 inhibitor 
alone as well as the combination of the DGAT1 inhibitor with Etomoxir, had no significant 
effect (for D1 alone) or enhancing effects (for Eto+D1) on aTAG and aDAG levels in DGAT1-/- 
hepatocytes (Figure 24, panels A (aTAG), B (aDAG), ΔDGAT1: lanes labeled D1, Eto+D1). 
Treatment with the DGAT2 inhibitor alone, did lead to overall changes in aTAG and aDAG 
levels in DGAT1-/- hepatocytes (Figure 24, panels A (aTAG), B (aDAG), ΔDGAT1: lanes 
labeled D2), compared to those, where DGAT1 and 2 inhibitors were combined in WT 
hepatocytes (as previously described in Figure 22). The combination of Etomoxir with the 
DGAT2 inhibitor, did not further decrease aTAG levels or increase aDAG levels within the 
DGAT1-/- hepatocytes (Figure 24, panels A (aTAG), B (aDAG), ΔDGAT1, lanes labeled 
Eto+D2). Overall changes in levels of aPC and aPA upon inhibitor treatment were analyzed 
as well (Supplementary figure 9, panels A (aPC) and B (aPA)). aPA levels were significantly 
reduced upon either inhibitor treatment, both, in WT and DGAT1-/- hepatocytes. Overall aPC 
levels were significantly increased in WT cells only upon DGAT1 inhibition whereas in 
DGAT1-/- hepatocytes only upon DGAT2 inhibition.  
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Figure 24: Fold change analysis of alkyne-labeled TAG (A) and DAG (B) based on relative 
amounts (mol per mile) from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from wildtype mice (WT) or mice lacking DGAT1 (ΔDGAT1), treated with 
different inhibitor combinations, pulsed with alkyne-palmitate and decanoic acid. After isolation, 
primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were 
preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-Inhibitor 
(D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells were then co-
pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were 
extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and click 
reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. 
Mass signals were identified using LipidXplorer MFQL analysis with internal standard quantification for 
aTAG, aDAG, aPC, aPA, aCE and aCER. Fold changes (FC) in relative concentrations (from mol per 
mille) of alkyne TAGs and DAGs for each inhibitor treatment were calculated by normalization to the 
negative control. The data represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, ** 
for p≤0.0021, *** for p≤0.0002 and **** for p≤0.0001. ns=not significant. Isolation of hepatocytes and 
fatty acid pulse was done by CL, lipid extraction and MS/TLC analysis were done by KW. 
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Next, the normalized fold change array analysis was applied to the data derived from the 
data set described in Figure 24. 
Strikingly, the NFC pattern from aTAG species in WT mice upon Etomoxir treatment, did 
resemble the pattern upon DGAT1 inhibition (Figure 25, panel A, lanes labeled Eto, D1). 
 
Figure 25: Detailed normalized fold change (NFC) analysis of alkyne-labeled TAG species from 
primary hepatocytes, isolated from wildtype mice (A: WT) or mice lacking DGAT1 (B: ΔDGAT1), 
treated with inhibitor combinations and pulsed with alkyne-palmitate and decanoic acid. After 
isolation, primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. 
Cells were preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-
Inhibitor (D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells were 
then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids 
were extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and 
click reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by 
MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Normalized fold changes (NFC) in 
concentrations of each lipid species for each inhibitor treatment were calculated by normalization to 
the negative control and to the average class fold change. The data represent mean values for n=3 
biological replicates. Isolation of hepatocytes and fatty acid pulse was done by CL, lipid extraction and 
MS/TLC analysis were done by KW. 
 
As seen in the TLC- and pulse-chase-experiments, the MCFA-aTAG levels (C41-47) were 
downregulated in the same way as upon treatment with the DGAT1 inhibitor (Figure 25, 
panel A, lanes Eto, D1). 
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 A combination of both inhibitors led to an even stronger downregulation of these species, 
which additionally confirms the previous experiments (Figure 25, panel A, lanes Eto+D1). 
Overall, Etomoxir treatment did increase the effects of the DGAT1 inhibitor. When combined 
with the DGAT2 inhibitor, the resembling effect of Etomoxir as an DGAT1 inhibitor was not as 
prominent as if the DGAT1 inhibitor would act upon combination with the other inhibitor.  
Surprisingly, in the DGAT1-/- hepatocytes, Etomoxir treatment alone led to a comparable NFC 
pattern as in the WT controls (Figure 25, panel B, lane labeled Eto). The MCFA-aTAG 
species (C41-47) were as well downregulated with values in between 0.23 – 0.77. The 
species with longer acyl chains were as well regulated in a similar manner as in the WT 
hepatocytes. As expected, the DGAT1 inhibitor showed little effect on the aTAG pattern 
compared to the negative control, as all values are located around 1 (Figure 25, panel B, 
lane labeled D1). Upon DGAT2 inhibition, the MCFA-aTAG pattern showed the same strong 
downregulation as when both DGAT inhibitors were combined in the WT controls (Figure 25, 
panel B, lane labeled D2). However, in DGAT1-/- hepatocytes absolute amounts of the main 
aMCTs were about half the concentration as in WT cells within the negative control 
(Supplementary figure 10). The aTAG species pattern with longer acyl chains did as well 
resemble the pattern as the one in WT hepatocytes treated with both inhibitors. As expected, 
the NFC pattern of Etomoxir combined with the DGAT1 inhibitor resembled the one as upon 
Etomoxir treatment alone (Figure 25, panel B, lane labeled Eto+D1). The combination of 
Etomoxir with the D2 inhibitor did increase the effects of the D2 inhibitor (Figure 25, panel B, 
lane labeled Eto+D2). This is best seen within the NFC pattern of the MCFA-aTAGs (C41-
47), which showed a strong downregulation with values between 0.03-0.25 and stronger 
upregulation within the main aTAGs [51:5-3], with values over 2.2. This may be due to an 
over-compensatory effect of the remaining DGAT2 activity.   
For better visualization of the described effects, the NFC pattern of the MCFA-aTAG species 
[41:2] – [45:3] are presented as floating bars (min to max with the line indicating the mean) 
(Figure 26). Bars below the dashed line indicate a downregulation, bars above the line an 
upregulation of aTAG levels. The effects throughout the species pattern within one inhibitory 
group were consistent in both, the WT control (Figure 26, panel A) and DGAT1-/- hepatocytes 
(Figure 26, panel B), especially upon downregulation. The bars cover a small area and the 
mean lines from each species within one group are nearly aligned. Two main effects are 
observable within this visualization. First, the downregulation pattern upon Etomoxir 
treatment within WT- and DGAT1-/--hepatocytes showed similar levels in all MCFA-aTAG 
species. And secondly, in WT hepatocytes, DGAT2 inhibition led to a significant upregulation 
of all MCFA species compared to all other inhibitory conditions (Figure 26, panel A), whereas 
in DGAT1-/- hepatocytes, all inhibitory conditions (except DGAT1 inhibition) led to a 
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significant downregulation of MCFA-aTAGs (in comparison to the levels upon DGAT1 
inhibition (Figure 26, panel B)). 
 
Figure 26: Detailed normalized fold change (NFC) analysis of short chain (C41-C45) alkyne-
labeled TAG species from primary hepatocytes, isolated from wildtype mice (A: WT) or mice 
lacking DGAT1 (B: ΔDGAT1), treated with inhibitor combinations and pulsed with alkyne-
palmitate and decanoic acid. After isolation, primary mouse liver hepatocytes were plated in 24 well 
plates with 7.5x104 cells per well. Cells were preincubated with either 50 µM Etomoxir (Eto), 3 µM 
DGAT1-Inhibitor (D1), 15 µM DGAT2-Inhibitor (D2) or combinations of Etomoxir with each DGAT-
inhibitor (Eto+D1, Eto+D2). Cells were then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM 
decanoic acid (C10) for 1 hour. Lipids were extracted with simultaneous addition of an internal 
standard mix for alkyne labeled lipids and click reaction with C175-XX reagents was performed. 
Multiplex samples were pooled and analyzed by MS. Mass signals were identified using LipidXplorer 
MFQL analysis with internal standard quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. 
Normalized fold changes (NFC) in concentrations of each lipid species for each inhibitor treatment 
were calculated by normalization to the negative control and to the average class fold change. The 
data is represented as floating bars (min to max) with the line indicating the mean value. n=3 biological 
replicates. **** stands for p≤0.0001. Isolation of hepatocytes and fatty acid pulse was done by CL, lipid 
extraction and MS/TLC analysis were done by KW. 
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Additionally, co-pulse experiments with C19- and C11-fatty acids were carried out, similar to 
the experiments described in the chapters 5.1 and 5.2.  
Here, the inhibitory effects of Etomoxir and JNJ-DGAT2-A (D2) in DGAT1-/- hepatocytes were 
observable as well. Like in the WT hepatocytes, Etomoxir treatment alone, reduced C11-
TAG levels significantly, whereas C19-TAG levels were not changed (Figure 27, panels A, B, 
lanes labeled Eto).  
Figure 27: Analysis of aTAGs upon DGAT2 inhibitor-, and Etomoxir-treatment in primary 
hepatocytes from wildtype mice (A: WT) and mice lacking DGAT1 (B: ΔDGAT1), co-pulsed with 
C11- and C19-fatty acids. After isolation, primary mouse liver hepatocytes were plated in 24 well 
plates with 7.5x104 cells per well.  Cells were preincubated with either 15 µM DGAT2-Inhibitor (D2), 50 
µM Etomoxir (Eto) or a combination of both inhibitors (D2/Eto) for one hour, in comparison to the 
respective vehicle as a negative control. Cells were then pulsed for 1 hour with a combination of 50 
µM C11- and 50 µM C19-fatty acid. The cells were washed, lipids were extracted and click reaction for 
TLC was performed. Finally, lipids were separated on a TLC plate and the signal was captured by 
fluorescent imaging (A, B). Panels C (WT) and D (ΔDGAT1) illustrate the normalized quantification of 
fluorescent intensities from C11 TAG (filled bars) and C19 TAG (grey hatched bars) upon either D2 
(blue), Etomoxir (orange) and combination of both (orange/blue) inhibitors, in comparison to the 
negative controls (black: C11, grey: C19). The data represent mean ±SD for n=3 biological replicates. 
* stands for p≤0.0332, *** for p≤0.0002 and **** for p≤0.0001. ns=not significant. Isolation of 
hepatocytes and fatty acid pulse was done by CL, lipid extraction and MS/TLC analysis were done by 
KW.      
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In DGAT1-/- hepatocytes, DGAT2 inhibition alone significantly reduced both, C11-TAG and 
C19-TAG levels, which decreased even further in combination with Etomoxir (Figure 27, 
panel B, lanes labeled D2, Eto/D2).  
Absolute amounts of overall labeled lipids upon all treatment conditions in DGAT1-/- 
hepatocytes were comparatively analyzed to those within the WT controls (Supplementary 
figure 8). Here any effects on the lipid levels other than the inhibitory treatment could be 
ruled out. 
Altogether, these experiments further solidify the hypothesis that DGAT1 is the key player in 
hepatic MCFA metabolism and that Etomoxir inhibits DGAT activity as a prominent off-target 
effect. This latter shall be elaborated within the discussion of this thesis.  
Also, for final clarification on the “Etomoxir-effect”, experiments with another liver-specific 
CPT1 inhibitor were conducted (see: Chapter 5.5). 
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5.4. DGAT inhibition during a short time in vivo LPS-stimulation 
Previous studies within the community and our group showed that an acute short time in vivo 
LPS stimulation in mice can induce a NAFLD-like, pro-steatotic phenotype, which is 
mediated via the TLR4 signaling pathway (Park et al., 2009) of Kupffer cells (Baffy, 2009). 
One of the key morphologic features of this pathological state, is the accumulation of TAG in 
hepatocytes (Baffy, 2009; Soares et al., 2010; Berlanga et al., 2014). In the following, 
previous results on this matter are expanded, by conducting DGAT specific inhibitory 
experiments on hepatocytes isolated from LPS induced mice, using alkyne lipid tracing 
followed by MS analysis.  
For that, mice were induced in vivo with 15 mg/kg LPS according to their respective body 
weight. 1.5 hours after the stimulation, hepatocytes were isolated by liver perfusion, seeded 
on 24 well plates and allowed to adhere for 2 hours. Then the hepatocytes were 
preincubated with a different combination of DGAT inhibitors (3 µM A922500 (D1), 15 µM 
JNJ-DGAT2-A (D2)) or Etomoxir, followed by a pulse with alkyne palmitate (C17:2) and 
decanoic acid (C10). The aim here was, not only to study the overall lipid composition, but to 
trigger as well the MCFA metabolism under the influence of an LPS induced pro-steatotic 
phenotype. 
First, the lipid profiles form hepatocytes, isolated from LPS stimulated mice, in comparison to 
the respective negative control, were analyzed. 
In three of the four major lipid classes which were analyzed, namely aTAG, aPA and aPC, 
significant changes in the absolute amount of all labeled lipids per class upon LPS- 
stimulation could be observed. All three of the lipid classes named above, showed at least 
one third higher amounts upon LPS stimulation than in the respective control (Figure 28, 
panels A, C, D, control: black bars, +LPS: red hatched bars). Only the labeled DAG showed 
no significant change in the absolute amount upon LPS stimulation (Figure 28, panel B, 
control: black bar, +LPS: red hatched bar).  
These results are comparable to previous findings from our group, where alkyne lipids had 
been used for metabolic tracing in pulse-chase experiments with hepatocytes isolated form 
either in vivo stimulated mice or in vitro stimulated hepatocytes (Piotrowitz, 2016).  
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Figure 28: Absolute amounts of alkyne-labeled lipid classes from primary hepatocytes, isolated 
from unstimulated (control: black bars) mice or mice stimulated with 15 mg/kg LPS for 1.5 
hours before hepatocyte isolation (+LPS: red hatched bars). Cells were pulsed with alkyne-
palmitate and decanoic acid. After isolation, primary mouse liver hepatocytes were plated in 24 well 
plates with 7.5x104 cells per well. Cells were co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 
µM decanoic acid (C10) for 1 hour. Lipids were extracted with simultaneous addition of an internal 
standard mix for alkyne labeled lipids and click reaction with C175-XX reagents was performed. 
Multiplex samples were pooled and analyzed by MS. Mass signals were identified using LipidXplorer 
MFQL analysis with internal standard quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. 
Absolute amounts of the lipid classes aTAG (A), aDAG (B), aPC (C) and aPA (D) are shown in pmol. 
The data represent mean SD± for n=18 technical replicates in n=3 biological replicates. *** stands for 
p≤0.0002 and **** for p≤0.0001. ns= not significant. 
 
Next, using the advantage of alkyne lipid detection for MS, changes on species level upon 
LPS-stimulation within the classes of aTAG, aDAG and aPC were analyzed (Figure 29, panel 
A (aTAG), panel B (aDAG) and panel C (aPC) Heatmap array of mean values from white (0 
pmol) to dark red (highest pmol value within each lipid class)).  
Within the classes of aTAG and aPC, absolute amounts from all analyzed species were 
equally elevated upon LPS treatment in comparison to the unstimulated control. This effect 
can be observed predominantly within the main species form each class: for TAG [45:4] and 
[45:3], representing the MCFA-aTAG species, and [51:4], [51:3], [53:5] and [53:4] 
representing the LCFA-aTAG species and the main aPC species [35:4], [35:3] (Figure 29, 
panels A (aTAG and C (aPC)). There were no obvious changes observable throughout all 
labeled DAG species (Figure 29, panel B (aDAG)). 
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Figure 29: Absolute amounts of alkyne-labeled lipid species from primary hepatocytes, isolated 
from unstimulated mice (control) and mice treated with 15 mg/kg LPS for 1.5 hours before 
hepatocyte isolation (+LPS). Cells were pulsed with alkyne-palmitate and decanoic acid. After 
isolation, primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. 
Cells were co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. 
Lipids were extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids 
and click reaction with C175-XX reagents was performed. Multiplex samples were pooled and 
analyzed by MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Absolute amounts of the lipid species 
within the lipid classes of aTAG (A), aDAG (B) and aPC (C) are shown in pmol. The data represent 
mean values for n=3 biological replicates. 
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To analyze the effects of a DGAT inhibition during the LPS-induced prosteatotic phenotype 
experiments for MS analysis of alykne labeled lipids, similar to those described earlier, were 
performed. Fold changes in aTAG and aDAG levels upon different combinations of DGAT 
inhibitors and Etomoxir in hepatocytes isolated from either LPS-induced mice or the 
respective control mice, were analyzed (Figure 30, panel A (TaAG), panel B (aDAG)). 
 
Figure 30: Fold change analysis alkyne-labeled TAG (A) and DAG (B) based on relative 
amounts (mol per mille) from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from unstimulated mice (filled bars) and mice treated with 15 mg/kg LPS 
for 1.5 hours before hepatocyte isolation (bars with dashed lines/ +LPS). Cells were treated 
with different inhibitor combinations and pulsed with alkyne-palmitate and decanoic acid. After 
isolation, primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. 
Cells were preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-
Inhibitor (D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells were 
then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids 
were extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and 
click reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by 
MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Fold changes (FC) in relative 
concentrations (from mol per mille) of alkyne TAGs and DAGs for each inhibitor treatment were 
calculated by normalization to the negative control. The data represent mean ±SD for n=3 biological 
replicates. * stands for p≤0.0332, ** for p≤0.0021, *** for p≤0.0002 and **** for p≤0,0001. ns=not 
significant. 
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In general, aTAG and aDAG levels responded similar under both conditions upon the 
treatment with the combination of different inhibitors.  
When treated with either D1 or Etomoxir alone, the decrease in aTAG levels  in hepatocytes 
from LPS stimulated mice was nearly as high as in hepatocytes form control mice (Figure 30, 
panel A, bars labeled Eto/Eto+LPS (orange/hatched), D1/D1+LPS (red/hatched)). Inhibition 
through D2 alone did not lead to a significant decrease in overall aTAG levels under both 
conditions (Figure 30, panel A, bars labeled D2 (blue/hatched)). A combination of Etomoxir 
with either one of the both DGAT inhibitors led to a further decrease of aTAG upon both 
conditions. However, in hepatocytes form control mice, the decrease was significantly higher 
upon both inhibitor combinations (Figure 30, panel A, bars labeled Eto+D1/LPS, 
Eto+D2/+LPS).  
Changes in aDAG levels in hepatocytes form LPS-stimulated mice upon inhibitory treatment, 
did as well resemble those from the control groups, with only minor differences observable.  
Etomoxir treatment, only led to a significant accumulation of aDAG upon LPS stimulation 
(Figure 30, panel B, bars labeled Eto (orange hatched)), whereas DGAT2 inhibition 
significantly increased only aDAG levels in the unstimulated animals. The combination of 
Etomoxir with both DGAT inhibitors, did lead to the same accumulation of aDAG in both, the 
LPS-stimulated and the control animals (Figure 30, panel B, bars labeled Eto+D1/LPS and 
Eto+D2/LPS), despite the significantly different response in aTAG levels. 
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5.5. Comparison of two CPT1 inhibitors: Etomoxir and Teglicar 
In the following chapter, the effects of Etomoxir on the hepatic TAG metabolism were 
experimentally compared with another CPT1 inhibitor, for further clarification on this matter. 
The small molecule inhibitor Teglicar (ST-1326) first described by R. Conti and colleagues in 
2011 (Conti et al., 2011), was chosen to fulfill that purpose. Teglicar has been in various 
clinical trials for Type-2 diabetes melitus until their discontinuation in 2015. Fortunately, it is 
freely available for scientific purposes since early 2018.  
As a first experimental setup, a co-pulse experiment with 50 µM of C11- and C19- alkyne 
fatty acid in hepatocytes, treated with either 50 µM Etomoxir, 10 µM Teglicar (Tegli) or a 
combination of both inhibitors, was done. The initial concentration of 10 µM for Teglicar was 
chosen according to the experiments done by R. Conti and colleagues in primary rat 
hepatocytes (Conti et al., 2011).  
 
Figure 31: Analysis of aTAGs upon Etomoxir- and Teglicar-treatment in primary hepatocytes, 
co-pulsed with C11- and C19-fatty acids. After isolation, primary mouse liver hepatocytes were 
plated in 24 well plates with 7.5x104 cells per well.  Cells were preincubated with either 50 µM 
Etomoxir (Eto), 10 µM Teglicar (Tegli) or a combination of both inhibitors (Eto/Tegli) for one hour, in 
comparison to the respective vehicle as a negative control. Cells were then pulsed for 1 hour with a 
combination of 50 µM C11- and 50 µM C19-fatty acid. The cells were washed, lipids were extracted 
and click reaction for TLC was performed. Finally, lipids were separated on a TLC plate and the signal 
was captured by fluorescent imaging (A). Panel B illustrates the normalized quantification of 
fluorescent intensities from C11 TAG (filled bars) and C19 TAG (grey hatched bars) upon either 
Etomoxir (orange), Teglicar (mint) and combination of both (orange/mint) inhibitors, in comparison to 
the negative controls (black: C11, grey: C19). The data represent mean ±SD for n=3 biological 
replicates. ** stands for p≤0.0021. ns=not significant.      
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As shown previously, the treatment with Etomoxir led to a significant decrease in C11- TAG 
levels (Figure 31, panel A, lanes labeled Eto, panel B orange bar, labeled Eto/C11).  
A treatment with Teglicar alone did not lead to a decrease in either C11- nor C19- TAG levels 
(Figure 31, panel A, lanes labeled Tegli, panel B green bars, labeled Tegli). The combination 
of Teglicar with Etomoxir did not increase the C11-TAG reduction, nor did it change C19-
TAG levels (Figure 31, panel A lanes labeled Eto/Tegli, panel B, orange/green hatched bars 
labeled Eto/Tegli). For better comparison of both CPT1 inhibitors, pulse experiments for MS 
analysis of alkyne labeled lipids were done. Here, hepatocytes were pre-pulsed with 50 µM 
Etomoxir and either 10-, 20- or 50 µM Teglicar or a combination of both inhibitors and pulsed 
afterwards with a combination of 50 µM C17:2 and 50 µM C10. 
 
Figure 32: Fold change analysis of alkyne-labeled TAG (A) and DAG (B) based on relative 
amounts (mol per mille) from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from WT mice treated with different combinations of Etomoxir and 
Teglicar and pulsed with alkyne-palmitate and decanoic acid. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were preincubated with 
either 50 µM Etomoxir (Eto), 10 µM Teglicar (Tegli 10), 20 µM Teglicar (Tegli 20), 50 µM Teglicar 
(Tegli 50) or combinations of Etomoxir with each Teglicar concentration (Tegli XX + Eto). Cells were 
then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids 
were extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and 
click reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by 
MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Fold changes (FC) in relative 
concentrations (from mol per mille) of alkyne TAGs and DAGs for each inhibitor treatment were 
calculated by normalization to the negative control. The data represent mean ±SD for n=3 biological 
replicates. *** stands for p≤0.0002 and **** for p≤0.0001. ns=not significant. 
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FC analysis for overall aTAG and aDAG levels upon inhibitory treatment revealed striking 
differences in between both CPT1 inhibitors. Whereas 50 µM Etomoxir decreased overall 
aTAG levels (Figure 32, panel A, bar graph labeled Eto), Teglicar treatment resulted in an 
opposite effect. 
Teglicar concentrations of 10- and 20 µM had no significant effect on overall aTAG levels 
(Figure 32, panel A, bar graphs labeled Tegli 10 and Tegli 20).  
When hepatocytes were treated with 50 µM Teglicar alone, overall aDAG and especially 
aTAG levels increased significantly (Figure 32, panels A (aTAG) and B (aDAG), bar graphs 
labeled Tegli 50). aDAG accumulation upon Teglicar treatment was not as high as upon 
Etomoxir treatment (Etomoxir about 2-fold increase and Teglicar about 1.5-fold increase, 
(Figure 32, panel B, bar graphs labeled Eto, Tegli 50).  
The combination of Etomoxir with 10- or 20 µM Teglicar only led to the same effects on 
aTAG levels, as with Etomoxir alone (Figure 32, panels A (aTAG), B (aDAG), bar graphs 
labeled Tegli 10/20 + Eto). The combinatorial treatment of both inhibitors did lead to a 
concentration-dependent increase in aDAG accumulation, with the highest values of 2.5-fold 
increase upon the combination of 50 µM Etomoxir and Teglicar each (Figure 32, panel B, bar 
graphs labeled Tegli 10/20/50 + Eto). 
Overall, the impact of Etomoxir on decreasing aTAG levels was more prominent compared to 
the accumulative effect form Teglicar, as in equimolar concentrations of both inhibitors, 
aTAG levels were significantly decreased (Figure 32, panel A, bar graph labeled Tegli 50 + 
Eto). 
FC analysis of overall aPA levels revealed no significant changes upon either treatment 
condition (Supplementary figure 11, panel B).  Interestingly, FC analysis of overall aPC levels 
did show a reduction upon treatment with 50 µM Teglicar alone, which was equaled in the 
combinatorial treatment with Etomoxir (Supplementary figure 11, panel A).  
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In order to see, whether the accumulative effect on aTAG levels upon treatment with 50 µM 
Teglicar affected all labeled TAG species, absolute amounts within all aTAG species from 
the previous experiments were visualized together with absolute amounts from the samples 
treated with either Eto, Tegli 50 + Eto and the negative control (Figure 33, Heatmap array of 
mean values from white (0 pmol) to dark green (over 130 pmol)). This analysis revealed, that 
the accumulative effect of Teglicar, indeed, affected aTAG species of all chain lengths.  
Figure 33: Absolute amounts of alkyne-labeled TAG species from primary hepatocytes, 
isolated from WT mice, treated with combinations of Etomoxir and Teglicar and pulsed with 
alkyne-palmitate and decanoic acid. After isolation, primary mouse liver hepatocytes were plated in 
24 well plates with 7.5x104 cells per well. Cells were preincubated with either 50 µM Etomoxir (Eto), 50 
µM Teglicar (Tegli 50) or combinations of both inhibitors (Tegli 50 + Eto). Cells were co-pulsed with 50 
µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were extracted with 
simultaneous addition of an internal standard mix for alkyne labeled lipids and click reaction with 
C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. Mass signals 
were identified using LipidXplorer MFQL analysis with internal standard quantification for aTAG, 
aDAG, aPC, aPA, aCE and aCER. Absolute amounts of the lipid species within the lipid class of aTAG 
are shown in pmol. The data represent mean values for n=3 biological replicates. 
  
This is best observable within the main species of each sub-class (Summarized in Figure 34, 
panel A (major MCFA-aTAGs) and panel B (major LCFA-aTAGs)). One can also observe, 
that the inhibitory effect of Etomoxir which cannot be compensated through the opposite 
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effect of Teglicar, is mainly due to the reduction in MCFA-aTAG levels. Upon treatment with 
50 µM Teglicar, absolute amounts from the four main MCFA-aTAG species were all 
significantly increased, whereas treatment with either Etomoxir alone or in combination with 
Teglicar, both strongly reduced these aTAG species (Figure 34, panel A). 
The major LCFA-aTAGs on the other hand, were not so strongly affected by the treatment 
with Etomoxir. Therefore, the accumulative effect of Teglicar was still visible even in the 
presence of Etomoxir. This is best observed within the aTAG species [51:4] and [51:3], from 
which TAG [51:4] was significantly increased, both in the presence of Teglicar alone and 
upon combination with Etomoxir (Figure 34, panel B). 
Figure 34: Absolute amounts of alkyne-labeled MCFA-aTAG (A) and LCFA-aTAG (B) species 
from primary hepatocytes, isolated from WT mice, treated with combinations of Etomoxir and 
Teglicar and pulsed with alkyne-palmitate and decanoic acid. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were preincubated with 
either 50 µM Etomoxir (Eto), 50 µM Teglicar (Tegli 50) or combinations of both inhibitors (Tegli 50 + 
Eto). Cells were co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 
hour. Lipids were extracted with simultaneous addition of an internal standard mix for alkyne labeled 
lipids and click reaction with C175-XX reagents was performed. Multiplex samples were pooled and 
analyzed by MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Absolute amounts of the lipid species 
within the lipid class of aTAG are shown in pmol. The data represent mean ±SD for n=3 biological 
replicates. * stands for p≤0.0332, ** for p≤0.0021, *** for p≤0.0002 and **** for p≤0.0001.  
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Both, Etomoxir and Teglicar are inhibitors of CPT1 and therefore inhibit mitochondrial β-
oxidation by hindering the transport of activated acyl-CoAs though the inner mitochondrial 
membrane towards the matrix, before entering the β-oxidation pathway (Turnbull et al., 1984; 
McGarry and Brown, 1997; Conti et al., 2011). This results in reduction of the cellular 
oxidation rate and should be therefore observable in a reduced OCR. In order to compare 
the ability of Etomoxir and Teglicar to inhibit hepatic CPT1 in equimolar concentrations, 
hepatocytes were treated with either 50 µM Etomoxir, 50 µM Teglicar as well as with 3 µM 
A922500 (D1) in addition to the respective negative control, followed by OCR measurement, 
using the Seahorse XF Analyzer Technology from Agilent. 
Figure 35: Normalized fold change analysis of live cell OCR measurement (pmol/min) in 
hepatocytes isolated from WT mice treated with Etomoxir, Teglicar or A922500 (D1). After 
isolation, primary mouse liver hepatocytes were plated in a Seahorse XF Analyzer 96 well plate with 
1000 cells per well. Cells were allowed to adhere for two hours before the assay procedure was 
started (see: Chapter 3.6.). After 5 measuring cycles of baseline OCR measurement the inhibitors 
were injected, and the measurement was resumed for 8 more cycles. The inhibitors were used with 
the following final assay concentrations: D1 (red line): 3 µM, Etomoxir (orange line): 50 µM, Teglicar 
(dark green line), 50 µM and the negative control (neg/black line). Normalized fold changes were 
calculated for each well with the average value of all 5 baseline measurements set as 1. The data 
represent mean ±SD for n=2 biological replicates with 4 technical replicates. ** stands for p≤0.0021 
and **** stands for p≤0.0001, ns=not significant. Results of the statistical analysis are only shown for 
the last measuring cycle (13). 
 
As expected, treatment with the DGAT1 inhibitor A922500 did not lead to a reduced cellular 
oxygen consumption rate (Figure 35, red line (D1)). Treatment with Etomoxir or Teglicar did 
lead to a significant drop in the measured OCR, proofing that both molecules indeed reduce 
β-oxidation via CPT1 inhibition. However, treatment with Teglicar did lead to a more 
significant drop in the OCR after 8 measuring cycles than Etomoxir, even though both are 
used in the same concentration (Figure 35, orange (Etomoxir) and green line (Teglicar)). 
Upon treatment of hepatocytes with 5 µM Etomoxir, no drop in the OCR could be observed 
(Supplementary figure 12).  
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6. Discussion 
6.1. DGAT1 primarily facilitates murine hepatic MCFA incorporation 
into TAG  
Although DGAT1 and DGAT2 seem to have different physiological functions, which is 
reflected by the different phenotypes of their knockout mouse models, the ability of hepatic 
DGAT1 and DGAT2 to partially compensate for each other in TAG synthesis, has been 
shown in previous studies (Smith et al., 2000; Stone et al., 2004; Li et al., 2015). In this work, 
the compensating ability of DGAT enzymes was analyzed in more depth, focusing on the 
analysis of chain length and saturation preferences of each DGAT enzyme, using different 
DGAT inhibitors and the DGAT1-/- mouse model combined with MS-based alkyne lipid tracing 
with species resolution. 
As already mentioned, there are various studies, dealing with acyl-chain length and 
saturation preferences from each DGAT enzyme. Studies working with mammalian and 
fungal DGAT enzymes proclaim a preference of DGAT2 for medium-chain CoAs, whereas in 
many plant species DGAT1 isoforms are associated with preference for medium-chain CoAs 
in seed oil production (Lardizabal et al., 2001; Aymé et al., 2015; Iskandarov et al., 2017; 
Klizaite, 2017). In the experiments presented in chapter 5.1 of this study using DGAT1 and 
DGAT2 inhibitors during an C19/C11-FA co-incubation, showed a drastic reduction of C11-
FA incorporation into TAG upon DGAT1 inhibition, whereas C19-FA incorporation was 
slightly elevated (Figure 11). Upon DGAT2 inhibition, the vice versa effect could be 
observed, whereas a combination of both inhibitors nearly abolished MCT production with a 
corresponding accumulation of DAGs (Figure 11). These observations from the TLC 
experiments already suggested a DGAT1 preference for MCFA in hepatocytes. 
 Using the newly developed MS-based detection system for alkyne lipids, similar experiments 
were conducted, utilizing only C17:2 for tracing aTAG levels upon DGAT inhibitory treatment. 
For overall aTAG levels, the MS experiments did show comparable results to these obtained 
from TLC analysis (Figure 22 A, B). The detailed NFC array analysis, however, revealed a 
complex pattern of up- and downregulated aTAG species upon inhibitory treatment. The 
proposed acyl-chain length preference for both DGATs was confirmed, as all shorter chain 
aTAG species showed a strong downregulation upon DGAT1 inhibition and a strong 
upregulation upon DGAT2 inhibition (Figure 23). Additionally, this dataset shows a tendency 
towards saturation preferences of each DGAT enzyme. DGAT1 seems to prefer more 
saturated species in the LCFA-aTAGs, as upon inhibition, the most saturated members in 
this group were downregulated. A combination of both inhibitors led to an even further 
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downregulation of aMCTs with a few strongly upregulated aLCT species. The latter 
correspond to TAGs synthetized from the most abundant FA species in murine hepatocytes, 
namely palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0) or oleic acid 
(C18:1) (Kindt et al., 2018). This may reflect a compensating effect of the remaining DGAT 
activity, maintaining FFA homeostasis by metabolizing DAGs which originate from 
remodeling of phospholipids, which contain mainly the FAs mentioned above.  
In DGAT1-/- hepatocytes, slightly reduced aMCTs and increased aLCTs were observed while 
overall aTAG levels were similar (Figure 20 A, Figure 21 A, Supplementary figure 10, lanes 
labeled neg). As both cell types were fed with C17:2-FA and C10-FA, differences due to a 
lack of C10-CoA can be ruled out. The analogous TLC-experiments also showed slightly 
reduced C11-TAG levels in comparison to C19-TAG levels (Figure 26 B, data not quantified). 
Upon DGAT2 inhibition, a TAG phenotype like the one in WT hepatocytes where both 
DGATs were inhibited could be reproduced. aMCT levels were further reduced as well 
(Figure 24 B, 25 B, 26 B/D). As no DGAT1 was present, this suggests, that the 
compensating ability of DGAT2 for DGAT1 includes a certain flexibility in DGAT2’s 
preference for acyl-CoAs, including those predominantly preferred by DGAT1. It is known, 
that DGAT2 locates both to the ER and LDs, whereas DGAT1 only locates to the ER 
(Kuerschner et al., 2008; Stone et al., 2009; Wurie et al., 2011). DGAT2 is also described to 
have a broader acyl-CoA specificity (Yen et al., 2008). The study of Li and colleagues 
suggests that the function of murine hepatic DGAT1 is mainly to channel FAs into TAG, 
which are then prone to be β-oxidized (Li et al., 2015). Altogether this may suggest, that 
hepatic DGAT1 acts mostly on MCFAs and that the DGAT2 population located at the ER is 
solely responsible for compensating the missing DGAT1 activity in DGAT1-/- hepatocytes. 
Thus, the pressure on the system created through additional DGAT2 inhibition may be 
reduced by direct oxidation of the acyl-CoAs without channeling them through a TAG pool 
first, resulting in further decrease of MCT levels. As hepatic β-oxidation of MCFAs was 
shown to be very abundant, the mechanisms mentioned above provide a possible 
explanation (Pégorier et al., 1988; Metges and Wolfram, 1991). Similar effects in DGAT1-/- 
hepatocytes were observed upon Etomoxir treatment, which are discussed in chapter 6.2.  
Also, the pulse-chase experiments presented in chapter 5.3.1. showed an DGAT1- 
dependent incorporation of MCFAs into TAG. As these experiments were also including a 
comparison to Etomoxir-treatment, they are discussed in chapter 6.2.  
In all experiments conducted with the DGAT inhibitors in WT hepatocytes, either within the 
TLC-based or the MS-based experiments, overall effects on aTAG levels were always more 
prominent upon DGAT1- rather than DGAT2-inhibition. A study in HepG2 cells, showed that 
DGAT1 is responsible for about 80% of overall TAG synthesis (Qi et al., 2012). This might 
serve as a possible explanation for the stronger overall effects on TAG levels upon DGAT1 
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inhibition, presented in this thesis. However, as the metabolic properties of HepG2 cells are 
not directly comparable to those of primary hepatocytes this interpretation should be 
considered with caution. It also has been proposed, that DGAT1 predominantly acts on FA 
from exogenous sources, whereas DGAT2 mainly utilizes FA from de novo synthesis 
(Villanueva et al., 2009; Qi et al., 2012). As the hepatocytes were always exogenously fed 
with fatty acids, one would expect a more drastic effect upon DGAT1 inhibition. However, as 
already mentioned, the experiments in DGAT1-/- hepatocytes, showed similar overall 
concentrations of aTAG. Also considering the fact that in DGAT1-/- hepatocytes, the overall 
labeled lipid concentrations were similar to those in WT controls (Supplementary figure 8), it 
may be postulated that DGAT2 can, at least in murine hepatocytes, fully compensate for the 
loss of DGAT1, to maintain the overall TAG levels.  
Changes in levels of aPC and aPA upon inhibitor treatment were visible as well 
(Supplementary Figure 9). aPA levels were significantly reduced upon either inhibitor 
treatment, both in WT and DGAT1-/- hepatocytes. This may be due to a positive feedback 
loop from accumulating DAG, which triggers a faster channeling of PA to form PI and PG. As 
the reduced aPA was also visible upon DGAT1 inhibitory treatment in DGAT1-/- hepatocytes 
it may represent an off-target effect form the DGAT1 inhibitor affecting other enzymes 
upstream of PA. However, as aPC and aDAG levels were not altered significantly in DGAT1-/- 
hepatocytes upon DGAT1 inhibition (Figure 24 B, Supplementary Figure 9), it is not possible 
to proof this hypothesis. aPC levels were significantly increased in WT cells upon DGAT1 
inhibition, but in DGAT1-/- hepatocytes only upon DGAT2 inhibition. This is most likely due to 
the highest increase of DAG levels upon the strongest DGAT inhibition in each condition, and 
therefore excess DAG is as well channeled into PC synthesis.  
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6.2. Etomoxir can act as a DGAT inhibitor, predominantly targeting 
DGAT1 
Etomoxir has been first described as an irreversible inhibitor of mitochondrial LCFA β-
oxidation by targeting CPT1 and therefore hindering the formation of acylcarnitine, which  are 
necessary for the translocation of LCFA into the mitochondrial matrix (Kiorpes et al., 1984). 
Alongside other selective inhibitors of CPT1 like Perhexiline, it soon came into focus as a 
possible antidiabetic drug by shifting the cellular energy utilization from fatty acids to glucose, 
leading to hypoglycemia, hypoketonemia, and hypotriglyceridemia (Selby and Sherratt, 1989; 
Wolf, 1992; Ashrafian et al., 2007). However, it never was fully approved in clinical trials due 
to severe systemic side effects, such as hepatic hypertrophy, inducing cellular oxidative 
stress and activation of transcription factors like PPARα and nuclear factor kappaB (NF-κB) 
(Yotsumoto et al., 2000; Merrill et al., 2002; Cabrero et al., 2003; Carracedo et al., 2013). 
With an increasing understanding of the role of FA oxidation in tumor growth and cancer 
metabolism in general, CPT1 and therefore its inhibitors have been most recently receiving 
rejuvenated attention as possible anti-cancer drugs (Qu et al., 2016). In a recent study, 
Etomoxir has been shown to suppress tumor progression and to induce cell cycle arrest via a 
PPARγ-mediated pathway in bladder cancer (Cheng et al., 2019). Also, an upregulated 
CPT1A activity in patients suffering from depression, has led to a recent study where the 
common antidepressant Escitalopram (SSRI) and Etomoxir have been comparatively 
analyzed on stress-induced depressed rats. Here, the blocking of FAO through the inhibition 
of CPT1 via Etomoxir has been shown to effectively reduce the stress-induced depression in 
the animals (Mørkholt et al., 2017). Through the renewed interest in Etomoxir as a candidate 
drug for various applications and the rising numbers of scientists from different fields dealing 
with the cellular effects of this drug in various cell types, more off-target effects of Etomoxir 
have been discovered. Many of these studies investigate off-target effects of Etomoxir in 
different immune cells, using relatively high concentrations between 40-200 µM (Raud et al., 
2018). It has been shown that Etomoxir effectively inhibits FAO in BMDMs at a concentration 
of 3 µM but a concentration of 100 µM affects IL4-mediated macrophage polarization, 
independent of CPT1 activity by disrupting intracellular CoA levels (Divakaruni et al., 2018). 
In the same study it was also shown that Etomoxir inhibits the adenine nucleotide 
translocase (ANT), increasing mitochondrial membrane potential (Divakaruni et al., 2018). It 
has been shown as well, that high concentrations (above 100 µM) of Etomoxir induce severe 
oxidative stress in T-cells and alters T-cell proliferation and differentiation (O'Connor et al., 
2018; Raud et al., 2018). As another off-target effect, it has been shown that at 
concentrations of 200 µM, Etomoxir inhibits Complex 1 of the respiratory chain (Yao et al., 
2018). Importantly, Etomoxir inhibiting DGAT activity, as a side effect has been reported, in a 
study using in H9c2 cells (Xu et al., 2003). In this study, H9c2 cells were treated with 40 µM 
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Etomoxir, resulting in a reduced [1-14C] palmitic acid incorporation into TAG due to a 
diminished DGAT activity. Additionally, Etomoxiroyl-CoA inhibited DGAT activity in vitro (Xu 
et al., 2003). Still, this study did not determine specifically whether DGAT1 or DGAT2 was off 
targeted by Etomoxir and focused only on incorporation of palmitic acid without determination 
of species-specific differences in the TAG profile upon Etomoxir treatment. The experimental 
data in the present work describes the inhibition of DGAT enzymes in murine primary 
hepatocytes by Etomoxir and identifies DGAT1 as the predominantly targeted family 
member.  
Interestingly, the present TLC analysis, did not show a reduced incorporation of alkyne 
palmitate (C17:2) upon Etomoxir treatment, but only a reduced incorporation of C11 into TAG 
(Figures 14, 15). This was also shown for alkyne oleate (C19) before (Klizaite, 2017).  
In contrast, the data on C19 incorporation upon Etomoxir treatment presented here, showed 
slightly (but not significantly) elevated aTAG labeling (Figures 11, 13 and 26 A) or a 
significant increase (Figure 12).  
Alike, an enhanced incorporation of [1-14C] oleic acid was observed in EL4 cells upon 
treatment with 100 µM Etomoxir (Boren and Brindle, 2012). Based on the findings above, an 
inhibition of DGAT1 by Etomoxir and DGAT2 compensating for DGAT1 appears the primary 
reason for the observed increase in LCTs, rather than an inhibition of CPT1, resulting in 
elevated acyl-CoAs through decreased oxidation. This hypothesis is supported by the data 
depicted in the NFC arrays, when hepatocytes were treated with Etomoxir and a D1 inhibitor 
(Figure 24 A). Both NFC arrays basically look the same in terms of up- and downregulated 
aTAG species, including the upregulated LCT species with either one or two molecules of 
oleic acid incorporated. The inhibition of DGAT1 by Etomoxir is best demonstrated by the 
diminished MCFA incorporation into TAGs or generally spoken the reduced levels of MCTs. 
Both, Etomoxir and the DGAT1 inhibitor show the same effects in TLC experiments, leading 
to decreased C11-TAG levels (Figures 12-15, 24 A). This finding was confirmed by extensive 
MS analysis. Here the effects on aMCTs could be observed by NFC array analysis showing 
a downregulation of the aMCT species TAG [41-47] upon action of Etomoxir and a D1 
inhibitor (Figures 24 A, 25 A).  
However, these experiments show a metabolic state after one hour of a constant pulse from 
the alkyne FA under inhibitory treatment. Thus, short term lipid remodeling of phospholipids 
or possible hydrolysis of TAGs via ATGL/HSL at LDs and subsequent re-esterification via 
DGAT2 (Eichmann and Lass, 2015), or TAG hydrolysis generating FFAs which are then 
catabolized through β-oxidation, may generate similar changes in lipid patterns, originating 
from different metabolic pathways. Also, the alkyne group of the C11-FA may influence the 
natural cellular metabolism of the FA, creating artifacts which lead to the discussed results. 
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These problems are overcome by conducting a pulse-chase analysis as presented in chapter 
5.3.1. As it has been shown, that hepatocytes are able to synthetize TAGs within 2 minutes 
form incorporated pools of extracellular free fatty acids (Stein and Stein, 1967), a short pulse 
in combination with several short chase time points is necessary, in order to follow the direct 
biosynthesis of endpoint metabolites such as TAG and PC by incorporation of an unlabeled, 
native FA-CoA into alkyne labeled precursor metabolites such as PA and DAG. This is 
exactly what these experiments could show. Not only, that from the technical point of view 
the metabolites behaved as expected from previous studies in our laboratory and from the 
literature (Stein and Stein, 1967; Piotrowitz, 2016), but additionally these experiments could 
also show the DGAT1 dependent incorporation of native decanoic acid into a labeled DAG 
pool (Figures 17-19). Here, both the DGAT1-inhibitor and Etomoxir did decrease the 
incorporation of decanoic acid in the same manner, decreasing levels even further when 
combined. It is unlikely, that the effect is due to a DGAT2 inhibition by Etomoxir, as the 
changes in medium-chain aTAG levels were never observed upon solely a DGAT2 inhibition, 
when both DGATs were present. In this scenario, Etomoxir creates only effects as seen from 
the DGAT1 inhibitors. 
Interestingly, in DGAT1-/- hepatocytes the treatment of Etomoxir did lead to the same NFC 
pattern change in aTAG levels. As expected, the DGAT1 inhibitor did not show any 
significant changes throughout all aTAG species (Figures 25 B, 26 B, 27 B). Nevertheless, 
even though Etomoxir creates nearly the same NFC pattern, absolute concentrations of the 
main aMCTs were about half the size as in WT cells in the neg control. Thus, the effects on 
aMCTs are not as prominent in DGAT1-/- hepatocytes in terms of absolute concentrations, 
even though they appear so in the NFC arrays. Generally, this effect can be explained with 
the compensating DGAT2 activity at the ER as mentioned before, presumably compensating 
for the loss of ER specific DGAT1 activity, which is then inhibited by Etomoxir. However, the 
overall effect on aTAG and aDAG levels by Etomoxir treatment was not as prominent in 
DGAT1-/- hepatocytes as in WT cells (Figure 27 A, B). Taken together this suggests that 
Etomoxir can act as a potent DGAT inhibitor which preferably inhibits DGAT1, but as well 
seems to partly inhibit DGAT2 activity which locates at the ER.  
Teglicar, the small molecule inhibitor for the liver isoform of CPT1, served as a perfect 
control drug concerning the proposed off-target effects of Etomoxir on DGAT enzymes. Both, 
Teglicar and Etomoxir, did significantly reduce the cellular oxygen consumption rate in 
equimolar concentrations of 50 µM (Figure 35). However, they did cause opposite effects on 
aTAG levels. In accordance with the initial study by Conti and colleagues where Teglicar 
treatment was described to elevate liver TAG levels in healthy rats and db/db mice (Conti et 
al., 2011), significantly elevated aTAG levels in 50 µM Teglicar-treated hepatocytes could be 
observed (Figure 32, 33). This is exactly what one would expect, when CPT1 is inhibited. 
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Acyl-CoAs are no longer shuttled into the mitochondria and start accumulating within the 
cytoplasm. As a protective result against the toxic effects of high intracellular acyl-CoA levels 
the cells start to incorporate excessive acyl-CoAs into TAG (Aon et al., 2014). It has been 
shown that peroxisomal β-oxidation can serve as a backup system when the mitochondrial 
function is impaired and that Teglicar does not alter peroxisomal oxidation (Conti et al., 2011; 
Violante et al., 2013). However, the present data suggests, that murine hepatocytes also 
expediently cope with excess acyl-CoA through direct incorporation into TAG and storage in 
LDs. Upon Teglicar treatment (50 µM), the four main MCFA-aTAG species including 
decanoic acid (C10), TAG [43:3], [43:2], [45:4] and [45:3], were as well elevated to a great 
extend (Figure 33). This allows the conclusion, that CPT1-dependent conversion of MCFAs 
plays indeed a bigger part in mitochondrial β-oxidation, other than the proposed diffusion of 
MCFA-CoAs through the mitochondrial membrane, independent of the carnitine shuttle 
system (Bremer, 1983; Odle et al., 1991). However, all experiments were done in medium 
containing glucose. FAO is shown to be more active during fasting conditions (Guo et al., 
2006). Hence, it would be interesting to repeat these experiments during glucose fasting 
conditions. Here, CPT1-dependent FAO would be higher and effects due to an inhibition of 
CPT1 could be stronger as well.   
As expected, the combination of Etomoxir and Teglicar, lead to reduction of aTAG species 
according to the discussed DGAT1-dependent inhibition by Etomoxir, whereas the aTAG 
species which are not affected through inhibition still showed accumulative effects (Figures 
33, 34). Through treatment of 50 µM Teglicar, a slight accumulation of aDAGs could be 
observed, likely via biosynthesis from elevated levels of acyl-CoAs and PA, as aPA levels 
were not elevated (Figure 32, Supplementary Figure 11 B). The treatment with 50 µM 
Teglicar alone, did lead to a reduction of overall aPC levels. This may be due to either an 
influence of Teglicar treatment on enhanced phospholipase C and/or enhanced 
sphingomyelin synthase activity at the ER and the plasma membrane. A shift form 
phospholipid synthesis to an enhanced TAG synthesis, dealing with the excess acyl-CoA 
levels due to reduced mitochondrial β-oxidation, could as well serve as an explanation.   
As Etomoxir was always used at a concentration of 50 µM, one might also consider the 
possibility of different off-target effects, affecting different enzymatic pathways, thus creating 
these results. However, as hepatocytes have high metabolic rates in general, and pilot 
experiments performed with lower concentrations of Etomoxir did not show a drop in OCR 
(Supplementary figure 12), it is plausible that the inhibition of DGAT enzymes is an off-target 
effect of Etomoxir, which already manifests at low concentrations, where only CPT1 is also 
effectively inhibited. Many of the other off-target effects, mentioned above manifested at 
higher concentrations over 100 µM and were described in other cell types like different 
immune cells. Those cells are likely to have a lower metabolic capacity then hepatocytes. 
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Therefore, it is unlikely that the off-target effects shown in immune cells, manifest in 
hepatocytes at even lower concentrations. Nevertheless, this may be addressed in future 
studies. Additionally, treatment with the second CPT1 inhibitor Teglicar lead to a detectable 
change in lipid profiles at concentrations of 50 µM, whereas no changes were observable at 
lower concentrations. Taken together, this allows the conclusion that the inhibition of DGAT 
enzymes by Etomoxir is an off-target effect, which appears at rather low concentrations in 
the same range as the effective concentration for CPT1 inhibition. 
6.3. DGAT inhibition upon an LPS-induced steatotic phenotype 
It has been shown, that a diminished DGAT1 activity can protect mice from a high fat diet 
induced hepatic steatosis, due to reduced exogenous FA incorporation into TAG (Villanueva 
et al., 2009). Moreover, it has been shown, that DGAT1 expression is increased within 
humans with NAFLD (Kohjima et al., 2007). Hence, as it has been shown by our group and 
by other studies that a short term in vivo LPS injection, mimics a hepatocellular response 
comparable to a prosteatotic phenotype (Baffy, 2009; Berlanga et al., 2014; Piotrowitz, 
2016), the intention was to investigate how inhibition of DGAT enzymes, especially DGAT1, 
influences the TAG profile upon these conditions. In accordance to the literature and 
previous findings from our group, overall lipid levels, especially aTAG and aPC (Figure 28), 
could be observed upon LPS-stimulation (Baffy, 2009; Berlanga et al., 2014; Piotrowitz, 
2016). From the technical point of view, this proofs indeed a response in hepatic lipid 
metabolism to the in vivo LPS-stimulation, shifting towards a prosteatotic phenotype. Upon 
comparison of aTAG lipid species, one could observe that all species were elevated in the 
same ratio, compared to the controls (Figure 29, panel A). This was also true for aDAG and 
aPC species (Figure 29, panel B, C). For aTAG synthesis, this already hints towards an 
equally upregulated DGAT1 and DGAT2 activity upon LPS-stimulation, at least under these 
experimental conditions. And indeed, when one observes overall responses of aTAG and 
aDAG levels upon DGAT- and Etomoxir-treatment (Figure 30, panels A, B), all responses 
upon inhibitory treatment were merely comparable to those of the control groups. Exceptions 
were the combinations of Etomoxir with each DGAT inhibitor. Here aTAG levels were 
significantly lower in the control group compared to the LPS induced group (Figure 30, panel 
A). Nevertheless, at least under these conditions, there was no evident preference of one 
DGAT enzyme over the other upon an LPS induced prosteatotic phenotype. In order to 
evaluate this matter further, more time resolved pulse-chase experiments and the inclusion 
of DGAT1-/- hepatocytes into the experimental setup would be beneficial. 
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6.4. Concluding hypothesis 
Based on the experimental data presented in this thesis in relation to what is known from the 
literature, a working model for hepatic DGAT1-dependent MCFA metabolism is introduced 
and summarized in Figure 36. The data from this thesis allows the conclusion, that murine 
hepatic DGAT1 acts predominantly on MCFA-CoA incorporation into TAGs. This MCFA-TAG 
pool might be then mostly used for catabolic processes, which appears logical, as MCFAs 
can be efficiently β-oxidized by hepatocytes (Pégorier et al., 1988; Metges and Wolfram, 
1991). When DGAT1 activity is diminished either through inhibition or in DGAT1-/- mice, the 
DGAT2 pool located on the ER can compensate for the lacking DGAT1 activity with a certain 
flexibility towards the acyl-CoA spectrum predominantly preferred by DGAT1. 
 
 
Figure 36: Proposed functional model of DGAT1 and DGAT2 in metabolizing MCFAs and 
LCFAs in murine hepatocytes. Activated MCFA-CoAs are predominantly incorporated by DGAT1 at 
the ER into a TAG pool, which is mainly used for catabolic processes via mitochondrial or peroxisomal 
β-oxidation. The DGAT2 pool, located at the ER can compensate for the loss or reduction of DGAT1 
activity. The CPT1 inhibitor Etomoxir, inhibits mostly DGAT1 and to some extent DGAT2 at the ER as 
a prominent off-target effect, thus reducing the TAG pool created by DGAT1. Teglicar, another CPT1 
inhibitor, does not show this off-target effect. TAG levels are elevated upon treatment, due to 
increased acyl-CoA incorporation, as the FAO of acyl-CoAs is efficiently impaired.  
  
In the literature, mammalian DGAT2 has been proposed to have a broader substrate 
specificity and might also favor MFCA-CoAs (Lardizabal et al., 2001; Cases et al., 2001), 
whereas in several plant species, DGAT1 isoforms have been shown to act predominantly on 
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MCFA-CoA incorporation, forming MCTs rich seed oils (Iskandarov et al., 2017; Rigouin et 
al., 2018). Newer studies proposed, at least for murine hepatocytes, that DGAT1 channels 
TAG synthesis for intracellular energy utilization, whereas DGAT2 channels TAGs for VLDL 
synthesis (Li et al., 2015; McLaren et al., 2018). The hypothesis based on the experimental 
data from this thesis supports evidence for hepatic DGAT1 to act predominantly on MCFAs. 
Apart from its various other published site effects, the CPT1 inhibitor Etomoxir does also 
efficiently inhibit DGAT activity, mostly acting on DGAT1 when both DGATs are present. In 
the case of a loss in DGAT1 activity, Etomoxir does as well inhibit DGAT2, creating similar 
NFC patterns in aTAG levels. This suggest the presence of a specialized DGAT2 pool also 
acting on the FA-CoA species normally metabolized by DGAT1. Upon an LPS-induced 
steatotic phenotype, activity from both DGAT enzymes seem to be upregulated in the same 
manner, as inhibitory treatments did not lead to any other effects as in the unstimulated 
control groups.  
As a control, Teglicar, another specific inhibitor for the liver isoform of CPT1, was used to 
compare its effects to those of Etomoxir. The effects of Teglicar did not show any inhibition of 
DGAT activity. Instead Teglicar treatment did only lead to effects which can be correlated to 
an efficient CPT1 inhibition, like reduced OCR and increase of aTAG levels. 
In conclusion, this work gives novel insights into the differing functions of hepatic DGAT1 and 
DGAT2, suggesting DGAT1 to function predominantly on MCFAs. Additionally, this work 
describes the inhibition of both DGAT enzymes through Etomoxir as a prominent off-target 
effect of this drug. Etomoxir is still widely used as a CPT1 inhibitor in various research fields, 
even though many other off-target effects were published over the past years. This thesis 
now adds more detail to the mentioned study form Xu and colleagues (Xu et al., 2003), by 
further defining the off-target effect of Etomoxir in murine hepatocytes. Hence, future studies 
should now carefully consider the use of Etomoxir as a CPT1 inhibitor, as it also acts on 
many other enzymes, including DGAT1 and DGAT2. 
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7. Outlook 
As the hypothesis for the role of DGAT1 in hepatic MFCA metabolism is solely based on ex 
vivo experiments in murine hepatocytes there are several important experiments, which 
should be addressed in future studies in order to support this hypothesis as a general model 
in mice, but also in order to transfer it to higher mammal species. There are recent studies 
which propose that DGATs function differently in other mammals. It has been shown for 
higher mammals (rhesus primates), that DGAT2 does not have a controlling role in hepatic 
TAG synthesis which leads to VLDL secretion, even though it has been shown to do so in 
rodents (Li et al., 2015; McLaren et al., 2018). DGAT2 has also shown to channel de novo 
synthesized FA into a TAG pool for rapid β-oxidation in brown adipocytes, comparable to the 
proclaimed DGAT1 activity in hepatocytes (Irshad et al., 2017). Also, expression pattern of 
both DGAT enzymes can differ between organs from mice and humans. DGAT1 is the 
predominant enzyme in the human intestine, with a practically absence of DGAT2, whereas 
in rodents DGAT2 is highly expressed in the intestine (Haas et al., 2012).  
Taking this to account, firstly in vivo studies in WT and DGAT1-/- mice should be performed, 
preferably feeding the mice labeled MCTs and LCTs followed by MS-based analysis of organ 
samples, in order to follow the natural metabolism as such in different organs. This 
experimental setup may as well include cohorts of mice treated with combinations DGAT- 
and other selective inhibitors targeting different enzymes in lipid metabolism.  
Also, pulse-chase experiments should be done, including DGAT1-/- hepatocytes, as well as 
selective inhibition of DGAT2 and the addition of several unlabeled fatty acids, differing in 
chain length and saturation. It would also be helpful if one would separate intracellular LDs 
and ER bound VLDL fractions via gradient ultracentrifugation, followed by a subsequent 
analysis of labeled TAGs in those fractions. With such an experiment one could distinguish 
between spatially separated DGAT activities. Here, the presence of TAG pools differing in 
acyl-chain length and saturation degrees could be experimentally confirmed. 
Whether the results obtained from the murine model can be applied to higher mammals and 
ultimately to humans, still needs to be confirmed. Here, a cooperation with clinics dealing 
with liver related diseases would be beneficial, as one might get the opportunity to conduct 
similar studies with primary hepatocytes obtained from liver biopsies. A cooperation with the 
scientists supervising the clinical study with patients lacking DGAT1 in the intestine (van Rijn 
et al., 2018) would also be very interesting, as one might get the chance to apply our alkyne 
lipid tracing technology on their patient-derived organoid cultures. 
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10. Supplements 
10.1. Validation of the MCFA-TAG effects with a different set of 
DGAT inhibitors 
In a study on the roles of DGAT1 and 2 in primary hepatocytes on TAG synthesis and 
secretion, a different set of small-molecule DGAT inhibitors from the company Pfizer was 
used (Li et al., 2015) (see: Materials 3.4). In order to validate the effects of DGAT1 inhibition 
on MCFA-TAG levels, described in this study, some of the experiments were repeated with 
the inhibitor set from Pfizer, using the same concentrations as described in the mentioned 
study (Li et al., 2015). 
In co-pulse experiments with C11- and C19-fatty acids for TLC detection, the DGAT1 
inhibitor from Pfizer showed the same effect in accordance to the experiments done with the 
inhibitor A922500. Levels of C11-TAGs were significantly reduced with either the DGAT1 
inhibitor alone, or even further reduced in combination with Etomoxir (Supplementary figure 
1, B). Levels of C19-TAGs showed no significant changes upon the inhibitor treatments.  
Supplementary figure 1: Analysis of aTAGs upon DGAT1 inhibitor- (from Pfizer), and Etomoxir-
treatment in primary hepatocytes, co-pulsed with C11- and C19 fatty acids. After isolation, 
primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well.  Cells were 
preincubated with either 5 µM DGAT1-Inhibitor from Pfizer (PFD1), 50 µM Etomoxir (Eto) or a 
combination of both inhibitors (PFD1/Eto) for one hour, in comparison to the respective vehicle as a 
negative control. Cells were then pulsed for 1 hour with a combination of 50 µM C11- and 50 µM C19-
fatty acid. The cells were washed, lipids were extracted and click reaction was performed. Finally, 
lipids were separated on a TLC plate and the signal was captured by fluorescent imaging (A). Panel B 
illustrates the normalized quantification of fluorescent intensities from C11 TAG (filled bars) and C19 
TAG (hatched bars) upon either PFD1 (red), Etomoxir (orange) and combination of both (orange/red) 
inhibitors, in comparison to the negative controls (black: C11, grey: C19). The data represent mean 
±SD for n=3 biological replicates. **** stands for p≤0.0001, ns=not significant. 
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Supplementary figure 2: Analysis of aTAGs upon DGAT2 inhibitor- (from Pfizer), and Etomoxir-
treatment in primary hepatocytes, co-pulsed with C11- and C19 fatty acids. After isolation, 
primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well.  Cells were 
preincubated with either 5 µM DGAT2-Inhibitor from Pfizer (PFD2), 50 µM Etomoxir (Eto) or a 
combination of both inhibitors (PFD2/Eto) for one hour, in comparison to the respective vehicle as a 
negative control. Cells were then pulsed for 1 hour with a combination of 50 µM C11- and 50 µM C19-
fatty acid. The cells were washed, lipids were extracted and click reaction was performed. Finally, 
lipids were separated on a TLC plate and the signal was captured by fluorescent imaging (A). Panel B 
illustrates the normalized quantification of fluorescent intensities from C11 TAG (filled bars) and C19 
TAG (hatched bars) upon either PFD2 (blue), Etomoxir (orange) and combination of both 
(orange/blue) inhibitors, in comparison to the negative controls (black: C11, grey: C19). The data 
represent mean ±SD for n=3 biological replicates. ** stands for p=0.0021, ns=not significant.  
 
As in the experiments done with the DGAT2 inhibitor JNJ-DGAT2-A, a combination of the 
inhibitor PFD2 with Etomoxir in C11/C19 co-pulse experiments did not result in a complete 
reduction of C11-TAG levels (Supplementary figure 2).  
These inhibitors were also used in a MS-based setup, like in the experiments shown in this 
thesis. Here, similar changes in the profile of aTAG and aDAG species upon inhibitor 
treatment, could be observed (data not shown).  
The results from the experiments done with hepatocytes from DGAT1-K.O. mice are as well 
in favor of these findings. Here the DGAT1 inhibitor A922500 did not have any effect, while 
an inhibition of DGAT2 via the compound JNJ-DGAT-2-A alone, did lead to effects similar to 
those, were both inhibitors were combined. This was true for both MS and TLC experiments. 
This shows the immense substrate specificity of both inhibitors. Taken together, the 
validation using a different set of inhibitors against DGAT enzymes, leads to the conclusion, 
that the observed effects are indeed a result of the substrate specific inhibition of both 
DGAT1 and 2. 
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10.2. Supplementary data for chapter 5.3.1. 
Supplementary figure 3 shows a lipid species resolution of all alkyne labeled DAGs after a 2-
minute pulse of alkyne 100 µM alkyne palmitate. As already described in chapter 5.3.1, out of 
18 detectable aDAG species, 79.4% of the whole class is formed from 4 major DAG species, 
consisting of alkyne palmitate (C17:2) in combination with either palmitic acid (C16:0), 
palmitoleic acid (C16:1), stearic acid (C18:0) or oleic acid (C18:1).  
Supplementary figure 3: Absolute amounts of aDAG species isolated from WT mice, pulsed for 
2 minutes with alkyne-palmitate. After isolation, primary mouse liver hepatocytes were plated in 24 
well plates with 7.5x104 cells per well. Cells were then pulsed with 100 µM alkyne palmitate (C17:2) for 
2 minutes. Lipids were extracted with simultaneous addition of an internal standard mix for alkyne 
labeled lipids and click reaction with C175-XX reagents was performed. Multiplex samples were 
pooled and analyzed by MS. Mass signals were identified using LipidXplorer MFQL analysis with 
internal standard quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Absolute amounts of the 
lipid species are shown in pmol. The data represent mean ±SD for n=3 biological replicates. 
Percentage value of the four major aDAG species (DAG [33:3], [33:2], [35:4] and [35:3]) is presented 
as mean.  
 
 
 
 
 
 
 
 
 
 
 
 Supplements 
 
 
 - 110 - 
 
  
10.3. Double alkyne-labeled TAG 
This chapter gives an overview on double alkyne-labeled triacylglycerol (dlTAG) species in 
comparison to their single-labeled counterparts. This is shown on the example of the dataset 
acquired form the DGAT1-K.O. mice (see: Chapter: 5.3.2.).  
Supplementary figure 4 visualizes a double alkyne-palmitate (C17:2)-labeled triacylglycerol 
molecule.  
 
Supplementary figure 4: Structure of double alkyne-palmitate (C17:2)- labeled triacylglycerol. 
R1 stands for any other fatty acid, incorporated into the molecule. 
 
Supplementary figure 5: Fold change analysis of double alkyne-labeled TAG (dlTAG) based on 
relative amounts (mol per mille) from dlTAG and dlPC species from primary hepatocytes, 
isolated from wildtype mice (WT) or mice lacking DGAT1 (ΔDGAT1), treated with different 
inhibitor combinations, pulsed with alkyne-palmitate and decanoic acid. After isolation, primary 
mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were 
preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-Inhibitor 
(D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells were then co-
pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were 
extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and click 
reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. 
Mass signals were identified using LipidXplorer MFQL analysis with internal standard quantification for 
dlTAG. Fold changes (FC) in relative concentrations (from mol per mille) of double labeled alkyne TAG 
for each inhibitor treatment were calculated by normalization to the negative control. The data 
represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, ** for p≤0.0021 and **** for 
p≤0.0001. ns=not significant. Isolation of hepatocytes and fatty acid pulse was done by CL, lipid 
extraction and MS/TLC analysis were done by KW. 
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Supplementary figure 6: Detailed normalized fold change (NFC) analysis of double alkyne-
labeled TAG with decanoic acid (dlTAG [44:4]) from primary hepatocytes, isolated from mice 
lacking DGAT1, treated with inhibitor combinations and pulsed with alkyne-palmitate and 
decanoic acid. After isolation, primary mouse liver hepatocytes were plated in 24 well plates with 
7.5x104 cells per well. Cells were preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-
Inhibitor (D1), 15 µM DGAT2-Inhibitor (D2) or combinations of Etomoxir with each DGAT-inhibitor 
(Eto+D1, Eto+D2). Cells were then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM 
decanoic acid (C10) for 1 hour. Lipids were extracted with simultaneous addition of an internal 
standard mix for alkyne labeled lipids and click reaction with C175-XX reagents was performed. 
Multiplex samples were pooled and analyzed by MS. Mass signals were identified using LipidXplorer 
MFQL analysis with internal standard quantification for dlTAG. Normalized fold changes (NFC) in 
concentrations of each lipid species for each inhibitor treatment were calculated by normalization to 
the negative control and to the average class fold change. The data is represented as floating bars 
(min to max) with the line indicating the mean value. n=3 biological replicates. ** stands for p≤0.0021 
and **** stands for p≤0.0001. ns= not significant. Isolation of hepatocytes and fatty acid pulse was 
done by CL, lipid extraction and MS/TLC analysis were done by KW. 
 
In the following the results are briefly summarized. Etomoxir had no significant effect on 
overall dlTAG levels, whereas both DGAT inhibitors did show effects like those shown with 
single labeled species (Supplementary figure 5, panel A). Nevertheless, effects on MCFA-
aTAGs were similar both in WT and DGAT1-/- hepatocytes compared to the single labeled 
lipids. This is summarized in Supplementary figure 6, showing fold change analysis on the 
species dlTAG [44:4], consisting of the two C17:2 and one C10-FA, representing the MCFA. 
Data analysis form the TLC-based experiment was only based on single labeled species. For 
comparability, the MS-based data presented in the results part of this thesis is only based on 
single-labeled species.  
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10.4. Internal standard validation 
The validation of all measured intensities from the internal standards (IS) form the four lipid 
species which are presented in this work, shows the robustness of the MS system for aTAG 
and aDAG species. The intensities from all single measurements (n=540) were combined 
from all data sets presented in this thesis and a coefficient of variation was calculated. 
 
Supplementary figure 7: Intensities of the internal alkyne-labeled standards for the lipid 
species TAG, PC, DAG and PA with coefficient of variation (indicated percentage value). The 
bar graphs represent the measured intensities, combined form all experiments presented in this work. 
Values represent mean ±SD for n=6 experiment sets with a total sum of 540 single measured intensity 
values.  
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10.5. MFQL scripts 
aCholesterol-ester-IS 
QUERYNAME = multiCEIS;  
DEFINE PR1 = 'C[53] H[89] D[4] N[4] O[2]' WITH CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
REPORT 
NAME = "CE IS [%d:%d]" % ((PR1.chemsc[C] - 35), 
(PR1.chemsc[db] - 6.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 35); 
db = "%d" %  (PR1.chemsc[db] - 6.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 29.16; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCholesterol-ester species 
QUERYNAME = multiCE;  
DEFINE PR1 = 'C[40..60] H[50..130] D[4] N[4] O[2]' WITH DBR = 
(3.5,15), CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
isEven(PR1.chemsc[C]) 
 
REPORT 
NAME = "CE [%d:%d]" % ((PR1.chemsc[C] - 35), (PR1.chemsc[db] 
- 6.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 35); 
db = "%d" %  (PR1.chemsc[db] - 6.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 29.16; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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aCeraminde IS 
QUERYNAME = multiCERIS;  
DEFINE PR1 = 'C[44] H[80] D[4] N[5] O[3]' WITH CHG = 1; 
DEFINE PR2 = 'C[44] H[80] D[4] N[5] O[3]' WITH CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "d18:1-Cer(%d:%d)" % ((PR1.chemsc[C] - 26), 
(PR1.chemsc[db] - 3.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 26); 
db = "%d" %  (PR1.chemsc[db] - 3.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 8.43; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aCeraminde species 
QUERYNAME =multiCER;  
DEFINE PR1 ='C[39..70] H[50..130] D[4] N[5] O[3]' WITH DBR = 
(4.5,10), CHG= 1; 
DEFINE PR2  'C[39..70] H[50..130] D[4] N[5] O[3]' WITH DBR = 
(4.5,10), CHG  1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1 
AND PR2 IN M2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
isOdd(PR1.chemsc[C]) 
AND isEven(PR1.chemsc[H]) 
AND PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "alkyne-d19:2-Cer(%d:%d)" % ((PR1.chemsc[C] - 27), 
(PR1.chemsc[db] - 4.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 27); 
db = "%d" %  (PR1.chemsc[db] - 4.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 8.43; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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aDiacylglycerol IS 
QUERYNAME = multiDAGIS;  
DEFINE PR1 = 'C[43] H[79] D[4] N[4] O[5]' WITH DBR = (3.5,15), 
CHG = 1; 
DEFINE PR2 = 'C[43] H[79] D[4] N[4] O[5]' WITH DBR = (3.5,15), 
CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
 PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "DAG [%d:%d]" % ((PR1.chemsc[C] - 11), 
(PR1.chemsc[db] - 2.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 11); 
db = "%d" %  (PR1.chemsc[db] - 2.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 16.7; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aDiacylglycerol species 
QUERYNAME = multiDAG;  
DEFINE PR1 = 'C[28..58] H[50..130] D[4] N[4] O[5]' WITH DBR = 
(3.5,15), CHG = 1; 
DEFINE PR2 = 'C[28..58] H[50..130] D[4] N[4] O[5]' WITH DBR = 
(3.5,15), CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
isEven(PR1.chemsc[C]) 
AND isOdd(PR1.chemsc[H]) 
AND PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "DAG [%d:%d]" % ((PR1.chemsc[C] - 11), 
(PR1.chemsc[db] - 2.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 11); 
db = "%d" %  (PR1.chemsc[db] - 2.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 16.7; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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aPhosphatidic acid IS 
QUERYNAME = multiPAIS;  
DEFINE PR1 = 'C45 D4 H82 O8 N4 P1' WITH DBR = (2.5,15), 
CHG = 1;  
DEFINE PR2 = 'C45 D4 H82 O8 N4 P1' WITH DBR = (2.5,15), 
CHG = 1;  
DEFINE NL1 = 'C4 H14 P1 N1 O4' WITH CHG = 0; 
DEFINE NL2 = 'C4 H12 D2 P1 N1 O4' WITH CHG = 0; 
DEFINE NL3 = 'C4 H11 D3 P1 N1 O4' WITH CHG = 0; 
DEFINE NL4 = 'C4 H10 D4 P1 N1 O4' WITH CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+  
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
REPORT 
NAME = "PA [%d:%d]" % ((PR1.chemsc[C] - 11), (PR1.chemsc[db] 
- 2.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 11); 
db = "%d" %  (PR1.chemsc[db] - 2.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 14.06; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPhosphatidic acid species 
QUERYNAME = multiPA;  
DEFINE PR1 = 'C[36..60] H[50..130] D4 N[4] P[1] O[8]' WITH DBR 
= (0.5,15), CHG = 1;  
DEFINE PR2 = 'C[36..60] H[50..130] D4 N[4] P[1] O[8]' WITH DBR 
= (0.5,15), CHG = 1;  
DEFINE NL1 = 'C4 H14 P1 N1 O4' WITH CHG = 0; 
DEFINE NL2 = 'C4 H12 D2 P1 N1 O4' WITH CHG = 0; 
DEFINE NL3 = 'C4 H11 D3 P1 N1 O4' WITH CHG = 0; 
DEFINE NL4 = 'C4 H10 D4 P1 N1 O4' WITH CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+  
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
isEven(PR1.chemsc[C]) 
AND isEven(PR1.chemsc[H]) 
AND PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "PA [%d:%d]" % ((PR1.chemsc[C] - 11), (PR1.chemsc[db] 
- 2.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 11); 
db = "%d" %  (PR1.chemsc[db] - 2.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 14.06; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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aPhosphatidylcholine IS 
QUERYNAME = multiPCIS;  
DEFINE PR1 = 'H93 D4 C50 O8 P1 N5' WITH CHG = 1; 
DEFINE PR2 ='H93 D4 C50 O8 P1 N5' WITH  CHG = 1; 
DEFINE NL1 = 'C9 H25 P1 N2 O4' WITH CHG = 0; 
DEFINE NL2 = 'C9 H23 D2 P1 N2 O4' WITH  CHG = 0; 
DEFINE NL3 =  'C9 H22 D3 P1 N2 O4' WITH  CHG = 0; 
DEFINE NL4 =  'C9 H21 D4 P1 N2 O4' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+  
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "PC [%d:%d]" % ((PR1.chemsc[C] - 16), (PR1.chemsc[db] 
- 2.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 16); 
db = "%d" %  (PR1.chemsc[db] - 2.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 124.78; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPhosphatidylcholine species 
QUERYNAME = multiPC;  
DEFINE PR1 = 'C[30..60] H[50..130] D[4] N[5] P[1] O[8]' WITH 
DBR = (4.5,15), CHG = 1; 
DEFINE PR2 = 'C[30..60] H[50..130] D[4] N[5] P[1] O[8]' WITH 
DBR = (4.5,15), CHG = 1; 
DEFINE NL1 = 'C9 H25 P1 N2 O4' WITH CHG = 0; 
DEFINE NL2 = 'C9 H23 D2 P1 N2 O4' WITH  CHG = 0; 
DEFINE NL3 =  'C9 H22 D3 P1 N2 O4' WITH  CHG = 0; 
DEFINE NL4 =  'C9 H21 D4 P1 N2 O4' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+  
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
isOdd(PR1.chemsc[C]) 
AND isOdd(PR1.chemsc[H]) 
AND PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "PC [%d:%d]" % ((PR1.chemsc[C] - 16), (PR1.chemsc[db] 
- 2.5)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 16); 
db = "%d" %  (PR1.chemsc[db] - 2.5); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 124.78; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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aTriacylglycerol IS 
QUERYNAME = multiTAGIS;  
DEFINE PR1 = 'C[59] H[107] D[4] N[4] O[6]' WITH CHG = 1; 
DEFINE PR2 = 'C[59] H[107] D[4] N[4] O[6]' WITH CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "TAG IS [%d:%d]" % ((PR1.chemsc[C] - 11), 
(PR1.chemsc[db] - 3)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 11); 
db = "%d" %  (PR1.chemsc[db] - 3); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 117.74; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aTriacylglycerol speices 
QUERYNAME = multiTAG;  
DEFINE PR1 = 'C[40..80] H[50..130] D[4] N[4] O[6]' WITH DBR = 
(3.5,18), CHG = 1; 
DEFINE PR2 = 'C[40..80] H[50..130] D[4] N[4] O[6]' WITH DBR = 
(3.5,18), CHG = 1; 
DEFINE NL1 = 'C4 H11 N1' WITH CHG = 0; 
DEFINE NL2 =  'C4 H9 D2 N1' WITH  CHG = 0; 
DEFINE NL3 =  'C4 H8 D3 N1' WITH  CHG = 0; 
DEFINE NL4 =  'C4 H7 D4 N1' WITH  CHG = 0; 
 
IDENTIFY 
PR1 IN MS1+ 
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2+ 
AND NL4 IN MS2+ 
 
SUCHTHAT 
isEven(PR1.chemsc[C]) 
AND isOdd(PR1.chemsc[H]) 
AND PR1.chemsc == PR2.chemsc 
 
REPORT 
NAME = "TAG [%d:%d]" % ((PR1.chemsc[C] - 11), 
(PR1.chemsc[db] - 3)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 11); 
db = "%d" %  (PR1.chemsc[db] - 3); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 117.74; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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Double labeled aTriacylglycerol IS 
QUERYNAME = multiTAGdlIS;  
DEFINE PR1 = 'C70 H124 D8 N[8] O[6]' WITH CHG = 2; 
DEFINE PR2 = 'C70 H124 D8 N[8] O[6]' WITH CHG = 2; 
DEFINE NL1 = 'C62 H102 D8 N6 O6'  WITH CHG = 2; 
DEFINE NL2 = 'C62 H106 D4 N6 O6'  WITH CHG = 2; 
DEFINE NL3 = 'C62 H108 D2 N6 O6'  WITH CHG = 2; 
DEFINE NL4 = 'C62 H110 N6 O6'  WITH CHG = 2; 
 
IDENTIFY 
PR1 IN MS1+ 
AND PR2 IN MS2+ 
AND NL1 IN MS2+ 
AND NL2 IN MS2+ 
AND NL3 IN MS2  
AND NL4 IN MS2+ 
 
REPORT 
NAME = "dlTAG-IS [%d:%d]" % ((PR1.chemsc[C] - 19), (PR1.chemsc[db] - 4)); 
MASS = PR1.mass; 
chemsc = PR1.chemsc; 
C = "%d" %  (PR1.chemsc[C] - 19); 
db = "%d" %  (PR1.chemsc[db] - 4); 
MASS = "%4.4f" % "(PR1.mass)"; 
ERROR = "%2.2f ppm" % "(PR1.errppm)"; 
ISpmol = 22.48; 
INT73 = NL1.intensity; 
INT75 = NL2.intensity; 
INT76 = NL3.intensity; 
INT77 = NL4.intensity; ; 
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10.6. Wt vs ΔDGAT1 experiments: total labeled lipids 
The following figure shows the absolute amounts of all single alkyne labeled lipid species in 
the experiments done with the DGAT1-/- mice and the respective WT controls. This is done to 
rule out any false conclusions concerning the differences in the amount of certain lipid 
species in comparing these different biological systems.   
Supplementary figure 8: Absolute amount of all single alkyne-labeled lipids in pmol from 
primary hepatocytes, isolated from wildtype mice (WT) or mice lacking DGAT1 (ΔDGAT1),  
treated with different inhibitor combinations, pulsed with alkyne-palmitate and decanoic acid. 
After isolation, primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per 
well. Cells were preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM 
DGAT2-Inhibitor (D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells 
were then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. 
Lipids were extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids 
and click reaction with C175-XX reagents was performed. Multiplex samples were pooled and 
analyzed by MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCer. The data represent mean ±SD for n=3 
biological replicates. * stands for p≤0.0332 and ns=not significant. Isolation of hepatocytes and fatty 
acid pulse was done by CL, lipid extraction and MS/TLC analysis were done by KW. 
 
There are no significant changes in the amount of labeled lipids between the treatment 
groups (Eto, D1, D2, Eto+D1, Eto+D2) and the respective negative control in either the WT 
or the DGAT1-/- animals, when compared internally. The amounts in each treatment group 
between WT and DGAT1-/- animals are slightly higher on the side of the DGAT1-/- animals, 
however only significantly higher in the two treatment groups where Etomoxir and either one 
of both DGAT inhibitors are combined. Nevertheless, in the negative controls the amounts of 
all labeled lipids were nearly the same, thus making the direct comparison of the two animal 
groups meaningful.   
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10.7. Supplementary data for chapters 5.3.2 and 5.5 
Supplementary figures 9 and 10 refer to the experiments done in chapter 5.3.2. 
Supplementary figure 9: Fold change analysis of alkyne-labeled PC (A) and PA (B) based on 
relative amounts (mol per mille) from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from wildtype mice (WT) or mice lacking DGAT1 (ΔDGAT1), treated with 
different inhibitor combinations, pulsed with alkyne-palmitate and decanoic acid. After isolation, 
primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were 
preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-Inhibitor 
(D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells were then co-
pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were 
extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and click 
reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. 
Mass signals were identified using LipidXplorer MFQL analysis with internal standard quantification for 
aTAG, aDAG, aPC, aPA, aCE and aCER. Normalized fold changes (NFC) in relative concentrations of 
alkyne PCs and PAs for each inhibitor treatment were calculated by normalization to the negative 
control. The data represent mean ±SD for n=3 biological replicates. * stands for p≤0.0332, ** for 
p≤0.0021, *** for p≤0.0002 and **** for p≤0.0001. ns=not significant. Isolation of hepatocytes and fatty 
acid pulse was done by CL, lipid extraction and MS/TLC analysis were done by KW.   
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Supplementary figure 10: Absolute amounts (pmol) of the four main MCTs from primary 
hepatocytes, isolated from wildtype mice (WT) or mice lacking DGAT1 (ΔDGAT1), treated with 
different inhibitor combinations, pulsed with alkyne-palmitate and decanoic acid. After isolation, 
primary mouse liver hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were 
preincubated with either 50 µM Etomoxir (Eto), 3 µM DGAT1-Inhibitor (D1), 15 µM DGAT2-Inhibitor 
(D2) or combinations of Etomoxir with each DGAT-inhibitor (Eto+D1, Eto+D2). Cells were then co-
pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids were 
extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and click 
reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by MS. 
Mass signals were identified using LipidXplorer MFQL analysis with internal standard quantification for 
aTAG, aDAG, aPC, aPA, aCE and aCER. Absolute amounts from MCTs (Σ of [43:3], [43:2], [45:4], 
[45:3]) are presented in pmol. The data represent mean ±SD for n=3 biological replicates. * stands for 
p≤0.0332, ** for p≤0.0021 and **** for p≤0.0001. ns=not significant. Isolation of hepatocytes and fatty 
acid pulse was done by CL, lipid extraction and MS/TLC analysis were done by KW. 
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Supplementary figures 11 and 12 refer to experiments done described in chapter 5.5. 
 
Supplementary figure 11: Fold change analysis of alkyne-labeled PC (A) and PA (B) based on 
relative amounts (mol per mille) from aTAG, aDAG, aPC, aPA, aCE and aCER, from primary 
hepatocytes, isolated from WT mice treated with different combinations of Etomoxir and 
Teglicar and pulsed with alkyne-palmitate and decanoic acid. After isolation, primary mouse liver 
hepatocytes were plated in 24 well plates with 7.5x104 cells per well. Cells were preincubated with 
either 50 µM Etomoxir (Eto), 10 µM Teglicar (Tegli 10), 20 µM Teglicar (Tegli 20), 50 µM Teglicar 
(Tegli 50) or combinations of Etomoxir with each Teglicar concentration (Tegli XX + Eto). Cells were 
then co-pulsed with 50 µM alkyne palmitate (C17:2) and 50 µM decanoic acid (C10) for 1 hour. Lipids 
were extracted with simultaneous addition of an internal standard mix for alkyne labeled lipids and 
click reaction with C175-XX reagents was performed. Multiplex samples were pooled and analyzed by 
MS. Mass signals were identified using LipidXplorer MFQL analysis with internal standard 
quantification for aTAG, aDAG, aPC, aPA, aCE and aCER. Normalized fold changes (NFC) in relative 
concentrations of alkyne lipids for each inhibitor treatment were calculated by normalization to the 
negative control. The data represent mean ±SD for n=3 biological replicates. * stands for p≤0.032, ** 
stands for p≤0.0021 and **** for p≤0.0001. ns=not significant. 
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Supplementary figure 12: Live cell OCR measurement (pmol/min) in C11-FA fed hepatocytes 
isolated from WT mice treated with either 5 or 50 µM Etomoxir. After isolation, primary mouse liver 
hepatocytes were plated in a Seahorse XF Analyzer 96 well plate with 1000 cells per well. Cells were 
allowed to adhere for two hours before the assay procedure was started (see: Chapter 3.6.). After 3 
measuring cycles of baseline OCR measurement Etomoxir was injected, and the measurement was 
resumed for 3 more cycles. A drop in OCR was only visible with treatment of 50 µM Etomoxir and not 
with 5 µM. 
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